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Abstract
Guinea pig eosinophils, human eosinophils and the eosinophilic cell lines Eol-1 and 
Eol-3 were compared with a range of added agonists. The three functional responses 
measured were hydrogen peroxide production (H20 2), cellular adhesion and the 
elevation of intracellular free calcium ([Ca2+]i). Human recombinant C5a, PAF, 
MCP-3 and RANTES were able cause H20 2 production, cellular adhesion and [Ca2+]i 
elevations from human eosinophils. M IP -la  was able to elevate [Ca2+]i5 but not 
produce H20 2, whereas IL-5 had the opposite effect. C5a, LTB4 and to a lesser extent 
PAF, were able to elicit H20 2 production from guinea pig eosinophils. In addition, all 
three caused cellular adhesion and [Ca2+]j elevations in guinea pig eosinophils. C5a, 
PAF, RANTES, MCP-1 and IL-8 were able to cause [Ca2+]j elevations in the human 
eosinophilic cell lines, but no agonist caused any significant H20 2 production. 
Extracellular Ca2+ and Mg2+ were required for eosinophil H20 2 production and cellular 
adhesion, whereas only extracellular Ca2+ was required for [Ca2+]j elevation. SK&F 
96365, a reported blocker of receptor operated calcium channels, exposed a disparity 
between guinea pig and human eosinophil responses. Ro 31-8220/002, a selective 
protein kinase C (PKC) inhibitor, caused a concentration-dependent inhibition of H20 2 
production and adhesion by both guinea pig and human eosinophils. Ro 31-8220/002 
caused a concentration-dependent potentiation of agonist-stimulated elevations in 
[Ca2+]i in guinea pig eosinophils. Eosinophils appear to have extensive tyrosine kinase 
phosphorylation, but the specific inhibitors genistein and herbimycin-A, had no 
significant effects on H20 2 production or [Ca2+]j elevations. Finally, wortmannin, a 
proposed inhibitor of phosphoinositide 3-kinase (PI 3-kinase) concentration-dependently 
inhibited eosinophil H20 2 production. Also, wortmannin had no effect on elevations 
of [Ca2+]j in human eosinophils stimulated with various agonists.
This thesis indicates that differences exist between guinea pig and human eosinophils 
and the agonists that elicit responses. However, there appears to be a dissociation of 
the respiratory burst mechanism and rapid elevation of free calcium in eosinophils. In 





Paul Ehrleich in 1879 (1) first characterised the eosinophil leukocyte that is 
derived from the haematopoietic stem cell primarily in the bone marrow. The special 
properties of eosinophils is their capacity to bind negatively charged dyes including the 
brominated fluorescein compound which had been synthesised and called eosin (Eos 
was the goddess of dawn in greek mythology) in 1866.
Blood eosinophils obtained from healthy individuals have a diameter o f 8 i^m 
and a volume of 275/1. The nucleus occupies approximately one fifth o f the cell 
volume and the specific granules one fifth of the cytoplasm (2). Figure 1.1 shows an 
electron micrograph of an eosinophilic leukocyte.
Electron micrograph of an eosinophil leukocyte. Reproduced with kind
permission from 'The molecular biology of the cell', figure 17.27C, page 975, 2nd 
edition, edited by Alberts et al (1989), Garland Publishing Inc. courtsey o f Dorothy 
Bainton.
Eosinophils are tissue cells as they are normally recruited to fight diseases and 
large numbers can be found in tissues even when blood counts are low. The number 
of eosinophils in the blood are a poor indication o f disease due to the relationship of 
the number o f cells that are 1) in the marrow, 2) marginating and then leaving the
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blood and 3) the number present in the tissues (3). There is virtually no recirculation 
of eosinophils back from tissues to blood. Figure 1.2 shows a schematic representation 
o f the eosinophil life cycle.
bone marrow
103h intramedullary 
maturation &  storage (4) 
Differentiation factors:
IL-1, IL-3, IL-5 &  GM-CSF
die after activation by 
programmed cell death 
(apoptosis)/phagocytosis (7)
migration from bone 
marrow to blood, 
3.5days(5)
half life o f eosinophil 
in blood, 18h (prolonged 
in eosinophilia); mean 
transit time, 26h (4)
removed in the spleen 
and liver i f  damaged 
or altered
eosinophils marginate 
and emigrate into 





not known how long eosinophils 
survive in tissues, several days to 
a week; can be induced to survive 
in vitro with growth factors 
GM-CSF, IL-3 and IL-5 (6,7)
F igure 1.2 Schematic diagram o f the life cycle o f the eosinophil.
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The nucleus of the eosinophil is bilobed but can increase to four lobes in some 
diseases. Four cationic proteins comprise the bulk of the protein within the distinctive 
eosinophil cytoplasmic granules. Major basic protein (MBP) (mw. lOkDa) is localised 
in the core and accounts for 55 % of the granule protein. MBP is not present in other 
eosinophil organelles nor plasma cells, mast cells, lymphocytes or neutrophils. 
Eosinophil cationic protein (ECP) (mw. 21kDa), eosinophil peroxidase (EPO) (mw. 
75kDa) and eosinophil derived neurotoxin (EDN) (mw. 18kDa) are all localised in the 
matrix of the leukocyte. Similarly acetylcholinesterase, acid glycerophosphatase, 
adenosine triphosphatase, a-mannosidase, arylsulphatase, catalase, p-glucuronidase, 
nonspecific esterase, ribonuclease, cathespin, acid and alkaline phosphatase, 
histaminase, phospholipase D, phospholipase p, serine pyruvate aminotransferase have 
also been found (8). The small granules of eosinophil contain arylsulphatase and acid 
phosphatase (8).
During purification of eosinophils from humans and animal models, a 
population of eosinophils with a lower than normal density have been isolated and have 
been since named light density or hypodense eosinophils. Hypodense eosinophils are 
connected with eosinophilia-associated diseases, parasitism and allergy and their 
numbers are positively correlated with the degree of eosinophilia (9). They have a 
peak density of 1.075-1.077 g/1 as opposed to the peak density of normodense 
eosinophils 1.088g/l (9-11). In peripheral blood cells of normal persons less than 10% 
of the eosinophils are hypodense. Hypodense eosinophils are considered to be 
activated cells as they are 1) present in higher proportions in patients with eosinophilia, 
2) appear to be more metabolically active than normodense eosinophils as they have
Introduction 5
an increased generation of the superoxide ion and release more ECP and EDN in 
hypereosinophilic syndrome (12). They have an increased LTC4 production, an 
increased cytotoxicity for antibody-coated targets and have more receptors for IgGFc, 
IgEpc and complement (11). There is controversy as to whether hypodense eosinophils 
originate from the bone marrow or are derived in the blood and tissues from 
normodense cells. Hypodense eosinophils may be partially degranulated by a prior 
activation step and the smaller granule size may be due to piecemeal degranulation 
(13).
Another property of eosinophils is that they exhibit a marked autofluoresence 
in comparison with other leukocytes. The excitation 380nm and 450nm and single 
emission of 520nm exhibited is characteristic of the flavins. Mayeno et al (14) have 
identified flavin adenine dinucleotide (FAD) as the predominant fluorophore in 
eosinophil granules. It is unclear whether the flavin exists as free FAD within the 
granules or as a prosthetic group via non-covalent attachment to granule proteins. The 
eosinophil granule FAD may be associated with granule oxidases and may serve as a 
flavin reservoir enhancing the activity of the NADPH oxidase (see section 1.4).
In addition to the recruitment of eosinophils in inflammatory processes they can 
affect other cells because of the mediators/cytokines they produce. Some of the 
cytokines they produce also cause autoactivation. Other receptors expressed include 
FcyR II for IgG, FceR II for IgE and Fc.R for IgA (15-17).
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1.2 Recruitment of eosinophils
Once eosinophils have been produced in the bone marrow and are circulating 
in the blood, they must be recruited before they can interact at the site of inflammation 
and exert their functional responses (see figure 1.2). First eosinophils loosely tether 
to the endothelial cells lining the vascular lumen. Next the cells spread then once 
firmly adhered undergo diapedesis. They then migrate up a chemotactic gradient 
through the extracellular matrix to the inflammatory focus, for example the bronchial 
lumen in the case of respiratory diseases.
1.2.1 Eosinophil adhesion
Adhesion is now considered to be an important stage in cellular recruitment. 
Adhesion proteins can determine the type of cells that infiltrate into the tissues and also 
can enhance the adhesiveness of activated cells. Adhesion molecules can be divided 
into three families: 1) the integrins,which are heterodimeric molecules that function 
both as cell-substratum and cell adhesion receptors, 2) the immunoglobulin 
superfamily, which is important in cell-cell adhesion especially during embryogenesis, 
wound healing and the inflammatory response and 3) the selectins, which mediate 
whole blood cell/endothelial cell adhesion (18).
The general mechanism of cellular recruitment is thought to be as follows: 
Inflammatory substances activate the circulating leukocytes and the adjacent 
endothelium. This activation results in changes in the adhesion molecule expression 
by upregulation or conformational changes with the consequence that the endothelium, 
the leukocytes or both become more adhesive. The leukocytes then migrate to the
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vessel wall and form a loose association with the endothelium and slowly 'roll' along 
the surface. The cell then firmly adheres to the endothelium and diapedeses between 
the junctions of endothelial cells and finally makes its way through the extracellular 
matrix to the site of inflammation. Evidence is increasing that adhesion molecules are 
present on eosinophils and have an important role, though differences may exist 
depending whether the cells are recruited in the lung or other organs. Eosinophils 
express various adhesion receptors which are summarised in table 1, together with the 
endothelium counter receptor. These have been identified using a variety of 
monoclonal antibodies.
Table 1.1 Possible eosinophil adhesion receptors
Receptor Family /Type Counter receptor Family/Type Reference





VLA-6 (a6p,) Integrin (Laminin) (matrix protein) (21,22)
L-selectin Selectin Sialyated Lewis X? (carbohydrate)
PEC AM-1 Ig 9 Integrin? (17)
Sialyated Lewis X (carbohydarte) E-selectin Selectin (43)
CDlla/CD18 
(LFA-1 aLp2>
Integrin ICAM-1, ICAM-2 Ig (20,22)


















The integrin family (25), are transmembrane heterodimeric glycoproteins 
consisting of noncovalently associated a and p subunits. There are at least eleven
Introduction 8
different a-subunits and seven different p-subunits that are associated to form at least 
fourteen different integrins.
The p2 integrins are also known as leukocyte integrins because their expression 
is limited to white blood cells. The a-subunits (mw. 150-180kDa) have a small degree 
of homology with each other though they are similar in structure. All are typical 
glycoproteins with a N-terminal signal peptide and a relatively short cytoplasmic 
region. Each has a domain of three cation binding repeats that underlines the Ca2+ and 
Mg2+ binding requirements of the leukocyte integrins. The p2 integrins (LFA-1, 
Mac-1 and p 150,95) are present on all leukocytes and have a wide range of adhesion 
dependent functions.
There appears to be an association of integrins with cytoskeletal actin filaments 
via an indirect linkage involving talin, vinculin and other cytoskeletal associated 
molecules (26) and this binding requires the cytoplasmic domain of the p-subunit. A 
tyrosine phosphorylation site exists in the cytoplasmic domains of the sequences of the 
pr  and p3-subunits (18,27). Much of the work on integrins and understanding has 
been established with the use of specific monoclonal antibodies to the different subtypes 
and the rare autosomal recessive immunodeficiency disease termed Leukocyte Adhesion 
Deficiency (LAD). This disease is caused by a defect in the common p2-subunit (28).
The pi integrins consist of receptors that bind extracellular matrix proteins. 
VLA-4 is the only p! heterodimer which has been ascribed a role in cell-cell interaction 
and homotypic adhesions (29). VCAM-1, the ligand that binds to VLA-4, is expressed 
when cytokines stimulate vascular endothelial cells, which is a pathway distinct from 
the CD11/CD18 interaction. This was reiterated as eosinophils have been found in
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tissues from a patient with Leukocyte Dysfunction (30). VLA-4 is not expressed on 
neutrophils and its presence on eosinophils is likely to be highly important in eosinophil 
adhesion interactions.
Eosinophils have been shown in vitro to have increased adhesion to unstimulated 
endothelial cells by the cytokines IL-3 and IL -5, whereas neutrophil adhesion was 
unchanged. GM-CSF upregulated both eosinophil and neutrophil adhesion to 
unstimulated HUVEC. This could be inhibited using a monoclonal antibody to the 
a-chains eg. anti-Mac-1 and to a lesser extent anti-LFA-l(31). Optimal enhancement 
of eosinophil adhesion was between 60 and 120 minutes.
E-selectin is not constitutively expressed on endothelium but is rapidly induced in vitro 
on HUVEC by IL-1, LPS or TNFa with maximal expression at 4h. E-selectin acts as 
a lectin recognizing various forms of the Lewis X  glycan that may be attached to 
membrane glycoproteins or lipids. It appears to function in the early steps of binding 
to endothelium as demonstrated in the neutrophil (32).
From the immunoglobulin superfamily two intracellular adhesion molecules 
ICAM-1 (33) and ICAM-2 (34) have been identified. These are present in low levels 
in vitro on HUVEC and expression is increased upon stimulation with TN Fa, IL-1 and 
IFNy (34). In addition, these inflammatory cytokines cause expression of VCAM -1, 
which also belongs to the immunoglobulin superfamily (35). However, VCAM-1 is 
only minimally expressed on unstimulated HUVEC. When stimulated the rate of 









Figure 1.3 Various adhesion molecules and their counter-receptors thought to be 
involved in eosinophil adhesion to resting and cytokine-stimulated endothelial cells. 
Adapted from 'Immunopharmacology of eosinophils' edited by Smith, H. and Cook, 
R.M. (1993)
Using cos cells transfected with cDNA for ELAM-1 or ICAM-1, eosinophils 
can bind to either ELAM-1 or ICAM-1 expressed in isolation, and unlike Mac-1, 
adhesion did not depend on eosinophils being activated by preincubation with 
inflammatory substances. Figure 1.3 summarises possible eosinophil adhesion 
interactions.
1.2 .2  Eosinophil chemotaxis
Once eosinophils have adhered to the endothelium and diapedesed into the 
extracellular space, they move to the inflammation foci by chemotaxis. Many 
chemotactic agents for eosinophils have been described, but the majority are neither 
potent nor specific for the eosinophil.
Those that are well characterised are PAF (36), C5a (37) and LTB4 (38). Other 
weak eosinophil chemotactic agonists include the cytokines IL-3 (39), IL-5 (40) and 




potent than PAF and C5a as chemotactic agents include IL-2 (41) and lymphocyte 
chemoattractant factor (LCF) (42). In asthmatics numerous cells have been found to 
express the mRNA encoding IL-2 (43) suggesting that IL-2 may be released in an 
asthmatic reaction. LCF is produced from CD8+ T  lymphocytes in cell culture. Again 
activated CD8+ T lymphocytes are present in airways of asthmatics following allergen 
challenge (43). Whether IL-2 and LCF are actually produced in the airways remains 
to be determined (43). Finally, RANTES (a product from T-cells), has also been 
found to be chemotactic to eosinophils in vitro (44). Chemotaxis is very different in 
vitro to the in vivo conditions largely due to the very controlled conditions of the 
Boyden chamber in which in vitro experiments are performed and the vast number of 
mediators present at the site of inflammation in vivo. Experiments have been 
undertaken to measure chemotaxis in vivo to C5a, PAF and LTB4 using 
11 indium-labelled eosinophils in conjunction with various antagonists (45,46). These 
have failed to identify an agent specifically involved in the recruitment of eosinophils, 
suggesting the recruitment process is extremely complex.
It appears that chemoattractants such as C5a, LTB4 and PAF encourage 
eosinophil transendothelial migration through upregulation of adhesion molecules and 
IL -2 , IL -5, LCF and RANTES (47-49) aid migration through the tissue matrix and 
induce further cell influx. However, many of these chemotactic agents affect several 
cell types; eosinophil specificity may therefore arise through the adhesion molecules 
such as VLA -4/VC AM -1.
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1.3 Eosinophil Function
Once eosinophils have reached their destination they are capable of eliciting 
various functional responses. They can release their cytotoxic proteins via 
degranulation, toxic metabolites or a range of cytokines and mediators that activate and 
recruit additional cells.
1.3.1 Eosinophil degranulation
As already described eosinophils contain several highly basic proteins that are 
extremely toxic. These are located in the secretory granules of the eosinophil 
leukocyte. The granule proteins include MBP, ECP, EDN, and EPO.
MBP (mw. lOkDa) is toxic to parasites (50), murine tumour cells and many 
mammalian cells (51). MBP induces airway constriction and hyper-responsiveness in 
primates (52). This effect was specific to MBP as other granule proteins had no effect. 
MBP also causes histamine release from basophils and rat mast cells (53) and 
neutralizes heparin (54). The toxicity of MBP could be inhibited by acidic poly-amino 
acids (55). This represents proMBP that is altered by the endoplasmic reticulum before 
it is sequestered in the eosinophil granule as toxic MBP.
ECP shortens coagulation time (56) and alters fibrinolysis (57). It is also very 
toxic to parasites (58) though its structure and molecular weight is different to MBP. 
Also, like MBP, ECP causes histamine release from rat mast cells. ECP is a potent 
neurotoxin (8) and inhibits proliferation of peripheral blood lymphocytes in cultures 
(60). EDN is a potent neurotoxin (59). EPO exists as either a monomer or a dimer 
and both have the same specific activity. EPO is just one of the eosinophil associated
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enzymes. In the presence of H20 2 and halide it kills microorganisms (62) and tumour 
cells (63), initiates mast cell secretion (64), inactivates leukotreines (65) and causes 
histamine release from rat mast cells. Other enzymes present in the eosinophil include 
collagenase (66) and elastase (67).
Also present in the granules are other enzymatic proteins which include elastase, 
histaminase, phospholipase and arylsulphatase B. In vitro experiments have shown 
exposure of the human eosinophil to immunoglobulins or some complement products, 
either in the form of immune complexes or bound particles gives rise to the secretion 
of granule proteins. However, receptor binding is either not optimal or of a sufficient 
signal since there is very limited secretion unless the ligand is bound to a particle of a 
non-phagocytosable size. Therefore very little secretion actually takes place when the 
eosinophil is exposed to soluble stimuli such as PM A or calcium ionophores (68). The 
most potent particulate stimuli are particles coated with either slgA or C3b (69) that 
release 15-25% of the content of normal human eosinophils. However, patients with 
eosinophilia release significantly more granule proteins. This may be due to the 
priming of the cell. In vivo experiments provide no data on selective release of any 
granule protein indicating that all four granule proteins are released together. Unlike 
ECP, EDN and EPO, MBP can be released from different sources, therefore results 
from in vivo experiments must be interpreted with care. Eosinophils in diseased tissues 
have shown some granules with intact cores while other granules in the same cell have 
lost most of their cores. This may be a sign of early activation and the beginning of 
degranulation (70).
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1.3.2 Eosinophil superoxide release
Eosinophils have the capacity to generate and release toxic oxygen metabolites 
such as superoxide (0 2), hydrogen peroxide (H20 2) which results from superoxide 
dismutation and the potentially cytotoxic hypohalous acids.
First the enzyme NADPH oxidase converts 0 2 to its one electron product, 0 2, as 
shown in equation 1.1. Concurrently, glucose is metabolised through the hexose 
monophosphate shunt (71) to regenerate the NADPH that was consumed by the 
NADPH oxidase.
20 2 + NADPH NADP + + H *  + 202" (1.1)
Superoxide is a free radical since it contains an unpaired electron. Radicals are 
very reactive and are considered to be a mediator of cytotoxicity. However, 0 2 is a 
precursor for the production of many, more-reactive, oxygen species. As already 
stated, 0 2 can undergo dismutation to form H20 2 and 0 2 and this is facilitated in vivo 
by superoxide dismutases (72) as shown in equation 1.2.
SOD
202 + 2H + -  H^)2 + 0 2 (1.2)
H20 2 is a relatively potent oxidant and about 80% of the H20 2 generated by 
human neutrophils arises from the dismutation of 0 2 (73). H20 2 can be reduced to 
form a hydroxyl radical, which is a highly unstable oxidizing agent. It is believed to 
be formed via the Fenton reaction in conjunction with the metal ion, Fe3+, that is first 
reduced by the 0 2 anion as shown in equations 1.3 and 1.4.
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Oo + Fe 3+ Fe 2+ + O. (1.3)
Fe 2+ + H£> 2 Fe3* + OH ~ + OH * (1.4)
Finally H20 2 can react with different halides to form hypohalous acids. EPO 
is a major protein present in the eosinophilic granules and superoxide production is 
often associated with degranulation. Thus, EPO with a bromide ion and H20 2 leads 
to the production of hypobromous acid as shown in equation 1.5. Again this is an 
extremely reactive product and can either oxidize biological molecules such as bacteria, 
fungi, viruses and mycoplasma to kill them, react further with H20 2 or it can react with 
primary or secondary amines to form N-bromoamines, which are stable oxidizing 
agents (74).
EPO
H £ 2 + Br~ -► HOBr + H^> (1.5)
Superoxide anions are the least damaging of the toxic products of oxygen 
metabolism, spontaneous or enzyme-catalyzed dismutation to H20 2 generates an 
extracellular source of the highly reactive, membrane-perturbing hydroxyl radical. 
Concomitmant release of EPO in response to agonists of 0 2 production therefore 
establishes conditions for the formation of potentially harmful, tissue damaging 
products of oxygen metabolism (75).
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1.3.3 Eosinophil production of mediators
As already indicated, eosinophils can elicit a wide range of mediators to aid the 
inflammation response. Eicosanoids are formed from the oxidative metabolism of 
arachidonic acid or other polyunsaturated fatty acids. Arachidonate is oxidatively 
metabolized via either the cyclooxygenase pathway or the 5- or 15-lipoxygenase 
pathways (76,78).
Human eosinophils do contain microsomal cyclooxygenase and along with 
terminal enzymes of this oxidative pathway, lead to the generation and release of 
prostaglandin (PGE2) and thromboxane 2 (TXB2) (34,76,79,80).
Human eosinophils also possess 5- and 15-lipoxygenase activity. In contrast to 
human neutrophils that release the dihydroxy acid LTB4 as their major 5-lipoxygenase 
product, human eosinophils preferentially generate and secrete LTC4 with small 
amounts of LTB4 (81). There is some doubt as to whether the 15-lipoxygenase is 
activated in eosinophils under physiological conditions. Detectable concentrations of 
15-hydroxyeicosatetraenoic acid have been measured in vivo in the inflamed asthmatic 
airway, but this may be produced via other cells. Eosinophils also possess the 
necessary acetyl transferase enzyme to synthesize another lipid mediator, PAF (82).
Eosinophils have the capacity to produce a number of cytokines. The first 
cytokine to be recognized as being formed by human eosinophils was TGFa (83). 
TGFa has been found within eosinophils in various neoplastic and inflammatory 
lesions. More recently TGFp has also been demonstrated to be synthesized by 
eosinophils (84). TGFp has been shown to promote extracellular matrix formation and 
could have a role in tissue fibrosis in various organs. Numerous interleukins are also
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produced by eosinophils. IL -la  has the potential to serve as a co-stimulatory factor 
for lymphocytes during eosinophil antigen presentation (85). IL-3 (86), IL-5 (87) and 
GM-CSF (88) probably exert autocrine activities by activating the functional responses 
of mature eosinophils as well as potentially stimulating other cell types. IL -6 also has 
a role in acute inflammation (89). Finally, M IP -la  (90) and TNFa (90,91) are also 
produced from human eosinophils.
Hence eosinophils possess the ability to produce a wide and diverse collection 
of lipid and polypeptide mediators leading up to and during inflammatory reactions. 
However, the extent to which they are produced in vivo is uncertain due to the
complexity of the immune response with various other leukocytes being present.
1.4 Cellular Signalling
Various signalling pathways in eukaryotic cells have been established. 
Classically, this includes G-protein receptor activation leading to diacylgycerol (DAG) 
and inositol 1,4,5-trisphosphate (Ins (1,4,5)P3) production, resulting in protein kinase 
C (PKC) activation and intracellular Ca2+ release (see figure 1.4). However, further 
investigation has shown a rich diversity of mechanisms exist in the signalling cascade.
1.4.1 NADPH oxidase - structure and assembly
As already indicated the respiratory burst is an important mechanism used by 
phagocytes (neutrophils, monocytes and eosinophils) in host defence on ingestion of 
microorganisms and by soluble stimuli. The biochemical basis for the respiratory burst 
is not accomplished by mitochondrial respiration, but by the NADPH (nicotinamide
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adenine dinucleotide phosphate - reduced form) oxidase (71). The enzyme is located 
in the plasma membrane with its NADPH binding site projecting into the cytosol and 
Oi molecules being released extracellularly (92). This location guarantees optimum 
delivery of oxidants onto phagocytosed microorganisms.
Much of the work on NADPH oxidase has been ascertained from patients with 
chronic granulomatous disease (CGD) in which there is a defect in the NADPH oxidase 
or its activating apparatus (93). NADPH oxidase complex is made up of several 
components that have been characterised over the last few years (see figure 1.5). 
Cytosolic NADPH acts as the electron donor and oxygen acts as the acceptor (see 
equation 1.1). The complex is dissociated in resting neutrophils and its components 
are located in both the membrane and the cytosol. Upon activation the complex 
consists of at least six components. An NADPH dehydrogenase transfers the electrons 
from NADPH to the haem as the prosthetic group in the oxidase system. This was 
thought to be a 45kDa membrane-bound flavoprotein. This was inhibited by 36% 
using the inhibitor diphenylene iodonium (DPI) at a 1:1 stoichiometry (94). This has 
since been questioned as cytochrome b is also said to be a target for DPI. Cytochrome 
b accepts the single electron and donates to oxygen at the external face of the plasma 
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F igure 1.4 Activation of the signalling pathways via receptor coupling to PLC and 
PLD in neutrophils. Adapted from Garland, L.G. 1992. FEMS Microbiol. Immunol. 
105:229-238
The interaction o f NADPH with the oxidase appears to be Mg2+-dependent since O2 
formation is inhibited by the metal-complexing agents EGTA and EDTA in proportion 
to their Mg2+ affinity. EDTA prevents the reduction o f the FAD component o f the 
oxidase by NADPH (94).
Introduction 20
1.4.1.1 Plasma membrane components
Cytochrome b is the main membrane-associated component which has been 
characterised as having a peak of absorbance in the reduced state at 558nm and a low 
midpoint potential of -245mV (95). It is known as either cytochrome b558 or 
cytochrome b.245. The cytochrome is a heterodimer consisting of a small a-subunit of 
22-23kDa (p22phax, phox indicates phagocyte oxidase) which carries the haem and is 
reported to be the terminal component of the respiratory-burst electron system (92), 
and a large p-subunit of 76-92kDa (gp9P/K“) that is highly glycosylated. Other plasma 
membrane components include Rap-1 a small GTP-binding protein of 21-22kDa has 
been found to associate with the heterodimeric cytochrome b558.
1.4.1.2  Cytosolic components - p47phox and p67phox
Again using studies from patients with CGD who have a genetically defective 
oxidase that is incapable of generating significant amounts of 0 2 and H20 2 it was 
elucidated by variants of the disease, two distinct cytosolic proteins of 47-48kDa and 
54-67kDa named p47pAOT and p67phax were required for normal function of the NADPH 
oxidase complex (96,97). p47phax takes up phosphate when neutrophils are activated 
and lose it again when cells are returned to the resting state. Phosphorylation of 
isolated p47phax has been observed in the presence of purified PKC suggesting p47pfwx 
is a direct substrate for PKC. p47phax shows a number of potential phosphorylation sites 
characterised by serine residues flanked by arginine residues clustered within highly 
basic carboxyl-terminal of the protein (98).
Other cytosolic components involved in the NADPH oxidase have been
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identified as members of a ray-related superfamily. Rac-1 and rac-2 that have a 
molecular weight of 22kDa are GTP-binding proteins. This implies that rac regulatory 
proteins such as GTPase-activating protein, GDP dissociation inhibitors and GDP/GTP 
dissociation stimulators will also be important in controlling the activity of the NADPH 
oxidase system.
Similar results on the NADPH oxidase complex have been obtained using 
HL-60 cells differentiated to granulocytic cells (99), where upon differentiation 
towards eosinophils leads to increase in cytochrome b558 in the membrane and thus 
superoxide generation. Results indicate the amount of oxidase activity is dependent 
on the amount of cytochrome b558 in the membrane and the level of the translocated 
cytosolic factors on the membrane. A schematic diagram of the NADPH oxidase is 













Figure 1.5 Schematic diagram o f the NADPH oxidase complex in neutrophils
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1.4.2 Role of intracellular and extracellular cations on cellular 
function
Cells must regulate ion concentrations, which means transporting specific ions 
into or out of the cell. The selective permeability of biological membranes to simple 
ions creates large differences in the ionic composition of the cell interior compared to 
the extracellular fluid. For example the total intracellular calcium concentration in a 
typical mammalian cell for calium and magnesium is l-2m M  (0.1/xM is free) and 
30mM respectively whereas the extracellular concentrations for these ions are 2.5-5mM  
and l-2m M (100). This enables cell membranes to store potential energy in the form 
of ion gradients. Transmembrane ion gradients are used to make ATP, to drive various 
transport processes and to convey electrical signals (100).
Calcium has a very dynamic role in cell signalling both inside and outside the 
cell and is present in all eukaryotic cells. An increase in [Ca2+]j can trigger 
contraction, cellular proliferation, secretion, metabolic adjustments and changes in gene 
expression. Two basic mechanisms by which the cell may increase its [Ca2+]j exist. 
Firstly via release of Ca2+ from its intracellular store such as the endoplasmic reticulum 
(ER) or secondly via the transport of ions across the lipid bilayer (which is achieved 
by specific transmembrane proteins) either using voltage operated (VOCC) and/or 
receptor operated calcium ion channels (ROCC). The Ca2+ ATPase in internal 
membranes or the Ca2+ ATPase and Na2+/Ca2+ exchanger in the plasma membrane 
terminate the Ca2+ signal by moving Ca2+ into the internal stores or the extracellular 
fluid respectively (101). In non-muscle cells, a Ca2+-storage organelle consists of three 
components. 1) a Ca2+pump (slow-type Ca2+-ATPase; mw. lOOkDa); 2) a Ca2+- 
storage protein (eg. calreticulin and possibly endoplasmin) which acts as a Ca2+ buffer
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in the lumen of the Ca2+-storage organelles. They reduce the lumen/cytosol Ca2+ 
gradient and diminish the risk of precipitation. Also they may be actively involved in 
the regulation of Ca2+ release; and 3) a Ca2+-release channel known as the 
Ins(l,4,5)P3-sensitive Ca2+ release channel (the Ins(l,4,5)P3 receptor) which releases 
Ca2+ during cellular activation (102). The changes in the calcium concentrations can 
be accurately measured using fluorescent dyes such as fura-2 (103) and fluo-3 (104) 
to evaluate the physiological role of cytosolic free Ca2+.
[Ca2+]i has been shown to change in eosinophils during chemotaxis. 
Experiments have shown that cells moving in one direction had a high level of [Ca2+]j 
at the rear of the cell and low levels of [Ca2+]j at the front of the cell suggesting a role 
in organization and local activity of cytoskeletal proteins (105) however another group 
has shown eosinophils depleted of Ca2+ appeared to still undergo shape change (106).
Evidence also suggests a role exists for [Ca2+]j in 0 2 formation, as blocking 
[Ca2+]i mobilization or depleting the [Ca2+]j prevents O2 generation from being 
produced (107). However, this rise in [Ca2+]j that precedes 0 2 generation in 
neutrophils is not sufficient to activate the respiratory burst unless the cells have been 
previously primed (108-110).
The first stage in eosinophil recruitment is the adhesion to the endothelial cells 
via various selectins and integrins. The amino acid sequence of the integrin aM 
(C D llb ) derived from cDNA predicts three divalent cation binding sites (111) and this 
requirement for Ca2+ and Mg2+ probably reflects stabilization of a conformation of the 
molecule necessary for ligand binding. Removal of extracellular Ca2+ in neutrophils 
affects the role of Mac-1 with regard to phagocytosis but not adhesion (112). In
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neutrophils, substitution of extracellular Ca2+ and Mg2+ with Mn2+ increased their 
adhesion, as Mn2+ alters the affinity of integrins for their ligands (113). Further 
investigations to study the role of divalent cations have shown neutrophil adhesion to 
depend on magnesium but not calcium (114). The role of divalent cations in functional 
responses has also been partly characterised in eosinophils.
Guinea pig eosinophils have been shown to require extracellular Mg2+ for PAF 
induced 0 2 production (107). Indeed as already noted in section 1.4.1 Mg2+ is 
involved in the NADPH oxidase complex (situated in the plasma membrane) (94) 
possibly at the level of the G-protein (115).
The external cations are also important in producing a localised signals. For 
example, to maintain a sustained elevation of [Ca2+]i5 replenish [Ca2+L extruded from 
the cell or regulate [Ca2+]j oscillations (116). Mn2+ can be used as an indicator of 
divalent cationic influx as fura-2 has a high affinity for Mn2+and its fluorescence is 
quenched by Mn2+. Two general classes of agents have been employed to block 
voltage-dependent Ca2+ entry. These include a diverse range of organic compounds 
for example nifedipine, diltiazem and verapamil. These were identified for their potent 
pharmacological actions rather than specific antagonists of L-type VOCC's. Also 
known to block Ca2+ currents are the divalent and trivalent cations including N i2+, 
Co2+, Cd2+ and La3+. These inorganic ions also block ROCC's (117). Another group 
of compounds, the imidazoles, are also potent inhibitors of divalent calcium uptake. 
These include econazole, miconazole and SK&F 96365 (120). The selectivity of these 
compounds for ROCC’s over internal release does not translate to a selectivity between 
ROCC’s and VOCC's (117). Influx of Ca2+ has been detected in platelets (119),
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lymphocytes (120) and neutrophils, where experiments show agonist-induced Ca2+ 
influx is secondary to the emptying of the intracellular stores which in turn activates 
the plasma-membrane Ca2+ channels by a mechanism involving microsomal P-450, 
(121).
1.4.4 Protein kinases
Protein phosphorylation of a selected protein either increases or decreases its 
functional activity. A protein kinase catalyses the transfer of phosphate from a 
nucleotide (usually ATP) to a substrate protein. The activity of this substrate protein 
is thus modulated by a conformational change effected by the highly charged 
phosphate. The protein kinases that catalyse this reaction recognize the substrate as a 
specific protein or proteins and transfer the phosphate to the hydroxyl group of the 
serine, threonine or tyrosine residues.
1.4.4.1 Protein kinase C
Protein kinase C (PKC) acts by phosphorylating selected free hydroxyl groups
on the amino acid side chain of either serine or threonine residues. The regulatory
enzyme, PKC has been established to have a wide variety of roles on cellular 
processes. These include effects in the endocrine systems, exocrine systems, nervous 
systems, muscular systems, inflammation and immune systems and in metabolic 
systems ranging from signal transduction to tumour promotion (122). PKC is activated 
by the receptor-mediated hydrolysis of inositol phospholipids, and relays information 
in the form of a variety of extracellular signals across the membrane to regulate many
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Ca2+ dependent processes. Frequently a positive signal is followed by a negative 
feedback regulation. PKC was identified as a proteolytically activated protein kinase 
in 1977 and is ubiquitous in tissues and organs. PKC requires Ca2+ and phospholipid 
for its activation, particularly phosphatidyl serine (124). DAG dramatically increases 
the affinity of this enzyme for Ca2+ and subsequently activates the enzyme without a 
net increase in the Ca2+ concentration (123). The activation of PKC is thought to be 
biochemically dependent on Ca2+, but under some conditions physiologically 
independent of Ca2+. As a consequence, phorbol esters have been widely used to try 
to establish the role of PKC in signal transduction. PKC has been studied extensively 
and ten different isoforms of PKC have been described. These include the 
conventional PKCs (cPKC) -a , -pj, -pn and -y which are Ca2+-dependent forms, the 
novel PKCs (nPKC) -5, -e, -rj, and -6 which are Ca2+-independent forms, and the 
atypical PKCs (aPKC) -C, and -X which are not activated by DAG or phorbol esters 
(125-127a).
In human neutrophils, protein kinase C translocates from the cytosol to the 
plasma membrane upon stimilation (127). This process is Ca2+-dependent and 
reversible. It is not known whether the kinase is truly cytosolic or rather localized in 
the periplasmic space in loose connection with the membrane (128). There are few 
studies of the different isoenzymes of PKC in eosinophils, but in neutrophils the a-, 
p- and C- but not y-isotypes have been revealed. The most abundent isoenzyme in 
neutrophils appears to be PKC-p which does translocate to the plasma membrane in 
the presence of Ca2+ (129). Several reports have implicated a role for PKC in the 
respiratory burst in neutrophils (130,131) and in eosinophils (75). The cytosolic
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component of the NADPH oxidase, pAlphox (see figure 1.5), contains several 
recognition sites for PKC and becomes rapidly phosphorylated after receptor activation 
or phorbol esters (98,132). Ca2+-independent PKC isoenzymes in macrophages may 
also have a role in the activation of the NADPH oxidase (133).
1.4.4.2  PKC Inhibitors
To investigate the role of PKC in cells, various inhibitors are available. 
Classically, chlorpromazine, dibucaine and other phospholipid-interacting drugs 
including polymyxin B were used. These inhibited PKC by competing with the 
phospholipid with relatively low potency (134). Isoquinoline sulphonamides including 
H-7 and H-9 are more specific inhibitors of PKC with an Kt of 6pM  and 18/xM 
respectively (135). These act by competing with ATP for its binding site on PKC 
(136). Another PKC inhibitor trifluoperzine dihydrochloride, has an IC 50 value 7- 
10/iM in guinea pig eosinophils (75). To identify PKC in any mechanism inhibitors 
do not only have to be potent at low concentrations, but selective as well, especially 
if  inhibition of PKC might represent a target mechanism of therapeutic agents. 
Staurosporine, a microbial alkaloid, inhibits the proteolytically generated catalytic 
domain of PKC (137). Other members of the family include K252a (138) and UCN01 
(139). Staurosporine and its related compounds were found to be potent inhibitors of 
PKC with an IC50 value of 2-5nM (140). Because they inhibited by competing with 
ATP for the ATP co-substrate site common to all protein kinases, they had limited 
selectivity for PKC (139). Since the use of staurosporine was introduced, other PKC 
inhibitors have been produced. Calphostin C inhibits PKC with an IC 50 value of 50nM,
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but does not inhibit protein kinase A or the protein-tyrosine kinase (PTK) of pp60vjrc 
even at 50/*M (140,141). In addition, calphostin C does not inhibit the catalytic 
domain of PKC but appears to interact with the regulatory domain.
A series of potent selective inhibitors of PKC based on the structure of 
staurosporine have been produced. Though competing with ATP for the co-substrate 
site of PKC, the structural modifications of the compounds have demonstrated a 
selectivity for PKC over both protein kinase A and Ca2+/calmodulin dependent kinase 
(142).
1.4.5 Tyrosine phosphorylation
The vast majority of phosphorylations occur on serine. The discovery that the 
transforming gene of Rous sarcoma virus (src) encodes a protein kinase specific for 
tyrosine (143), initiated a whole new field of investigation to isolate other PTKs and 
their substrates (144). The PTKs can be divided into two groups, the transmembrane 
receptor family (including growth factors such as EGF and PDGF) and the cytosolic 
non-receptor family (including oncogene products such as pp60vjrc).
Phosphotyrosine can be detected using several techniques. These include: (1) 
radiolabelling proteins with 32P (either [32P]ATP in vitro or with 32P04 in vivo). The 
proteins are purified and subjected to partial acid hydrolysis, mixed with phosphoamino 
acid standards and resolved by one- or two-dimensional thin layer electrophorsis. 
Finally autoradiography allows comparisons between [32P]phosphoamino acid with the 
known standards (143); (2) Phosphotyrosine is known to be relatively resistant to the 
base hydrolysis compared to phosphothreonine and phosphoserine and this property has
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been exploited to analyse p-Tyr-containing proteins by SDS-PAGE. The gel is then 
soaked in base (KOH) and subjected to autoradiography (145); and (3) Anti- 
phosphotyrosine antibodies have been used in conjunction with immunoblotting.
1.4.5.1 Possible roles of tyrosine kinase in cellular signalling
One hypothesis for the mechanism of action of the PTKs, is the transmission 
of a signal to another class of proteins - the serine/threonine kinases. Early studies on 
the effects of PTK activation noted a parallel activation of serine/threonine kinases. 
Several such tyrosine-phosphorylated kinases have now been identified. These include 
the CDC2 protein (146), MAP kinase (147) and possibly ra/kinase (148).
Several proteins have been shown to possess an amino acid sequence similar to 
already defined regions of the non-receptor PTK family known as SH2 and SH3 
domains (SH =  src homology regions). The SH2 domains are known to mediate direct 
interaction between the SH2-containing protein and phosphotyrosine, with some 
specificity observed in the amino acid sequence surrounding the phosphorylated 
tyrosine. One model for the mechanism of action of growth factor receptors that 
emerges is that upon ligand binding the PTK domain is activated or inactivated leading 
to autophoshorylation and association with SH2-containing proteins. The SH2- 
containing proteins then become tyrosine phosphorylated and activated in their own 
signal transduction pathway. This model suggests that the PTK substrate specificity 
resides at a site distant from the actual tyrosine phosphorylation site (144). These SH2 
proteins include phospholipase CY (149), GTPase activating protein (144), and 
phosphatidyl inositol 3-kinase (PI 3-kinase) (150).
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Several membrane proteins involved with communication are also tyrosine 
phosphorylated. These include connexin-43 (151), the nicotinic acetylcholine receptor 
(152), the T-cell antigen receptor (153), caveolin (154), coated pits (155) and cAMP 
phosphodiesterase (156).
Tyrosine phosphorylation also occurs in cytoskeletal proteins including the focal 
contact proteins such as vinculin (157), paxillin (158), tensin (159), talin (160) and 
integrins (161) and other cytoskeletal tyrosine phosphorylated proteins such as annexin 
I  (162), annexin II (163) and ezrin (164).
Finally there are a few other proteins that are tyrosine phosphorylated which do 
not belong to any particular group but may be just as important (144).
1.4.5.2  Tyrosine phosphorylation and effect on neutrophil 
function
No protein tyrosine phosphorylation had been established in eosinophils at the 
start of this project. The typical amount of tyrosine phosphorylated proteins present 
in well characterised cells is no more than 0.5-2% of the total protein content (eg. 
platelets (210)), thus the elucidation of the role that PTKs play in eosinophils is 
impeded by the low number of eosinophils that are available.
A rapid increase in the phosphotyrosine content of several proteins has been 
observed in neutrophils after stimulation with chemotactic agonists (77,165-167), but 
the mechanism of tyrosine kinase activation in these cells is still poorly understood. 
It is also apparent that the seven transmembrane-segment receptors lack tyrosine kinase 
domains and there is no indication that they associate with PTKs (168). A member of 
the src family p55°^r is expressed in neutrophils. It is translocated on activation from
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the granules to the plasma membrane and may be involved in agonist-induced 
exocytosis (169). The cytosolic components of the NADPH oxidase, p47/*te* and 
p67phac contain the src homology domains SH2 and SH3 (which are known to mediate 
the phosphotyrosine-dependent association of cytosolic and membrane proteins) 
(98,170), however, phosphoamino acid analysis reveals no tyrosine phosphorylation 
of the components of the NADPH oxidase, suggesting that its assembly and activation 
do not depend on PTKs (171).
1.4.5.3  Tyrosine kinase inhibitors
As already noted, protein-tyrosine phosphorylation has the potential to initiate 
many signal transduction mechanisms, therefore as with PKC, potent and specific 
inhibitors of TK may provide useful means to identify the role of tyrosine 
phosphorylation in a variety of cellular events.
Erbstatin is produced by Streptomyces MH435-hF3. Erbstatin inhibits EGF receptor- 
associated tyrosine kinase, but does not appear to inhibit purified rabbit brain PKC and 
weakly inhibits protein kinase A and phosphatidyl inositol kinase. From inhibition 
studies, erbstatin competes with the peptide substrate. Erbstatin is easily inactivated 
in serum and more stable analogues have been produced. The only stable analogue to 
date is methyl 2,5-dihydroxy cinnamate. This analogue inhibits tyrosine kinase in vitro 
but is not expected to be active in vivo, because it is a polar molecule and would 
penetrate the cells poorly (172).
Genistein is produced by Pseudomonas (173). Genistein has been shown to 
inhibit EGF receptor and pp60VnJ7r in vitro and the EGF receptor in vivo, but poorly the
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activity of the serine and threonine kinases such as cAMP-dependent protein kinase 
(174). Genistein, unlike erbstatin is a competitive inhibitor with respect to ATP. 
However, genistein is noncompetitive with the phosphate acceptor as it bears no 
structural relationship to ATP, so inhibition may occur by genistein binding in multiple 
places in the reaction pathway (173). Genistein does not appear to be completely 
selective as it has reported to inhibit p-galactosidase (175), DNA topoisomerases n  and 
I  (176) and S6 kinase activity (177).
Herbimycin A is produced by Streptomyces (MH237-CF8) and was found to 
inactivate v-src, in particular pp60vjrc in vitro. In addition to src, herbimycin A is 
effective against the tyrosine kinase oncogenes yes, fps, ros, abl and erbB, but not ras, 
rrrys and the serine/threonine kinase raf. The effects of herbimycin A on cAMP- 
dependent kinase and PKC were also negative. Herbimycin A binds to active SH 
group(s), which are not essential for kinase activity. However, binding of the bulky 
compound is thought to restrict access of the ATP molecule (178).
Tyrphostins are synthetic copolymers of amino acids which contain tyrosine 
residues, but are devoid of serine and threonine. They have been shown to inhibit 
protein-tyrosine kinases (PTKs) both in vitro and in vivo (179). They act by binding 
ATP and thus prevent the activation of TKs (competitive inhibitor). Depending on 
their structure, tyrphostins can have either a broad or restricited specificity for the Tks.
1.4.6 Role of PI 3-kinase in signalling pathways
As indicated in section 1.4.5.1, tyrosine kinases can activate various pathways, 
each leading to highly specific responses. PI 3-kinase is involved in just one of these
Introduction 34
pathways. Phosphatidyl inositol is a unique phospholipid that can be modified by 
phosphorylation at any of the five hydroxyls on the inositol ring. Phosphorylation at 
different positions on the inositol ring provides a means for generating a wide variety 
of second messenger signalling molecules (180). PI 3-kinase is a heterodimer with an 
85kDa regulatory subunit, which binds to tyrosine phosphorylated proteins via either 
of its two SH2 domains, and a llOkDa catalytic subunit, with dual specificity 
possessing both lipid and serine kinase activities.
PI 3-kinase, acts on phosphatidylinositol, phosphatidylinositol 4-phosphate, and 
phosphatidylinositol 4,5-bisphosphate to produce phosphatidylinositol 3-phosphate, 
phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate 
respectively (181).
PI 3-kinase activity has been found to be associated with PTK activity more 
frequently than any other intracellular signalling molecule and thus PI 3-kinase is 
important for intracellular signals initiated by PTKs.
Phosphatidylinositol 4,5-bisphosphate is a substrate for phospholipase CY leading to the 
production of the second messenger signalling molecules inositol 1,4,5-trisphosphate 
and DAG. However this does not appear to be the case for phosphatidylinositol 3,4,5- 
trisphosphate which maybe a second messenger itself. A possible target in vitro for 
phosphatidylinositol 3,4,5-trisphosphate is the Ca2+- and phorbol ester-independent 
PKC-C (182).
Wortmannin, a fungal metabolite inhibits many cellular functions at micromolar 
concentrations. However, at low nanomolar concentrations wortmannin specifically 
inhibits PI 3-kinase by binding to the catalytic subunit. It has been shown to
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successfully inhibit the respiratory burst in neutrophils (183), but not eosinophils.
1.5 Eosinophilic cell lines
As already indicated, the number of eosinophils present in normal subjects is 
low (approximately 2-5%). The number can be greatly increased in allergic or 
parasitic patients though these cells are more likely to be primed or activated. 
Therefore, obtaining large quantities of normal cells is very difficult. The advent of 
eosinophil cell lines has produced an alternate source of human eosinophils. These not 
only allow the study of functional responses to added agonists, but yield information 
on eosinophil differentiation and maturation. The HL-60 promyelocytic leukaemia line 
can be differentiated to the eosinophil subline in alkaline medium and subsequently 
cultured in the presence of sodium butyrate (184). A more specific cell line (Eol) has 
since been established.
1.5.1 Eol-1 and Eol-3 eosinophilic cell lines
Satio et al (185) established the first eosinophilic leukaemia cell line from the 
peripheral blood of a 33-year old French man with Philadelphia chromosome-negative 
eosinophilic leukaemia. Clinical examination in 1978 showed no abnormal findings 
except hypereosinophilia with 55% of the white blood cells (14.8xl03cells//d) being 
eosinophils. In 1984 the white blood cell count rose to lb^xK^cells/z-il with 
eosinophils at 43 % and blasts 54 %. Peripheral blood was obtained and the blast-rich 
population was purified and cultured in supplemented media. The patient was then 
treated with chemotherapy, unfortunately no remission could be obtained and the
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patient died. Three clones with eosinophilic features were observed out of the six 
clones obtained and designated Eol-1, Eol-2 and Eol-3. Most of the Eol cells had a 
blastic appearance without cytoplasmic granules and were morphologically similar to 
myeloblasts or monoblasts. However a small percentage (2%) contained granules 
similar to eosinophilic granules. Eol-1 and Eol-3 appeared to be the dominant clones 
during evolution and when differentiated under various conditions matured into 
eosinophils. HL-60 cells however have the ability to mature to either eosinophils or 
neutrophils depending on the extracellular conditions. It thus seems that the Eol blasts 
are committed to the eosinophil lineage.
The most common maturation agent used with Eols is some form of butyrate. 
For example Saito et al used butyric acid (0.5mM) on Eol-Is for 4-7 days (186). In 
addition soluble factors are also thought to promote eosinophil maturation such as a 
derived factor from the human adult T-cell leukemia line H IL-3 or G-CSF/TNFa(187) 
and TN Fa/IFN y (188). IL-3, GM-CSF and IL-5 with butyric acid were able to 
enhance eosinophilic differentiation (186).
1.5.2 Advantages and disadvantages of the eosinophilic cell 
lines
The Eol-1 and Eol-3 eosinophilic cell lines are derived from a human source 
and if some fully matured cells can be obtained, very accurate in vitro experiments can 
be performed to elucidate structural and functional information. The cells can be 
grown very rapidly to produce large numbers allowing greater experimentation. 
However, the eosinophilic cell lines very rarely differentiated to mature eosinophil 
leukocytes. They are usually still someway removed from the final state of the cell.
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This implies receptors may not be fully expressed and the molecular mechanisms may 
not be fully operational. In addition down-regulation or shedding of some receptors 
may not have occurred, giving the cell properties that would not be present in the 
matured cell. No in vivo experiments are possible.
Various animal models of eosinophilia exist. These include mouse, rat, guinea 
pig, rabbit, dog, sheep and monkey. These have been used to establish eosinopoiesis, 
tissue distribution of the eosinophils and the effects eosinophils have at the site of 
inflammation. Like the cell lines, problems exist with all the animal models. They 
have a degree of variation between species including the number of eosinophils in 
normals, the proportions of the cellular proteins they contain, the different mediators 
to which they react and mediators that are consequently produced. Eosinophils that are 
elicited in animals for in vitro experiments may already be preactivated. Hence though 
the cell lines are not ideal, they will help further the understanding of the eosinophil.
1.6 Selection of assays
To analyse the different functions of eosinophils, three key assays were adapted, 
namely the hydrogen peroxide assay, rose bengal adhesion assay, and measurement of 
intracellular free calcium elevation.
Many documented studies measure the superoxide produced from granulocytes 
(in suspension) via a spectrophotometric assay as the superoxide dismutates (SOD) 
inhibitable reduction of cytochrome c described by Yamashita (189). The experiments 
described in this study were to be carried out in microtitre plates coated with an 
appropriate matrix protein to try and mimic in vivo conditions; as demonstrated in
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asthma and other inflammatory processes (190-194). The H20 2 assay introduced by 
Andreae in 1955 (195), is based on the horseradish peroxidase-catalysed oxidation of 
fluorescent scopoletin by H20 2. It has been used successfully by other researchers to 
measure the release of H20 2 from human neutrophils (196) and macrophages (197). 
This assay was more sensitive and gave a greater window of detection than the 
cytochrome c assay. The rose bengal adhesion assay (198) was chosen as a simple way 
of determining the number of cells adhered to the plate. It was convenient to measure 
this parameter after the H20 2 assay rather than carrying out a separate assay just to 
measure adhesion. The rose bengal stain (which is taken up by the cells) was more 
appropriate than a product that measures protein eg. Bradford’s reagent, as this would 
measure the protein used to coat the plate as well.
Calcium appears to be important in many of the cellular signalling pathways. 
To establish the extent that Ca2+ has in a particular process requires a method that 
quantitates it accurately. One of the first fluorescent dyes developed was quin-2 (199). 
This has many limitations. Due to the fluorescent properties of the dye, significant 
autofluorescence from the cells occurs causing possible biological side effects; to 
overcome this autofluorescence, high loadings of quin-2 are necessary, however, this 
significantly buffers the [Ca2+]j transients. Quin-2 signals calcium by increasing its 
fluorescent intensity without much shift in excitation and emission, this gives inaccurate 
results as the fluorescence is dependent on many other factors that are not quantified
(103). Also, quin-2 binds other divalent cations such as Mg2+. The fluorescent dye 
fura-2 has now been developed. This is 30-fold brighter in fluorescence, it also 
changes in wavelength upon Ca2+ binding, has a slightly lower affinity for Ca2+, has
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a slightly longer wavelength of excitation, and is considerably more selective for 
Ca2+over divalent cations. In addition, as fura-2 operates with a dual excitation and 
single emission the loading is not a crucial factor between different cell preparations
(103). Fura-2 was used for all experiments except when tyrosine kinase inhibitors were 
used. These interfered with the fluorescent properties and thus fluo-3 was utilised
(104).
1.7 Eosinophils and their role in disease
The role of the eosinophil is implicated in a variety of respiratory diseases 
including asthma. Asthma is a disease characterized by the reversible obstruction of 
the airways or bronchi. This is accompanied by nonspecific bronchial 
hyperresponsiveness, which is the tendency of the bronchi in asthmatics to constrict in 
response to a wide variety of irritant and pharmacological stimuli. It is now widely 
accepted that chronic inflammation of the bronchial mucosal lining plays a fundamental 
role in the genesis of these clinical manifestations (200).
The asthmatic response occurs in two stages, the early and late phase. Initially, 
the Fc region of the IgE molecule binds with high affinity to specific receptor proteins 
on the surface of mast cells in tissues (and basophilic leukocytes in the blood). Bound 
IgE molecules in turn serve as receptors for antigen. Antigen binding to the IgE 
molecule then triggers the mast cell to secrete a variety of biologically active products. 
The early asthmatic reaction results from the release of histamine, prostaglandin D2 
(PGD2) and leukotreine C4 (LTC4) from IgE-mediated bronchial mast cell 
degranulation. The spasmogenic effects of histamine account for much of the onset of
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bronchoconstriction, while PGD2 and LTC4 and their respective metabolites become 
increasingly important in maintaining the early response for up to two hours after the 
initial challenge (201). Mast cells are present in higher numbers and have a greater 
ability to release mediators in asthmatic subjects compared to normal subjects. The 
mechanism of the late asthmatic reaction is unknown, but it appears to involve T-cell 
activation and the selective recruitment of the eosinophil leukocytes. Patients who have 
a biphasic asthmatic response following allergen challenge, seem to have a more 
serious type of bronchial asthma (201). Therefore, the late asthmatic reaction may 
induce an increase in bronchial hyperreactivity.
1.7.1 Role of eosinophils in asthma - clinical evidence
Initially, the presence of eosinophils were considered as modifiers of 
inflammation, but the fact that they are: (1) present in increased numbers in the 
circulation (9), bronchial secretions (202) and the lung parenchyma itself; (2) capable 
of generating substances that can cause injury to the lung and are directly toxic; (3) 
increased quantities of these toxic mediators are detected in the lung, eg. observed as 
Charcot-Leydon crystals that represent the crystaloid form of the enzyme lysolecithase 
from degenerated eosinophils (203), and (4) reducing the numbers of the eosinophils 
leads to the improvement of the clinical symptoms of asthma (204), the eosinophil is 
now considered to be a proinflammatory cell.
The understanding of the role the eosinophil plays in asthma and inflammatory 
diseases has increased rapidly. In addition, the understanding of signalling mechanisms 
in different cell types has moved on immensely. Various new approaches are currently
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under investigation ranging from selective phosphodiesterase isoenzyme inhibitors to 
5-lipoxygenase inhibitors, specific PAF and leukotriene antagonists to more specific 
muscarinic receptor antagonists. The pursuit of a drug that is easily administered to 
the site of action, highly specific, non-toxic and which reverses existing symptoms/ 
conditions is the ultimate goal.
1.8 Aims of this project
The aim of this study was to characterise the relationship between activation of 
transduction mechanisms and functional responses in eosinophils. Specifically the 
functional responses investigated were H20 2 production, cellular adhesion and 
elevations in free calcium in guinea pig eosinophils, human eosinophils and the 
eosinophilic cell lines Eol-l/Eol-3 induced by soluble stimuli implicated in the allergic 
response. The effect of the extracellular cationic conditions and the role of calcium 
influx using manganese, nickel and the ROCC blocker, SK&F 96365 were also 
investigated. Finally, the role of protein kinase C, protein-tyrosine kinases and PI 3- 
kinase were investigated using the selective inhibitors Ro 31-8220/002 (142), 
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2.1 Materials
2-mercaptoethanol BDH Laboratory Supplies, Lutterworth, UK
Aluminium hydroxide BDH Laboratory Supplies, Lutterworth, UK
Ammonium persulphate Sigma Chemical Co., Poole, UK
Antiphosphotyrosine PY20 antibody
ICN Biomedicals Ltd, Thame, UK
Antiphosphotyrosine 4G10 antibody
TCS Biologicals Ltd, Buckingham, UK 
Bovine serum albumin-low endotoxin
Sigma Chemical Co., Poole, UK  
Sigma Chemical Co., Poole, UK 
Sigma Chemical Co., Poole, UK 
Fisons Pharmaceuticals, Loughborough, UK 
BOC Ltd, Guilford, UK 
Eurogenetics UK, Teddington, UK 







Chromatography filter paper 3mm
Whatman Labsales Ltd, Maidstone, UK
Sigma Chemical Co., Poole, UK
Sigma Chemical Co., Poole, UK
Sigma Chemical Co., Poole, UK
BDH Laboratory Supplies, Lutterworth, UK
Sigma Chemical Co., Poole, UK
University of Bath, UK
Amersham International Pic, Little Chalfont, UK 
Sigma Chemical Co., Poole, UK 
Sigma Chemical Co., Poole, UK 
Gift-Bayer UK, Slough, UK 
Calibiochem-Novabiochem Ltd, Nottingham, UK 
Fisons Pharmaceuticals, Loughborough, UK 
Rhone Merieux, Dublin, Ireland 
Pharmacia Biotech Ltd, St. Albans, UK 
















Falcon 250ml culture flasks-vented
Fahrenheit Laboratory Supplies Ltd, Bristol, UK 
Falcon 96 U-bottomed/flat-bottomed flexiplates
Fahrenheit Laboratory Supplies Ltd, Bristol, UK 
Fahrenheit Laboratory Supplies Ltd, Bristol, UK 
Sigma Chemical Co., Poole, UK 
Gibco Life Technologies Ltd, Paisley, UK 
Gibco Life Technologies Ltd, Paisley, UK 
Molecular Probes Inc., Eugene. USA 
Molecular Probes Inc., Eugene. USA 
Fisons Pharmaceuticals, Loughborough, UK 
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Genistein Gibco Life Technologies Ltd, Paisley, UK
Gentamycin Gibco Life Technologies Ltd, Paisley, UK
Glycerol Fisons Pharmaceuticals, Loughborough, UK
Goat anti-mouse IgG horseradish peroxidase conjugate
Bio-Rad Laboratories, Hemel Hempstead, UK 
Hanks' balanced salt solutions without phenol red
Gibco Life Technologies Ltd, Paisley, UK 





Human interleukin 5 
Human RANTES 
Human complement 5a 
Human interleukin 8
Gibco Life Technologies Ltd, Paisley, UK 
Gibco Life Technologies Ltd, Paisley, UK 
CP Pharmaceuticals Ltd, Wrexham,UK 
Gibco Life Technologies Ltd, Paisley, UK 
Sigma Chemical Co., Poole, UK 
Gift-Glaxo, Stevenage, UK 
Gift-Glaxo, Stevenage, UK 
Sigma Chemical Co., Poole, UK 
Gift-Glaxo, Stevenage, UK
Human granulocyte macrophage-colony stimulating factor
Gift-Glaxo, Stevenage, UK 
Human monocyte inflammatory protein-la
Preprotech, London, UK 





Fisons Pharmaceuticals, Loughborough, UK 









Marvel Non-fat milk 
Methanol-SLR 
Mouse IgG-whole 







Millipore (UK) Ltd, Watford, UK
Gift-Glaxo, Stevenage, UK
Gibco Life Technologies Ltd, Paisley, UK
Sigma Chemical Co., Poole, UK
Gift-Bayer UK, Slough, UK
Vestric Hospital Service, Bristol, UK
Eurogenetics UK, Teddington, UK
Fisons Pharmaceuticals, Loughborough, UK
Fisons Pharmaceuticals, Loughborough, UK
Premier Brands UK Ltd, Stafford, UK
Fisons Pharmaceuticals, Loughborough, UK
Sigma Chemical Co., Poole, UK
Gift-Glaxo, Stevenage, UK
Fisons Pharmaceuticals, Loughborough, UK
Sigma Chemical Co., Poole, UK
Gibco Life Technologies Ltd, Paisley, UK
Pharmacia Biotech Ltd, St. Albans, UK
Wellcome Research Laboratories,
Bechenham,UK
Sigma Chemical Co., Poole, UK




Platelet activating factor 
Ponceau S
Sigma Chemical Co., Poole, UK 
Sigma Chemical Co., Poole, UK 
Sigma Chemical Co., Poole, UK 
Bachem UK Ltd, Saffron Walden, UK 
Sigma Chemical Co., Poole, UK














Sterile distilled water 
Sterile saline (0.9% )
Sterile sodium bicarbonate (7.5%)
Sulphuric acid 
TEMED
Gibco Life Technologies Ltd, Paisley, UK
National diagonostics, Atlanta, USA
Gift-Dr Nixon, Roche, Wellingborough, UK
Sigma Chemical Co., Poole, UK
Gibco Life Technologies Ltd, Paisley, UK
Gift-Bayer UK, Slough, UK
The Dow Chemical Co., USA
Sigma Chemical Co., Poole, UK
Sigma Chemical Co., Poole, UK
Gift-Bayer UK, Slough, UK
Gift-Bayer UK, Slough, UK
Gift-Bayer UK, Slough, UK
Sigma Chemical Co., Poole, UK
Fisons Pharmaceuticals, Loughborough, UK
Steripak, Runcorn, UK
Steripak, Runcorn, UK
Gibco Life Technologies Ltd, Paisley, UK 
Fisons Pharmaceuticals, Loughborough, UK 
Sigma Chemical Co., Poole, UK
Terumo Insulin syringe-lml, 27G x D/2"
Prodotto Da, 3001 Leuren, Belgium 
Tris/glycine/0.1%SDS (lOX)-running buffer










Sigma Chemical Co., Poole, UK
Sigma Chemical Co., Poole, UK
Sigma Chemical Co., Poole, UK
Sigma Chemical Co., Poole, UK
Sigma Chemical Co., Poole, UK
Gift-Glaxo, Stevenage, UK
BDH Laboratory Supplies, Lutterworth, UK
Calibiochem-Novabiochem Ltd, Nottingham,
UK
Sigma Chemical Co., Poole, UK
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2.2 Production and isolation of guinea pig eosinophils
Peritoneal eosinophilia was elicited in guinea pigs as described by Litt (205). 
Dunkin-Hartley guinea pigs (450-600g, male and female), received a minimum of 
seven injections of horse serum (0.5ml, ip.) at 3-4 day intervals with the last injection 
a day before cell harvesting. Animals were killed by C 02 asphyxiation. Peritoneal 
cells were collected by lavage with 40ml of Hanks’ balanced salt solution (without 
Ca2+/M g2+) with BSA (w/v 0.1%) (HBSS) and EGTA (Im M ). The abdomen was 
gently massaged for 10-15seconds before the removal of fluid with a sterile plastic 
pastette. Cells were pelleted (400g, lOmin at 20°C) and the blood cells were removed 
by hypotonic lysis with ice cold sterile distilled water (0.5ml) and made up to 25ml 
with buffer. Cells were then resuspended at 5xl07cells/ml in Percoll (1.070g/l) with 
BSA (1% ). Lavaged cells were approximately 25% eosinophils and these were 
subsequently purified by centrifugation (1500g, 25 min at 20°C) on a discontinuous 
isotonic Percoll gradient with densities 1.070, 1.080, 1.085, 1.090 and 1.100g/l (10) 
made as detailed in table 2.1 below. One Percoll gradient was required for 1x10s 
leukocytes.
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1.100 2.0 4.0 1.03 8.0 2.06 12.0 3.09
1.090 3.0 4.8 2.19 10.29 4.68 15.09 6.87
1.085 2.0 3.13 1.88 6.26 3.76 9.39 5.64
1.080 2.0 2.84 2.16 5.68 4.32 8.52 6.48
1.070 2.0 2.27 2.73 4.54 5.46 6.81 8.19
+Light Percoll =  9 parts Percoll +  1 part 10XHBSS with Ca2+/Mg2+ pH 7.2-7.4 (store 
4°C). *1XHBSS = HBSS with Ca2+/M g2+ pH 1.2-1 A.
Figure 2.1 Schematic representation of Percoll gradients
1.070 + cells 2ml Macrophages/LymphocytesMacrophages>90%/Neutrophils
^108° 2ml Centrifuge
S' 1.085o 2ml -------------------- ► Neutrophils/Eosinophilso





Cells were removed sequentially and the eosinophils were removed at the 
1.090/1.100 g/1 density interface and washed once in HBSS with EGTA (Im M ) and 
then twice in HBSS. Approximately 2x l07 eosinophils/animal o f >90% purity as 
assessed by Leishman's stain and >99% viability determined by trypan blue exclusion
were isolated.
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2.2.1 Sensitization protocol for guinea pigs - bronchoalveolar 
eosinophils
Sensitiztion was performed as described by Watson et al (206). One day before 
primary sensitization, Dunkin-Hartley guniea pigs (400-600g, male and female) were 
injected with cyclophosphamide (lm g/kg, ip.) Animals were then sensitized by 
injection of ovalbumin (OA) (10/zg/animal, ip.) with pertussis vaccine (0.25ml) and 
aluminium hydroxide (1 mg/ml) as adjuvant, in a total volume of 1ml. Animals were 
boosted after 3 and 6 weeks with identical injections. Six to nine days later, conscious 
animals were restrained with snout in a plexiglass cone connected to a nebulizer. 
Animals were challenged by exposure to an aerosol of OA (10ml of 0.1% OA in 
physiological saline) or an aerosol of saline (10ml; sham-challenged) given over 1 
hour. A control group of animals that were sensitized but not challenged by aerosol 
was also performed.
Twenty-four hours after the above treatments, animals were sacrificed by a 
lethal overdose of Euthatal (lOOmg/kg, ip.). Lung cells were collected by 
bronchoaleveolar lavage (BAL) with 4 x saline/BSA (0.025%) (20ml). Eosinophils 
were then purified as described in section 2.2
2.3  Purification of human eosinophils
Human eosinophils were purified by a protocol slightly modified from that of 
Hansel et al (207). 100ml of heparinised blood (4U/ml) was collected from a variety
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of donors with informed consent. The whole blood was pelleted (1865g, 6min at 4°C) 
and the plasma was removed taking care not to disturb the leukocyte-rich layer at the 
interface. The red pellet was diluted to twice the original volume with RPMI 1640 
with pen/strep and then layered onto Ficoll (35/15, v/v, blood/Ficoll) and centrifuged 
(450g, 30min at 20°C-no break to slow down). The peripheral blood mononuclear 
cells were removed and the granulocyte rich pellet was made up to the original volume 
(100ml) with RPMI 1640/EDTA (5mM) and layered onto dextran/saline 6 % (1/1, 
v/v). This was allowed to sediment under gravity for least 1 hour. The granulocyte 
rich supernatent was then pelleted (350g, lOmin at 4°C). The contaminating 
erythrocytes were removed by hypotonic lysis with ice-cold sterile distilled water (1ml) 
for approximately 30seconds then diluted to a final volume of 50ml with RPMI 
1640/EDTA (5mM). The granulocytes were pelleted (200g, lOmin at 4°C) and 
resuspended to 2xl09cells/ml in RPMI 1640/EDTA (5mM)/FCS (2%). The cells were 
incubated with CD 16 microbeads 2x l08 granulocytes/100/xl (30-45min on ice).
The MACS column was prepared as follows. First the column (type C) was 
flushed with ethanol and then RPMI 1640/EDTA (5mM) making sure no air bubbles 
entered the column. Next a 21G xl1/2w needle with the tip removed with wire strippers 
but still in its plastic sheath was attached to the bottom of the column. Finally, the 
column was flushed through with RPMI 1640/EDTA (5mM)/FCS (2%) (30ml at 
4°C).
Next the granulocyte preparation was made up to 1ml with RPMI 1640/EDTA 
(5mM)/FCS (2%). This was added to the top of the column and allowed to run into 
the column. The granulocytes were left in the column for l-2min and then the column
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was flushed through with RPMI 1640/EDTA (5mM)/FCS (2%) (30ml at 4°C ). The 
CD 16 negative cell elutant was collected as the eosinophil granulocyte population.
The MACS column was regenerated as follows (maximum of 6 times). The 
column was removed from the magnetic field and flushed through with RPMI 
1640/EDTA (5mM)/FCS (2%) to remove the CD16 positive cells. Next the column 
was flushed through with RPMI 1640/EDTA (5mM) to remove any protein. The 
column was finally sterilised by flushing through ethanol. A ll the column openings 
were capped and then the column was stored upright at 4°C.
The eosinophils were pelleted (200g, lOmin at 4°C) and resuspended in HBSS. 
Approximately lx l0 7cells/100ml whole blood of >90%  purity as assessed by 
differential cell count using Leishman's stain and >99%  viability determined by trypan 
blue exclusion were isolated.
2.4  Culture of eosinophilic cell lines Eol-1 and Eol-3
The human eosinophil cell lines Eol-1 and Eol-3 were established from the 
peripheral blood of a patient with Philadelphia chromosome-negative leukaemia (185). 
Eol-ls and Eol-3s were a generous gift from Dr Mayumi, Kyoto University, Japan. 
The Eol’s were maintained in RPMI 1640 supplemented with antibiotics (penicillin- 
streptomycin 100U/ml-100^g/ml) and FCS (10%). Cells were split twice a week to 
a cell concentration SxKPcells/ml and cultured in vented culture flasks (500ml) at 37 °C 
and 5% C 0 2/95% air. Cell concentration increased to ~  1.5xl06cells/ml before 
splitting.
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2.4.1 Maturation of eosinophilic cell lines Eol-1 and Eol-3
Cells were matured using various methods to try and establish cells as true to 
eosinophilic granulocytes as possible. Routinely the final differentiation step used was 
some from of butyrate. Either dibutyryl cAMP (0.2mM) or butyric acid (0.4-0.5m M) 
was added to freshly fed Eol cells. Cells were left to mature in flasks for 3,4,7 or 10 
days without any additional feeding.
2.5 Measurement of hydrogen peroxide release
Hydrogen peroxide was determined by the oxidation of fluorescent scopoletin 
to a non fluorescent product at 37°C as previously described by Nathan (196). 96-well 
U-bottomed/flat-bottomed flexiplates were precoated with laminin (150/d/well, 
3/xg/ml) for an hour at 37°C. The plate was washed once with HBSS. To each well, 
cells (100/d at 2xl06 cells/ml) with calcium/ magnesium (1.5m M) were added. Then 
buffer (50/d) and reaction mixture (10/d) containing scopoletin (3.6nmol), horseradish 
peroxidase (10/tg), sodium azide (150nmol) and calcium/magnesium (20nmol) were 
also added. The plate was incubated at 37°C.
Stock solutions required for assay:
i) Scopoletin: 1.38mg/ml (7.2mM) in HBSS w/o BSA. 5mg
dissolved in DMSO (50/d). Made up to volume 
with HBSS. Stored at RT and protected from 
light.
ii) Horseradish peroxidase: 20.0mg/ml. Stored at -20°C in 300/d aliquots.
Materials sc Methods 52
iii) Sodium azide: 19.5mg/ml (300mM). Stored at RT.
iv) Calcium chloride: (200mM). Stored at -20°C in 1ml aliquots.








Test agonists (10/d) were added to start the reaction. The following agonists - 
PAF, C5a, LTB4, fMLP, LPS, PMA; human cytokines - IL-5, GM-CSF, IFNy, TNFa 
and human chemokines IL-8, NAP-2, MCP-1, MCP-3, M IP -la , M IP -lp  and 
RANTES were tested (lOpM-lOOnM).
H20 2 release was detected as a decrease in fluorescence (excitation 355nm and 
emission 460nm) using a Titertek II platereader (ICN Biomedicals). A time zero 
reading was taken immediately before addition of the test agent, and then every 5min 
for 30min and subsequently every 15min for a further 1-2 hours. Controls were also 
performed in the presence of catalase (3000U/ml) and in the absence of horseradish 
peroxidase. In each assay, agents were tested in replicates of 3-4.
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2.5,1 Calibration of H20 2 production
The amount of H20 2 was calibrated by adding known amounts of H20 2 to the 
reaction mixture. Two types of calibration curves were obtained.
type a) To blank wells containing buffer (150/d) and reaction mixture (10/zl), 
a range of H20 2 standards (10/d) (0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 nmols) were added. 
The standards were made up as follows:
i) 100/d H20 2 (30%) to 8.7ml of milli-Q distilled H20  (lOOmM H20 2).
ii) 100/d of lOOmM H20 2 to 9.9ml of milli-Q distilled H20  (Im M  H20 2).
iii) 50/d Im M  H20 2 to 950/d m illi-Q distilled H20  (50/zM or 0.5nmol/10/d) etc. 
Standards stored at 4°C and remade weekly.
type b) H20 2 standards (10/d) were also added to wells that contained
eosinophils (100/d), buffer (50/d) and reaction mixture (10/d). This produced an 
identical curve but with a vertical shift, due to the auto fluorescence of eosinophils
For each assay, if cells allowed, a type b standard curve was done. I f  however 
cells were limited, as was frequently the case for human eosinophils, a type a standard 
curve was performed and the whole curve was shifted by a factor determined by the 
difference in fluorescence of cells with vehicle control compared to no cells with Onmol
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To calculate the H20 2 produced by the samples, an exponential curve equation





Rearranging this equation and as Jto= 0  equation 2.4 becomes:
wherex =  nmol of H20 2 produced by the cells; y =  remaining fluorescence after the 
cells have released H20 2; y0, A and t are constants determined when fitting the standard 
curve. The spreadsheet Excel (version 5) was used to manipulate the data and calculate 
the H20 2 produced from the changes in fluorescence.
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2 .5 .2  The effect of PKC inhibitors
In order to determine the effects of protein kinase C (PKC), a specific PKC 
inhibitor, Ro 31-8220/002 (142) (Dr Nixon, Roche) was used. After addition of the 
cells to the microtitre plate, either vehicle or Ro 31-8220/002 (0.3-3/*M ) (50/xl) was 
incubated with the cells (20min at 37 °C) before monitoring H20 2 production in 
response to added agonist.
2 .5 .3  Extracellular divalent cations and calcium influx
experiments on H20 2 production
In order to determine the effects of extracellular divalent cations, H20 2 
experiments were performed in the presence of calcium/magnesium (Im M ), calcium 
only (Im M ), magnesium only (Im M ), the specific calcium chelator EGTA (Im M ) and 
the nonspecific chelator EDTA (Im M ). Also experiments were carried out in the 
presence of nickel/ calcium (Im M ).
To investigate the role of calcium influx, cells were incubated in the presence and 
absence of the receptor operated calcium channel (ROCC) inhibitor, SK&F 96365 (10- 
lO fyM ) (lOmin at 37°C).
2 .5 .4  The effect of tyrosine kinase inhibitors on H20 2 
production
To determine the role of tyrosine kinase on H20 2 production, cells were 
incubated (2-4 hours at 37°C) in the presence or absence of the specific tyrosine 
inhibitors, genistein, herbimycin A , erbstatin and tyrphostin A-47 (1-lOOfiM) before 
the addition of the agonist and monitoring of H20 2 production. Due to the fluorescent
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nature of these compounds, a standard calibration curve in the presence or absence of 
these tyrosine kinase inhibitors was also performed.
2.5.5  The effect of wortmannin on H20 2 production
To determine the role of phosphoinositol 3-kinase (PI 3-kinase) in eosinophil 
activation, cells were incubated (lOmin at 37°C) in the presence or absence of the PI 
3-kinase inhibitor, wortmannin (3-30nM) before monitoring H20 2 production (183).
2.5 .6  NADPH oxidase in H20 2 experiments
To determine that the H20 2 produced from eosinophils was via the NADPH  
oxidase complex cells were incubated (30min at 37°C in the presence or absence of the 
NADPH oxidase inhibitors diphenyleneiodonium (DPI) (10/*M) (94) and 4'-hydroxy- 
3'-methoxy-aceto-phenone (HMAP) (10/iM) (208). Due to the fluorescent nature of 
these compounds, a standard calibration curve in the presence or absence of these 
inhibitors was also performed.
2 .5 .7  Cytochrome c assay
In addition another experiment to confirm H20 2 production was produced from 
the superoxide ion (O ), experiments were performed to measure the superoxide release 
via the inhibition of cytochrome c reduction. 96-well flat bottomed flexiplates were 
precoated with laminin (100/d) (3/zg/ml for 1 hour at 37°C). The plate was washed 
with HBSS. To each well cytochrome c (50/d) (100/*M), test agents (50/d), 
superoxide dismutase (SOD) (lOOU/ml) or buffer (50/d) were added. The reaction
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was started by adding eosinophils (50/d) (4xl06cells/ml). The release of 0 2 was 
detected as an increase in absorbance (550nm) compared with agonist and SOD, using 
a microtitre platereader. In each assay agents were tested in quadruplicate.
2.6  Measurement of eosinophil adhesion
Non-adherent cells were removed after the H20 2 assay by washing the plate 
once with HBSS. Adhesion was measured as described by Gamble (198). Briefly, 
rose bengal (200/d) (2.5mg/ml in phosphate buffered saline (PBS)) was added. After 
5min the plate was gently washed three times with PBS. After removal of the PBS the 
remaining adherent cells were then lysed with ethanol/PBS (100/d) (v/v 1/1) for 
30min. The absorbance was measured in a microtitre platereader at an optical density 
of 540nm. Eosinophil adhesion was calibrated by staining lx l0 8eosinophils with 
excess rose bengal. These cells were washed seven times in PBS. The cells were 
resuspended at 2xl06cells/ml. The eosinophils were then lysed with an equal volume 
of ethanol/PBS for 30min. The lysed suspension was then diluted to represent different 
cell concentrations, plated-out (100/d/well) and the absorbance was measured as 
describe above. This resulted in a linear relationship:
y = A + Bx (2.6)
Rearranging this formula, equation 2.6 becomes:
where x =  number of cells adhered to the plate; y =  optical density of rose bengal dye
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from lysed eosinophils; A and B are constants determined by linear regression when 
fitting the standard curve. The spreadsheet Excel (version 5) was used to manipulate 
the data to calculate the total number of eosinophils adhered to the microtitre plate.
2.6.1 Microtitre coating protein in the H20 2/adhesion assay
Initially when setting up the H20 2 and adhesion assays, an investigation was 
needed to ascertain the best microtitre plate and which protein to coat the plate if 
necessary. The following plates were tested: Limbro Titertek plates (IC N  Biomedicals 
Ltd), Nunc ELISA plates (Gibco-Life Sciences) and Falcon flexiplates. First the 
proteins were quantified to establish the amount of protein present using Bradford's 
reagent (bovine serum albumin was used as a standard). The following proteins were 
assessed: bovine serum albumin (100ng/ml-20mg/ml), foetal calf serum (0.1-100%), 
fibrinogen (10/xg/ml-lOmg/ml), fibronectin (100ng/ml-100/*g/ml), gelatin (10/zg/ml- 
lOmg/ml) and laminin (10ng/ml-10fig/ml). Each protein (200/xl) was added to a 
Titertek plate. Next, Bradford’s reagent (50/xl) (Bio-rad) was added. After 5min the 
solutions were aspirated and the optical density was measured on a Titertek platereader 
at 620nm.
The following proteins were then subsequently used and assessed in the H20 2 
and adhesion assays: foetal calf serum (1-10%), fibrinogen (l-10m g/m l) and laminin 
(l-3^g/m l).
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2 .7  Measurements of intracellular free calcium ([Ca2+]j) 
elevation
Eosinophil or Eol [Ca2+]j was measured by monitoring the fluorescence of 
eosinophils loaded with the calcium indicators fura-2 or fluo-3 (103,104). Fura-2 was 
used for the majority of the experiments. Fluo-3 was used when the tyrosine kinase 
inhibitors interfered with the fluoresece of fura-2.
2.7.1 Fura-2 loaded cells
Purified cells (107 cells/ml) were loaded by incubation with fura-2 
acetoxymethyl ester (2.5juM) in HBSS (30min at 37°C), washed twice and resuspended 
at 106 cells/ml in HBSS, Im M  Mg2+ and 100/xM Ca2+. Aliquots (2ml) were dispensed 
into a quartz cuvette and the external calcium adjusted to Im M . The fluorescence 
signals of stirred aliquots were monitored at 37°C in a Deltascan fluorimeter (PTI 
Inc., NJ, USA) with a slit width of 5nm and dual excitation wavelengths of 340nm 
and 380nm and a single emission wavelength of 510nm before and up to 5min after the 
addition of test agents (20/x\). The [Ca2+]j was calculated using PTI software and the 
ratio method (103) after calibration of the signal in the presence of digitonin (12.5piM) 
and EDTA (lOmM) to obtain values of and respectively as shown in equation
2.8 below (where fura-2 Kd37oC =  2.24xlO*7M , X1 =  340nm, X2 ~  380nm and V=  1).
- (R-V.Rnit)  No bound (XJ
[Ca 21( = W37c.- ---------------- —  (2.8)
(V .R^-R) r n  bound
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Signal (Aj)
where Kd37oC =  dissociation constant for fura-2 at 37°C; R =   —  and
Signal (A2)
V =  viscosity coefficient.
A typical experiment is shown schematically in figure 2.2
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Figure 2.2 Schematic diagram of fluorimetery experiments
2.7 .2  Fluo-3 loaded cells
Purified cells (107cells/ml) were loaded by incubation with fluo-3 acetoxymethyl 
ester (5/jlM) in HBSS (45min at 37°C), washed twice and resuspended at 106cells/ml 
in HBSS with Mg2+ (Im M ) and Ca2+ (lOOpiM). Aliquots (2ml) were dispensed into 
a quartz cuvette and the external calcium adjusted to Im M . The fluorescence signals 
of stirred aliquots were monitored at 37 °C with a single excitation wavelength 506nm 
and a single emission wavelength of 526nm before and up to 5 min after the addition 
of test agents (20pi). The calcium concentration was again calculated using PTI
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software (fluo-3 Kd37°c =  4.0xl0'7M ). Photobleaching of fluo-3 occurred rapidly, 
therefore loaded cells were protected from light at all times.
2 .7 .3  The effect of the PKC Inhibitors, Ro 3 1 -8 2 2 0 /0 0 2
See section 2.5.2
2 .7 .4  Calcium influx experiments with nickel and manganese
Nickel and manganese could both be used to investigate the role of calcium 
influx. Aliquots (2ml) of fiira-2 loaded cells (106cells/ml) were dispensed into a quartz 
cuvette. The fluorescence signals were monitored as described in section 2.7.1. N iC l2 
(l-5m M ) was added after basal levels of [Ca2+]i had been established. 60 seconds after 
addition of nickel, the test agent (20/zl) was added and the signal was monitored.
Aliquots (2ml) of fura-2 loaded cells (106cells/ml) in HBSS, Mg2+ (Im M ) and 
Ca2+ (100/iM ) were briefly pelleted (500g, lOsecs) to remove any leaked fura-2 and 
resuspended in HBSS, Mg2+(lm M ) and Ca2+ (100/xM) and dispensed into a quartz 
cuvette. The fluorescence signals of stirred aliquots were monitored at 37 °C with dual 
excitation wavelengths 340nm and 360nm (fura-2 isobestic point) and a single emission 
wavelength of 510nm before and after addition of the test agent (20/xl). 60 seconds 
after addition of the test agent, MnCl2 (100-500jnM) was added and the signal was 
monitored for a further 2 min. Finally the total calcium influx was measured by the 
addition of ionomycin (10^M).
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2.7 .5  The effect of SK&F 96365
Aliquots (2ml) of fura-2 loaded cells (106cells/ml) were dispensed into a quartz 
cuvette. The fluorescence signals were monitored as described in section 2.7.1. 
SK&F 96395 (10-100/zM) or vehicle (H20 ) was added after basal levels of [C a2+]j had 
been established. Approximately 60 seconds post addition of SK&F 96365, test agents 
(20fj.\) were added and the signal monitored.
2 .7 .6  Tyrosine kinase experiments with the specific inhibitors 
genistein, herbimycin A , erbstatin and tyrphostin A -47
Due to the fluorescent nature of these compounds, first the effects of these 
tyrosine kinase inhibitors were investigated on free fura-2 acid and fluo-3 acid. Free 
fura-2 (lOOnM) or free fluo-3 (1/xM) aliquots (2ml) were dispensed into a quartz 
cuvette and equilibrated to 37°C. Then after the addition of EGTA (2.5mM) to 
remove extracellular calcium, the tyrosine kinase inhibitors, genistein (100-300^iM), 
erbstatin ( l-100juM), herbimycin A (175nM-1.75/xM) and tyrphostin A 47 (1-100^M) 
were added. The signal was monitored at the appropriate wavelengths for each 
fluorochrome as described in sections 2.7.1 and 2.7.2.
After establishing which tyrosine kinase inhibitors could be used with each 
fluorescent dye, fura-2 and fluo-3 loaded cells in HBSS with Ca2+/M g2+ (Im M ) (2ml) 
were incubated to 37°C. The following inhibitors were then incubated with the cells; 
herbimycin A (875nM) in fura-2 and fluo-3 loaded cells and genistein (30-300/xM) in 
fluo-3 loaded cells only. Guinea pig eosinophils were incubated with the inhibitors for 
20 min. Eol-ls were incubated with the inhibitors overnight. Briefly, the tyrosine
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kinase inhibitors were incubated with Eol-ls (106cells/ml) in media/culture flasks and 
loaded with fluo-3 just before investigating [Ca2+]i elevation (due to the instability of 
fluo-3). The test agents (20/xl) were then added and the signal was monitored at the 
appropriate wavelength for each fluorochrome as described in sections 2.7.1 and 2.7.2.
2.8 Measurement of tyrosine phosphorylation by western
blotting
To establish whether tyrosine kinase was involved in the signalling pathways 
of eosinophils, a technique known as western blotting was employed.
2.8.1 Western blotting method
Cells were prepared as previously described and resuspended to 
2.02xl07cells/ml in HBSS without BSA. A final protein concentration of 10/zg/20/xl 
sample/lane for a mini gel or 100/xg/100/d sample/lane for a large gel was required.
2.8.1.1 Preparation of western blotting samples
A 2x sample buffer (209), was prepared as described in table 2.2 below. Cells 
(297/xl) were dispensed into an aggregometer tube and stirred with a magnetic flea 
(lm in at 37°C). The calcium concentration was then adjusted to Im M  by adding 3/xl 
of CaCl2 (lOOmM) and the cells were incubated for another two minutes.
Test agonist or similar (30jul) was added at t=0s. After addition of the test 
agent typically 2s-+5min, the reaction was stopped by adding 2x sample buffer (300/xl 
at 100°C). Due to the large amount of nucleic material, the samples were sheared 5
Materials St Methods 64
times through a 1ml insulin syringe (27G). The samples were then boiled for 5 min, 
allowed to cool and stored at -20°C until required.
Table 2.2 2x sample buffer
Component Volume Final ratio/ 
concentration
10% SDS 3.0ml (2%)
Glycerol 3.0ml (20%)
1M Tris pH 6.8 2.4ml (16%) 160mM
Distilled H20 5.1ml (53%)
2-mercaptoethanol 1.35ml (9%)
Bromophenol Blue 1 lump -
Molecular weight markers (15,00CK200,000) were made up by adding distilled 
H20  (0.5ml) to the lyophilised markers. The markers were boiled for 5 min, allowed 
to cool, aliquoted (to avoid repeated freeze/thawing) and stored at -20°C until required.
2 .8 .1 .2  Preparation and running of PAGE/SDS gels
The running gels were prepared as described in table 2.3 and table 2.4 below. 
The APS and TEMED were added just before the gel was poured.
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Table 2.3 Protocol for 10%/15% running and stacking gels
Components 10% Gel 15% Gel Stacking Gel
2 Large 1 Large/ 
2mini
2 Large 1 Large/ 
2mini
2 Large 1 Large/ 
2mini
(ml) (ml) (ml) (ml) (ml) (ml)
Protogel 20 10 30 15 1.7 0.85
1M Tris pH 8.8 22.5 11.25 22.5 11.25 - -
1M Tris pH 6.8 - - - - 1.25 0.625
H20 16.3 8.15 6.3 3.15 6.84 3.42
10% SDS 0.6 0.3 0.6 0.3 0.1 0.05
10% APS 0.6 0.3 0.6 0.3 0.1 0.05
TEMED 0.024 0.012 0.024 0.012 0.01 0.005
Total 60 30 60 30 10 5
60ml was sufficient for 2 large gels
30ml was sufficient for 1 large gel or 2 mini gels
For gradient gels the following protocol was used:







Protogel 3.5 8.5 1.6
1M Tris pH 8.8 5.6 5.6 -
lx  Upper Buffer - - 3.1
Sucrose - 1.5g -
H20 5.8 - 7.6
10%SDS 0.075 0.075 -
10% APS 0.15 0.15 0.12
TEMED 0.15 0.15 0.12
Total 30 12.5
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4x Upper buffer (stock): 6.06g Trizma Base andlO% (4ml) SDS; Dissolved in
H20  (85ml), pH 6.8 with 1M HC1, then made up to 
100ml. Store at 4°C.
Made up to lx  Upper buffer with distilled water before pouring gel.
The gel apparatus - large (Hoefer Scientific Instruments, Newcastle-Under- 
Lyme, UK) and mini (Bio-Rad laboratories, Hemel Hempstead, UK) were cleaned 
with methanol before use. First the running gel was poured to approximately 0.5cm 
below the point where the bottom the combs would reach. 50% methanol was layered 
on the top of the gel until set. When set, the methanol was washed off, the plastic 
combs were placed in position and then the stacking gel was poured on top of the 
running gel, making sure no air bubbles were trapped. When the stacking gel had set, 
the combs were carefully removed and the top of the gel was washed with distilled 
water. Running buffer was then applied to the top of the gel.
Samples (100/d - large or 20/d - mini) were added to individual lanes. 
Molecular weight markers were applied to at least one lane in each gel (7.5/xl - large 
or 3/d - mini). The gel apparatus was then assembled for running and power was 
passed through the gel using a suitable power pack at the appropriate constant voltage, 
as shown in table 2.5 below.
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Table 2.5 Voltage and time guide for the running of PAGE/SDS 
____________ gels__________________________________________________
Gel Stacking gel Running gel
Large Mini Large mini
Voltage 50V 50V 50V 150V
Time 15min 15min Overnight 1-11/2 hours
When the bromophenol blue dye reached the bottom of the gel, the power 
supply was disconnected. I f  the gel was to be stained to indicate the position of the 
proteins, the gel was placed in Coomaissie blue stain for at least 2 hours.
2 .8 .1 .3  Transfer of proteins from gels to nitrocellulose 
membranes
Rubber gloves were worn to avoid protein contamination from hands. Filter 
card and Immobilon-P transfer nitrocellulose membranes were cut to match the size of 
the gel. The gels were transferred to the nitrocellulose membrane using a Trans-Blot 
with transfer cells (Bio-Rad Laboratories, Hemel Hempstead, UK) as follows:
1) A transfer cell was opened, then a transfer pad soaked in transfer buffer was 
placed on the black side of the transfer cell.
2) Next a soaked filter card was placed on the transfer pad. At each stage, all the 
air bubbles were removed by rolling them out with a glass pasteur pipette.
3) The gel was then carefully placed on the filter card.
4) Next a piece of nitrocellulose paper, activated by immersing in methanol (3 
sec), distilled H20  (1 min) and transfer buffer (1 min), was placed on the gel.
5) On top of the membrane, another filter card soaked in transfer buffer was
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placed.
6) On top of the filter card, another transfer pad soaked in transfer buffer was 
placed.
7) Finally the cell was closed (nb. clear side of cell was on top of the final pad). 
The transfer cell was then placed in the Trans-Blot with the black side of the
cell facing the cathode side of the tank and the clear side facing the anode. It was 
important to get this the correct way round, otherwise the proteins would move towards 
the bottom filter card not the membrane. The above was repeated for each gel. The 
Trans-Blot was then assembled, filled with transfer buffer to the top and placed on a 
magnetic stirrer. The blots were then transferred at constant current using a suitable 
power pack as shown in table 2.6 below.
Table 2.6 Current, time and temperature guide for transferring 
gels to nitrocellulose membranes
Gel Large M in i
Voltage 50V maximum
Current (constant) 0.2A 0.333A
Time Overnight (min 20 hours) IV4 -IV 2 hours
Temperature 4°C Ice pack in transfer tank
After transferring, the transfer cell was dismantled and the membrane was put 
into a suitable container, with the protein side facing upwards ready for probing with 
appropriate antibodies (the membrane can be stored in PBS/0.1% NaN3 at 4°C  
overnight). The gel was then stained in Coomassie blue, to mark proteins left behind 
on the gel.
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2 .8 .1 .4  Blocking and probing of membranes
All steps were carried out at room temperature. First the nonspecific proteins 
were blocked using a suitable agent. Each membrane was covered with non-fat milk 
protein in PBS (5%), (200ml - large or 50ml - mini) and left on a shaker for IV2 - 2 
hours. Alternative blocking agents included gelatin (3%) and serum (5%). Blocked 
membranes were washed 3 times with PBS/Tween 20 (0.05 %) for 10 min on a shaker.
The membranes were then probed with the anti-phosphotyrosine antibodies 
PY20 (1/500 - 1/5000 dilution) or 4G10 (1/500 - 1/5000 dilution) in non-fat milk 
protein (0.5% )/NaN3 (0.1%)/PBS for 2 - 3 hours on a shaker. After probing, the 
antibody was removed to be reused for a maximum of 3 times, filtering each time 
before reuse.
The membranes were then washed 3 times with PBS/Tween 20 (0.05%) for 10 
min on a shaker. The membranes were then incubated with a goat anti-mouse IgG 
horseradish peroxidase conjugate antibody (1/500 - 1/2000 dilution) in non-fat milk 
protein (0.5%)/PBS for 1% - IV2 hours. The membranes were then washed 3 times 
with NaCl (500mM)/PBS/Tween 20 (0.05%) for 15 min and then twice with 
PBS/Tween 20 (0.05%) for 15 min.
Control first antibodies used:
•  mouse whole IgG (1/500 - 1/5000) - to indicate if nonspecific binding of 
PY20/4G10 was binding to eosinophils.
•  o-Phospho-DL-serine (Im M ) with PY20/4G10, o-Phospho-DL-threonine (Im M ) 
with PY20/4G10, o-Phospho-DL-tyrosine (Im M ) with PY20/4G10 - to 
demonstrate the antibody was only marking tyrosine phosphorylated proteins.
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Other control experiments included:
•  No first antibody (ie. non-fat milk protein (0.5 %)/NaN3 (0.1 %)/PBS)
•  No second antibody (ie. non-fat milk protein (0.5%)/PBS)
2 .8 .1 .5  Detection of tyrosine phosphorylation using enhanced 
chemiluminescence (ECL)
The PBS/Tween 20 (0.05%) was poured off from the membrane. An equal 
volume of reagent A was mixed with reagent B to give sufficient reagent to cover the 
membrane (final volume O.lml/cm2). The ECL reagent was incubated with the 
membrane for precisely 1 min at room temperature. The excess detection reagent was 
drained off and the blot was wrapped in Saranwrap, smoothing out any air pockets and 
sealing the edges with masking tape. This was repeated for each membrane. The blots 
were then immediately exposed to Hyperfilm-ECL for 15 sec and processed using a 
RGII Film processor (Fuji Photofilm Co. Ltd). A second exposure was then 
performed (1 min -1  hour). The length of the second exposure was assessed according 
to the amount of protein that appeared on the first exposure.
2 .8 .1 .6  Ponceau S staining of the nitrocellulose membranes
To stain the proteins on the membrane, temporarily or permanently, the stain 
ponceau S was used. Enough ponceau S (stock diluted in distilled H20 ) to cover the 
blot was added for approximately 2 min. The excess ponceau S was drained off, then 
enough PBS was added to liberally cover the blot. The blot was shaken for 
approximately 3 min, then replaced with fresh PBS. The protein bands were then
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clearly visible. To stain permanently, after draining the excess ponceau S, acetic acid 
(1 %) was added for 2 min. The blot was then allowed to air dry.
2 .8 .1 .7  Destaining and drying gels
Excess Coomaissie stain was poured off the gels and back into stock supply. 
The gels were then covered with destain (methanol/acetic acid/distilled H 20 , v/v/v, 
40/7/53). The gels were left on a shaker for about 2 hours replacing the destain as 
required. Finally the destain was replaced with distilled H20 .
A piece of filter paper cut to the size of the gel, soaked in H20  was placed in 
a gel dryer (Bio-Rad laboratories, Hemel Hempstead, UK). The gel was then carefully 
placed on the filter paper and covered with a piece of cellophane membrane soaked in 
H20 . This was repeated for each gel to be dried. The plastic seal of the dryer was put 
over the top of the gels and the lid closed. The gel was dried for 1 hour 10 min at 
80°C under vacuum. The vacuum pump was left running for Vi hour after the gels had 
finished drying while the equipment cooled down. The dried gels were then removed 
before switching off the vacuum pump.
2 .8 .2  Experiments with the specific tyrosine kinase inhibitors
genistein, herbimycin A , erbstatin and tyrphostin A -47
To try and inhibit cellular function via tyrosine phosphorylated proteins, the 
specific tyrosine kinase inhibitors, genistein, herbimycin A , erbstatin and tyrphostin 
A-47 were used. Eosinophils were prepared and resuspended at 2x l07cells/ml with 
Ca2+/Mg2+ (Im M ) and incubated with the tyrosine kinase inhibitors for 1 hour at 37°C
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(not stirred). For Eol-ls overnight incubations were performed. Briefly, the tyrosine 
kinase inhibitors genistein (30^M) and herbimycin A (875nM) were incubated with the 
cells (106cells/ml) in media and culture flasks. The cells were washed twice in HBSS 
without BSA, resuspended at 2xl07cells/ml with Ca2+/M g2+ (Im M ).
The cells were then incubated with test agents as described in section 2.8.1.1, 
stopping the reaction with 2x sample buffer. The samples were then used for 
immunoblotting.
2 .9  Statistical analysis
Minitab for windows (versionlO) was used for all statistical analaysis. Unless 
otherwise stated, a 2 way ANOVA was performed on the groups of data and the 
significance was calculated using the Dunnett’s method. In the result sections, all the 
figures have the same legend; significant increases above basal levels: *, p<0.05; * * , 
p < 0 .01  and significant decreases/inhibitions compared with vehicle controls: #, 
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3.1 Purity of eosinophils
3.1.1 Guinea pig eosinophils
As stated in the protocol for isolation of guinea pig eosinophils, 2xl07 
cells/animal were obtained of >90%  purity and >99%  viability. In the results 
section, no data was used from any experiment if the purity was <90% . The main 
contaminating cells were macrophages. Very few neutrophils or lymphocytes (<  1 %) 
were present. A typical purified eosinophil preparation is shown in plate 3.1.
3.1 .2  Human eosinophils
As stated in the protocol for isolation of human eosinophils, typically lxlO 7
cells/lOOml whole blood were obtained of >90%  purity and >99%  viability. In the
results section, no data was used from any experiment if the purity was <  85 %. The
lower number of human eosinophils obtained was the reason behind accepting a less
pure preparation in the data section. The contaminating cells were more varied in the 
human eosinophil preparations. Monocytes and lymphocytes were the main 
contaminants with neutrophils and basophils (< 3 % ) also being present.
3.2 Setting up the hydrogen peroxide assay
As outlined in the method section, different types of microtitre plates and 
protein coatings were investigated for their suitability with this assay. In any plate 
used, if there was no protein coating, the cells adhered to the plate and were activated 
to produce H20 2 from eosinophils without stimulation by an added agonist. Therefore 
the following proteins were tested: BSA; FCS; fibrinogen; fibronectin;gelatin and
Eosinophil Hydrogen Peroxide Release 75
laminin. BSA, fibronectin and gelatin were discounted due to the large quantites
needed for sufficient protein to coat the plate.
Plate 3.1 Photograph of purified eosinophils from a guinea pig
FCS did not adhere to the wells sufficiently to prevent activation of the 
eosinophils by the microtitre plate. Both fibrinogen (lOrrig/ml) and laminin (3^g/ml) 
prevented spontaneous activation of the eosinophils by the microtitre plate and allowed 
stimulation o f the purified cells by added agonist (figure 3.1).
Regardless o f the protein coating used, ELISA plates caused the cells to adhere and 
activate without stimulation. Figure 3.1 shows that laminin and fibrinogen gave 
measurable responses on either flexiplates or titertek plates. However the laminin 
coating caused a higher basal response on the titertek plate and fibrinogen lowered the 
response effected by C5a. Laminin-coated microtitre flexiplates was chosen as the
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preferred protein coating and plate for subsequent experiments due the larger window






Hydrogen peroxide released from guinea pig eosinophils in either 
flexiplates or titertek plates. Eosinophils were either unstimulated (□ ) or stimulated 
with C5a (100nM)(§§) or PMA (100nM)(H) in laminin-coated (3/ug/ml) or fibrinogen- 
coated (lOmg/ml) microtitre plates at t=30min. Bars indicate mean+sem nmol H20 2 
produced/2xl05cells for quadruplicate wells. Representative o f 2 experiments.
3 .3 Guniea pig eosinophils
3.3 .1  Effect of the added agonists C5a, LTB4 and PAF
Figure 3.2 shows a representative set o f standards calibrating the increasing 
amount o f hydrogen peroxide on the reduction of the fluorescent compound scopoletin. 
An exponential curve was fitted to the standards using equation 2.1 to give the 
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Representative standard curve of decreasing scopoletin fluoresence with 
increasing amounts o f H20 2. Trace indicates fluoresence measured at an excitation 
wavelength 355nm and emmission wavelength 460nm.







Both C5a and LTB4 were potent stimulators o f hydrogen peroxide production
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from guinea pig eosinophils causing a dose related release of H20 2, which was
significant at lOnM and lOOnM (figures 3.3 and 3.4) for both agonists compared with 
unstimulated cells.. Although causing some H20 2 release above basal levels, PAF (1 - 
lOOnM) was only a weak activator of H20 2 production. As it can be seen from figure 
3.3, nearly all the H20 2 was released within the first 30 min, with initial rates being 
comparable for the different agonists. There also appeared to be no lag between 
addition of the agonist and the commencement of H20 2 production. The results in 
figure 3.4 demonstrate the pronouced effects of C5a and LTB4 at lOnM and lOOnM 
compared with the response to PAF. IL-8, NAP-2, fMLP and LPS were inactive in 
this assay (table 3.2).
Table 3.2 Effects of IL-8, NAP-2, fMLP and LPS on H20 2 
production from guinea pig eosinophils at t=30min. Data indicates 
mean±sem for quadriplicate wells. Representative of 2-4 experiments.




NAP-2 (lOOnM) 0.55 ±0.02
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Figure 3.3 Time courses of H20 2 production from guinea pig eosinophils stimulated 
with different concentrations o f C5a, LTB4, PAF and PMA. Traces indicate 
mean±sem nmol H20 2 production from triplicate wells. Doses: lOOpM ( +  ); 300pM 
(O); InM (□); 3nM (▼); lOnM (A); lOOnM ( • )  and 1/xM (■). Representative of 4-9 
experiments.
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Figure 3.4 Hydrogen peroxide released from guinea pig eosinophils either 
unstimulated (□ ) or stimulated with C5a (11), LTB4 (^ )  and PAF (■) at t=30min. 
Bars indicate mean±sem nmol H20 2 produced/ 2x l05cells for n=4-9 different 
eosinophil preparations. Significantly increased H20 2 compared with vehicle treated 
cells: *, p<0.05 ; * *  p<0.01.
3 .3 .2  Effect of extracellular ionic conditions
The ability of eosinophils to produce hydrogen peroxide was greatly dependent 
on the extracellular cationic conditions. The calcium specfic chelator, EGTA, inhibited 
the H20 2 release stimulated with C5a, LTB4 and PAF (lOOnM) by 53%, 52% and 63% 
respectively (figure 3.5).
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Figure 3.5 Hydrogen peroxide released from guinea pig eosinophils with C5a, LTB4 
or PAF (lOOnM) with varying extracellular cationic conditions at t=30min: (■) ImM 
Ca2+/Mg2+; (H) ImM EGTA; (□) ImM EDTA. Bars indicate mean±sem nmol H20 2 
produced/2xl05cells for n=4-9 different preparations. Significantly increased H20 2 
produced compared with vehicle treated cells: *, p<0.05 ; ** , p<0.01. Significantly 
reduced H20 2 produced compared with Im M  Ca2+/Mg2+ containing cells: #, p<0.05;
p<0.01.
When the nonspecific chelator, EDTA, was tested it was found that H20 2 
production by each agonist was inhibited by more than 80% (figure 3.5), indicating 
that both extracellular calcium and magnesium were required for H20 2 release. 
Experiments in stirred cells showed that ImM EDTA prevented H20 2 production from 
guinea pig eosinophils by 30nM C5a (figure 3.5A). EDTA either completely inhibited 
H20 2 release when added at the start o f the experiment or stopped the reaction in
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progress when added during the course of the experiment (figure 3.8A). Figure 3.6
shows the decrease in fluorescence of the scopoletin-based reaction mixture in a cuvette 
detected by the PTI fluorimeter upon the addition o f known amounts o f H20 2. This 
was done to give a guide o f the amount o f H20 2 released from guinea pig eosinophils 
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Figure 3.6 Effect of hydrogen peroxide on scopoletin fluorescence detected by PTI 
fluorimeter. Ex=355nm, Em=460nm.
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3 .3 .3  Effect of Nickel on H 20 2 release
Having established extracellular calcium and magnesium were important for the 
release o f H20 2 from guinea pig eosinophils, it was next investigated to see if  the 
calcium influx rather than intracellular calcium release was effecting H20 2 production. 
Figure 3.7 shows that when calcium/magnesium (Im M ) and nickel (Im M ) were 
present together, no effect on H20 2 production was observed when guinea pig 
eosinophils were stimulated with C5a, LTB4 and PAF (lOOnM) (taking into account the 
increase in fluorescence caused by nickel chloride).
4-i
C /D
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Basal C5a LTB4 PAF
Figure 3.7 Hydrogen peroxide released from guinea pig eosinophils either 
unstimulated or stimulated with C5a, LTB4 and PAF (1-lOOnM) t=30min. Cells 
stimulated under normal conditions (□) or in the presence o f ImM N iC l2 (M). Bars 
indicate mean+sem nmol H20 2 produced/2xl05cells for triplicate wells. 
Representative o f 2 experiments.
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However, contrary evidence was obtained when the H20 2 experiments was
carried out on a stirred suspension of cells in the fluorimeter. These experiments were 
performed to mimic the conditions used for [Ca2H"]i experiments (see chapter 5). 
Figure 3.8B shows that even once the cells appear to be producing H20 2, the addition 
o f extracellular nickel (Im M ), stops this process, suggesting influx does have a role 




1 OOnM LTB4 + 1 mM NiCLj
30nM C5a + ImM EDTA (t=600s)
lOOnM LTB4 + Im M  NiC^ (t=300s)
30nM C5a
Agonist Agonist lOOnM LTB4
12000 200 400 600 800 1000 10001200 0 200 400 600 800
Time (seconds) Time (seconds)
Figure 3.8 Hydrogen peroxide released from guinea pig eosinophils in stirred 
suspensions at 37°C. (A) Effect o f EDTA (Im M ) on cells stimulated with C5a 
(30nM). (B) Effect o f NiCl2 (Im M ) on cells stimulated with LTB4 (lOOnM). Traces 
are representative o f 2 different eosinophil preparations.
Eosinophil Hydrogen Peroxide Release 85
3 .3 .4  Effect of SKetF 9 6 3 6 5  on H 20 2 release
To investigate further this role of calcium influx, the proposed specific receptor 
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Figure 3.9 Hydrogen peroxide released from guinea pig eosinophils either 
unstimulated (□ ) or stimulated with SK&F 96365 (30-100pM)(iS), C5a (100nM)(H) 
and PAF (100nM)(B) at t=30min. Bars indicate mean±sem nmol H20 2 
produced/2xl05 cells for n=5-6 different eosinophil preparations. Significantly 
increased H20 2 released compared with vehicle treated cells: * p<0.05 ; * * , p<0.01.
Surprisingly, SK&F 96365 (60^iM and lOOjicM) caused a significant release of 
H20 2 from guinea pig eosinophils (figure 3.9). The enantiomers o f SK&F 96365 were 
also tested and figure 3.10 shows that each component was able to cause H20 2 release 
(significant at 100/*M). However the combined values o f H20 2 released by the 
enantiomers did not equate the values o f H20 2 released by the racemic compound.
Eosinophil Hydrogen Peroxide Release 86
In conjunction with the added agonists C5a (lOOnM) and PAF (lOOnM), SK&F
96365 (30 - lOOpM) significantly enhanced the release o f H20 2 production from guinea 

















Hydrogen peroxide released from guinea pig eosinophils either 
unstimulated (□) or stimulated with the enantiomers o f SK&F 96365: - (30- 
100/xM)(iS); +  (30-100/xM)(^) at t=30min. Bars indicate mean±sem nmol H20 2 
produced^xlO5 cells for n=4 different eosinophil preparations. Significantly increased 
H20 2 compared with vehicle treated cells: *, p<0.01.
30 60 100 (pM )
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Figure 3.11 Hydrogen peroxide released from guinea pig eosinophils either 
unstimulated or stimulated with C5a (lOOnM) and PAF (lOOnM) in conjunction with 
SK&F 96365: vehicle (□); 30/liM (II); 60/xM (M) or lOO^M (■) at t=30min. Bars 
indicate mean+sem nmol H20 2 produced/2xl05 cells for n=4-5 different eosinophil 
preparations. Significantly increased H20 2 compared with vehicle treated cells: *, 
p<0.05; ** , p<0.01.
3 .3 .5  Effect of the specific PKC inhibitor, Ro 31 -8 2 2 0 /0 0 2
To investigate whether the agonists were stimulating H20 2 via a PKC 
mechanism, a selective PKC inhibitor, Ro 31-8220/002 was used in conjuction with 
suboptimal doses of C5a(30nM), LTB4 (30nM) and PM A (InM ). PM A (InM ) was an 
extremely rapid activator o f H20 2 production fom guinea pig eosinophils compared 
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produced the same amount of H20 2 (figure 3.3). PM A activates PKC directly and was
therefore used as a positive control. Figure 3.12 demonstrates that both C5a, LTB4 
(30nM) and PMA (300pM) were dose-dependently inhibited by Ro 31-8220/002. 
Furthermore, not only reducing the final amount o f H20 2 produced, Ro 31-8220/002 
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Figure 3.12 Effect o f Ro 31-8220/002 on guinea pig eosinophil H20 2 production. 
Eosinophils were pretreated with vehicle (O), 300nM (A), 1/xM (T) or 3/*M (■) Ro 
31-8220/002 for 20min at 37°C before stimulation with C5a (30nM), LTB4 (30nM) or 
PMA (300pM). Representative o f 5-6 experiments.
The effect of Ro 31-8220/002 was not due to cell cytotoxicity as eosinophils at 
the end o f the experiment were >99% viable as assessed by trypan blue exclusion. 
The results are summerized in figure 3.13. These experiments were also carried out 
in the stirred cell system, and a similar inhibition to that seen in the microassay with 
Ro 31-8220/002 (3/xM) was observed (figure 3.14).
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Figure 3.13 Hydrogen peroxide released from guinea pig eosinophils pretreated with 
vehicle (□), 300nM (11), 1/*M (8) or 3/xM (■) o f the PKC selective inhibitor Ro 31- 
8220/002 (for 20min at 37°C), either unstimulated or stimulated with C5a (30nM), 
LTB4 (30nM) or PMA (300pM) at t=30min. Bars indicate mean±sem nmol H20 2 
produced /2X105 cells for n=5-6 different eosinophil preparations. Significantly 
increased H20 2 released compared with basal H20 2 produced: *, p<0.05; **, p<0.01. 
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Figure 3.14 Hydrogen peroxide released from guinea pig eosinophils in stirred 
suspension pretreated with Ro 31-8220/002 (3/*M) for 20min at 37°C before 
stimulation with PMA (30nM) or C5a (30nM). Traces are representative o f 2 different 
eosinophil preparations.
3 .3 .6  Effect of the tyrosine kinase inhibitors genistein, 
erbstatin, herbimycin A  and tyrphostin-A47
Other signalling pathways may also exist, as 100% inhibition was not obtained 
by the PKC inhibitor Ro 31-8220/002. To investigate whether a tyrosine kinase 
mechanism was involved in guinea pig eosinophils, the specfic tyrosine kinase 
inhibitors genistein, erbstatin, herbimycin A and tyrphostin-A47 were used. Because 
these inhibitors were fluorescent, the effect o f each inhibitor was first investigated to 
see i f  it had any effect on the H20 2 assay. Figure 3.15 shows that erbstatin (10^tM), 
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Figure 3.15 Effect of the fluorescent properties of different specific tyrosine kinase 
inhibitors on the scopoletin based hydrogen peroxide assay: vehicle (□); herbimycin 
A (1mM)(♦ ); tyrphostin A-47 (10/xM)(B), (100mM)(A); genistein (100/xM)(0), 
(300/zM)(#) and erbstatin (10/iM)(Y).
The effect of herbimycin A (1/*M) and genistein (100/xM) was thus investigated 
on H20 2 production. After incubation for 2Vi and 4 hours (as shorter incubation times 
had no effect) with the respective tyrosine kinase inhibitors, the guinea pig eosinophils 
were plated out and the agonists C5a, PAF (30-100nM) and PMA (3nM) were added. 
As figure 3.16 shows, the time course o f H20 2 production was similar to that o f 
stimulated guinea pig eosinophils not incubated with the tyrosine kinase inhibitors. 
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Figure 3.16 Effect o f specific tyrosine kinase inhibitors on guinea pig eosinophil 
H20 2 production. Eosinophils were pretreated with vehicle (□ ), hebimycin A 
(1/*M)(4) or genistein (100^M)(O) for 2l/i hours at 37°C before stimulation with C5a 
(lOOnM), PAF(lOOnM) or PMA (3nM). Traces show change o f H20 2 release above 
basal levels. Representative of 2-5 experiments.
Very little  H20 2 was detected from cells that had been incubated for 4 hours 
(data not shown). Both herbimycin A (1/xM) and genistein (1 0 0 /z M ) inhibited the 
production of H20 2 elicited by C5a (lOOnM) in guinea pig eosinophils, though this did 
not reach significance. Only herbimycin A appeared to have an effect on PMA (3nM) 
stimulated cells. Figure 3.17 shows the small inhibition of H20 2 release caused by the 
pretreatment o f eosinophils with hebimycin A (1/xM). The cells were still >99% 
viable as assessed by trypan blue exclusion.
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Figure 3.17 Hydrogen peroxide released from guinea pig eosinophils pretreated with 
vehicle (□ ) or the selective tyrosin kinase inhibitor herbimycin A (l/xM)(H) (for 2xh 
hours at 37°C) then stimulated with C5a (lOOnM), PAF (lOOnM) or PMA (3nM) at 
t=30m in. Bars indicate mean±sem nmol H20 2 produced/2xl05 cells for n=3-5 
different eosinophil preparations. Significantly increased H20 2 released compared with 
basal H20 2 produced: *, p<0.05; ** , p<0.01. Significantly reduced H20 2 produced 
compared vehicle treated cells: ti, p<0.05.
3 .3 .7  Effect of wortmannin on H20 2 release
To ascertain whether a role for PI-3 kinase exists in guinea pig eosinophils, the 
specific PI 3-kinase inhibitor wortmannin was used together with C5a (lOOnM) and 
PAF (lOOnM). Figure 3.18 shows that wortmannin (3-30nM) inhibited H20 2 
production elicited by C5a stimulated guinea pig eosinophils (significant at 30nM). 
Again the effect o f wortmannin was not due to cell cytotoxicity as eosinophils at the
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end o f the experiment were >99% viable as assessed by trypan blue exclusion.
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Figure 3.18 Hydrogen peroxide released from guinea pig eosinophils pretreated with 
vehicle (□), 3nM (II), lOnM (8) or 30nM (■) of the PI-3 kinase inhibitor wortmannin 
(for lOmin at 37°C), then stimulated with either C5a (lOOnM), PAF (lOOnM) or PMA 
(InM) at t=30min. Bars indicate mean±sem nmol H20 2 produced^xlO5 cells for n=3 
different eosinophil preparations. Significantly increased H20 2 released compared 
with basal H20 2 produced: *, p<0.05. Significantly reduced H20 2 produced compared 
with vehicle treated cells: p<0.01 (2 way-ANOVA only).
3 .3 .8  Effect of priming guinea pig eosinophils
To establish whether the activity o f guinea pig eosinophils could be enhanced, 
they were incubated with the cytokine GM-CSF (lOOpM) for either 10 min or 1 hour 
before stimulation with a variety of agonists. A 10 min preincubation had no effect on 
enhancing H20 2 production. Though a 1 hour preincubation with GM-CSF was able
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to augment H20 2 release from C5a (10-100nM)-stimulated cells above vehicle treated
cells (figure 3.19), this effect is unlikely to be due to cellular priming. PAF (lOpM- 
1/uM), IL-8 (1-lOnM) or NAP-2 (1-lOOnM) treated cells which were poor activators 
o f H20 2 production had no enhanced activity when incubated with GM-CSF.
100 (nM)
Figure 3.19 Hydrogen peroxide released from guinea pig eosinophils pretreated with 
vehicle (□ ) or GM-CSF (100pM)(Si) (for 1 hour at 37°C) then stimulated with C5a 
(10-lOOnM) at t=30min. Bars indicate mean±sem nmol H20 2 produced/2xl05 cells 
for n=3-4 different eosinophil preparations. Significantly increased H20 2 released 
compared with respective basal H20 2 produced: *, p<0.05.
3 .3 .9  Effect of agonists on BAL eosinophils
The effect on H20 2 production elicited by various agonists was compared on 
eosinophils obtained from BAL to those elicited into the peritoneal cavity. The amount
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of H20 2 released from BAL eosinophils by activating them with C5a, PAF (30-lOOnM)
and PMA (3nM) was measured in eosinophils obtained from guinea pigs that had been 
sensitised and then challenged to ovalbumin (OA-challenged), challenged to saline 









Hydrogen peroxide released from guinea pig BAL eosinophils: non-/ 
sham-challenged animals (§§) or OA-challenged animals (H); either unstimulated, or 
stimulated with C5a (30-100nM), PAF (30-100nM) or PMA (3nM)at t=30min. Bars 
indicate mean+sem nmol H20 2 produced/2xl05 cells for n=3-6 different eosinophil 
preparations. Significantly increased H20 2 released compared with respective basal 
H20 2 produced: ** , p<0.01.
The number of eosinophils obtained from BAL's were very low, especially in 
the case o f non-challenged animals, thus the data from non-challenged and sham- 
challeged animals were pooled. C5a (30nM and lOOnM) and PMA (3nM) still elicited
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good amounts of H20 2 from BAL eosinophils from each source. PAF (30nM and
lOOnM) showed a lower amount of H20 2 production from eosinophils obtained from 
non-/sham-challenged animals, but an enhancement of H20 2 (though not significant) 
released from eosinophils of OA-challenged animals compared to that of non-/sham- 
challenged animals (figure 3.20).
3.4 Human eosinophils
3.4.1 Effect of added agonists, including C-C chemokines and
cytokines
C5a (l-100nM), PAF (l-100nM) and both the C-C chemokines RANTES (10- 
lOOnM) and MCP-3 (1-lOOnM) could stimulate H20 2 production from human 
eosinophils, causing a dose related release of H20 2 that was significant at lOnM and 
lOOnM (figures 3.21 and 3.22) for all agonists compared with unstimulated cells. Also 
the cytokine IL-5 was an extremely potent stimulator of H20 2 production by human 
eosinophils, again causing a dose-related release of H20 2 that was significant at lOpM 
and above (figure 3.22). Figure 3.21 shows that nearly all the H20 2 was released 
within the first 30min in C5a, PAF, RANTES and MCP-3 stimulated cells and within 
the first 60min for IL-5 stimulated cells. All the initial rates of reaction were 
comparable for the different agonists, without a negligible lag between the addition of 
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Figure 3.21 Time cx>urse of hydrogen peroxide production from human eosinophils 
stimulated with different concentrations o f C5a, RANTES, MCP-3 and IL-5. Traces 
indicate mean±sem nmol H20 2 production/2xl05 cells from triplicate wells. Doses: 
vehicle (x); lOpM (+ ); lOOpM (O); InM (□); lOnM (A); 40nM (■) lOOnM (• ) .  
Representative o f 3-20 experiments.
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Figure 3.22 Hydrogen peroxide released from human eosinophils either unstimulated 
(□) or stimulated with C5a (!$), RANTES (M), MCP-3 (H) or IL-5 (■ ) at t=30min. 
Bars indicate mean±sem nmol H20 2 produced/ 2xl05 cells for n=3-20 different 
eosinophil preparations. Significantly increased H20 2 produced compared with vehicle 
treated cells: *, p<0.05 ; ** , p<0.01.
The cytokines MCP-1, M IP-la and M IP-lp were also tested and were inactive 
in this assay (table 3.3), with C5a (lOOnM) being a positive control. IL-8 also 
activated human eosinophils to release H20 2.
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Table 3.3 Effects of M IP -la , M IP -lp , IL-8, MCP-1 and PAF on 
H20 2 production from human eosinophils at t=30min. Data indicates 
mean±sem nmol H20 2 produced/2xl05cells for triplicate wells. 
Representative of 3-5 experiments.
Agonist H20 2 produced (nmol/2xl05cells) 
(t=30min)
Basal 0.491 ±0.02
lOOnM M IP -la 0.349+0.04





3.4.2  Effect of priming human eosinophils with IL-5
The ability of IL-5 to upregulate human eosinophils was also tested. Human 
eosinophils were co-incubated with different concentrations of RANTES (KMOOnM) 
and IL-5 (0.4-40nM) and monitored for H20 2 release for up to 2 hours at 37°C. 
Figure 3.23 shows that the combined effects of RANTES and IL-5 were additive and 
not synergistic (due to sample variance, these increases were not significant).
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Figure 3.23 Hydrogen peroxide released from human eosinophils in response to 
RANTES (10-100nM)(lQ, IL-5 (0.4-40nM)(H), IL-5 (0.4-40nM) plus RANTES 
(10nM)(H) or IL-5 (4-40nM) plus RANTES (100nM)(H) at t=60min. Bars indicate 
the mean±sem nmol H20 2 produced/2xl05 cells for n=3 different eosinophils. 
Significantly increased H20 2 released compared with basal H20 2 produced: *, p<0.05;
p<0.01.
3 .4 .3  Effect of the ROCC blocker, SKscF 9 6 3 6 5 , on H20 2 
production on human eosinophils
On guinea pig eosinophils, SK&F 96365 appeared to have an agonistic effect 
on H20 2 release rather than an inhibitory effect, thus the compond was tested to see if  
it exerted similar properties on human eosinophils. Interestingly, the opposite was
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true, SK&F 96365 (3-60/*M) had no effect on H20 2 release from human eosinophils
(see table 3.4) and preliminary experiments suggested that H20 2 released from C5a 
(lOOnM) and RANTES (lOOnM) stimulated cells could be reduced by SK&F 96365 
(data not shown).
Table 3.4 Effect of the ROCC blocker, SK&F 96365, on H20 2 
production from human eosinophils at t=30min. Data indicates 
mean±sem nmol H20 2 produced/2xl05cells from n=3 different 
eosinophil preparations.
Agonist H20 2 produced (nmol/2xl05 cells) 
(t=30 min, n=3)
Basal 0.418 ±  0.065
3jtM SK&F 96365 0.437 ± 0 .1 1 2
IOjzM  SK&F 96365 0.342 ±  0.083
30/xM SK&F 96365 0.225 ±  0.086
60^M SK&F 96365 0.168 ±  0.071
lOOnM C5a 1.520 ±  0.466
3 .4 .4  Inhibition of H20 2 with the selective PKC inhibitor, Ro 
3 1 -8 2 2 0 /0 0 2
As for guinea pig eosinophils, human eosinophils were investigated for different 
signalling mechanisms. Again the selective protein kinase C inhibitor Ro 31-8220/002 
was used in conjunction with with C5a, RANTES, MCP-3, IL-5 and PMA. Figure
3.24 shows that Ro 31-8220/002 could dose-dependently inhibit H20 2 release from 
human eosinophils activated by each agonist. Ro 31-8220/002 (3piM) caused at least 
80% inhibition for each agent tested.












Basal C5a RANTES MCP-3 IL-5 PM A
Figure 3.24 Hydrogen peroxide released from human eosinophils pretreated with 
vehicle (□), 300nM (II), 1/xM (H) or 3juM (■) o f the PKC selective inhibitor Ro 31- 
8220/002 (for 20min at 37°C) in either unstimulated or C5a (lOOnM), RANTES 
(lOOnM), MCP-3 (lOOnM), IL-5 (40nM) or PMA (InM ) stimulated cells at t=30min. 
Bars indicate mean+sem nmol H20 2 produced^xlO5 cells for n=3 different eosinophil 
preparations. Significantly increased H20 2 released compared with basal H20 2 
produced: **, p<0.01. Significantly reduced H20 2 produced compared with vehicle 
treated cells: ##, p<0.01.
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3.4.5 Inhibition of H20 2 with the selective PI-3 kinase 
Inhibitor, wortmannin
Similarly, to investigate whether a role for PI-3 kinase existed in the signalling 
pathway of H20 2 production in human eosinophils, the selective PI-3 kinase inhibitor, 
wortmannin, was used together with C5a, RANTES, MCP-3, IL-5 and PMA. Figure
3.25 shows, wortmannin (3-30nM) dose dependently-inhibited unstimulated, C5a, 
RANTES, MCP-3 and IL-5 stimulated eosinophils. Figure 3.26 summarises the 
pooled data and shows that this inhibition was significant for RANTES, MCP-3 and 
IL-5 stimulated eosinophils at 3nM, lOnM and 30nM of wortmannin.
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Figure 3.25 Effect of wortmannin on time courses o f H20 2 production from human 
eosinophils. Eosinophils were pretreated with vehicle (□ ), 3nM ( • ) ,  lOnM (A) or 
30nM (▼) wortmannin for lOmin at 37°C before stimulation with C5a (lOOnM), 
RANTES (lOOnM), MCP-3 (lOOnM), IL-5 (40nM) or PMA (InM ). Traces indicate 
mean±sem nmol H20 2 production from triplicate wells. Representative o f 3-7 
experiments.
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Figure 3.26 Hydrogen peroxide released from human eosinophils pretreated with 
vehicle (□ ) , 3nM (II), lOnM (H) or 30nM (■) o f the PI 3-kinase inhibitor 
wortmannin(for lOmin at 37°C) then stimulated with either C5a (lOOnM), RANTES 
(lOOnM), MCP-3 (lOOnM), IL-5 (40nM) or PMA (InM ) at t=30min. Bars indicate 
mean± sem nmol H20 2 produced/2xl05 cells for n=3-7 different eosinophil 
preparartions. Significantly increased H20 2 released compared with basal H20 2 
produced: **, p<0.01. Significantly reduced H20 2 produced compared with vehicle 
treated cells: p<0.05; ##, p<0.01.
Wortmannin was unable to inhibit PMA (InM ) which is an extremely rapid 
activator of H20 2 production via a protein kinase C mechanism, indicating wortmannin 
was not affecting the PKC signalling mechanism. The effect of wortmannin was not 
due to cytotoxicity either, as human eosinophils at the end o f the experiment were 99% 
viable assessed by trypan blue exclusion.
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3.5 Eol-1 and Eol-3 responses to added agonists
Eol-ls and Eol-3s were very poor producers of H20 2. C5a (lOOnM), PAF
(lOOnM), various cytokines including MCP-1 (lOOnM) and RANTES (lOOnM) and 
even PMA (3-30nM) were tested for their ability to cause H20 2 release from Eol's. 
Unmatured Eol-ls, unmatured Eol-3s, butyric acid (0.5mM) four-day matured Eol-ls 
or butyric acid (0.5mM) four-day matured Eol-3s were all tested for H20 2 release. All 
were unable to produce measurable amounts of H20 2.
3.6 Control experiments
3.6.1 Cytochrome c experiments
To confirm that the superoxide ion was leading to the formation of H20 2, 
several cytochrome c experiments were carried out. These experiments demonstrated 
that similar results could be obtained via the superoxide dismutase-inhibitable reduction 
of cytochrome c as in the scopoletin-based assay. Figure 3.27 demonstrates that the 
same order of potency could be achieved using the cytochrome c assay with guinea pig 
eosinophils and added agonist, viz. PMA >  C5a >  PAF >  basal.
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Figure 3.27 Superoxide release from guinea pig eosinophils either unstimulated (□ ) 
or stimulated with C5a (100nM )p), PAF (100nM)(«) or PMA (lnM )(B ) at 
t=15m in. Bars indicate mean±sem increase in absorbance at 550nm o f agonist 
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3 .6 .2  Effect of catalase and HMAP on H20 2 detection
To inhibit the H20 2 assay catalase prevents horseradish peroxidase reducing the 
scopoletin fluoresence by breaking down H20 2. Figure 3.28A shows that H20 2 can be 
inhibited by 70% and 75% with catalase (3000U/ml) for C5a (lOOnM) and LTB4 
(lOOnM) respectively.
Figure 3.28 (A) Hydrogen peroxide released from guinea pig eosinophils stimulated
with C5a (lOOnM), LTB4 (lOOnM) or PAF (lOOnM) in the presence o f vehicle (□), 
without HPO (II) or with HPO and catalase (3000U/ml)(B) at t=60min. (B) 
Hydrogen peroxide released from human eosinophils stimulated with C5a (lOOnM) or 
PMA (InM ) in the presence o f vehicle (□) or HMAP; 3/xM (0 ), 10/xM (E), 30^M 
(£!), 100/xM (» ), 300fxM (P) or ImM (■) at t=60min. Bars indicate mean±sem 
AH20 2 nmol produced/2xl05cells above basal levels from triplicate wells. 
Representative o f 2-3 experiments.
Two NADPH oxidase inhibitors were investigated for their effect on H20 2 
production from eosinophils. DPI and HMAP were highly fluorescent compounds, 
thus their effect on the standard calibration curve was also measured (data not shown).
DPI was very insoluble (and expensive) so no H20 2 assay was successfully carried out
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in the presence or absence of added agonists. HMAP (3^M -lm M ) was used effectively
and found to dose-dependently inhibit H20 2 release from human eosinophils (figure
3.28B). This confirmed that the H20 2 being measured by the scopoletin-based assay
was produced via the NADPH oxidase complex.
3.7 Summary of H20 2 experiments
•  Guinea pig and human eosinophils can be stimulated to produce H20 2 with 
various soluble stimuli.
•  Order of potency for H20 2 production from guinea pig eosinophils: C5a >  
LTB4 >  PAF.
•  Order of potency for H20 2 production from human eosinophils: IL-5 >  MCP-3 
>  C5a >  RANTES >  PAF.
•  Responses of human eosinophils could be enhanced by IL-5. GM-CSF failed 
to significantly increase guinea pig eosinophil responses.
•  Guinea pig eosinophils obtained from BAL rather than the peritoneal cavity, 
could also be made to release H20 2. Eosinophil activity from challenged 
animals appeared to be upregulated.
•  Extracellular calcium and magnesium were required for H20 2 release. This was 
demonstrated with the chelators EGTA and EDTA. Some extracellular calcium 
may be influxing into the cell as shown by the NiCl2 experiments in stirred 
cells, however the amount of calcium in intracellular stores may be sufficient 
to elicit a response.
•  The ROCC blocker SK&F 96365 appeared to be an activator of H20 2
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production in guinea pig eosinophils but not in human eosinophils.
Guniea pig eosinophils were sensitive to the tyrosine kinase inhibitor, 
herbimycin A.
Both guinea pig and human eosinophil H20 2 release by added agonist could be 
inhibited by micromolar conctrations of the selective PKC inhibitor, Ro 31- 
8220/002.
Both guinea pig and human eosinophil H20 2 release by added agonist could be 
inhibited by nanomolar concentrations of the specific PI-3 kinase inhibitor, 
wortmannin.
The eosinophilic cell lines Eol-1 and Eol-3 were unable to release H20 2 when 




4.1 Rose bengal adhesion assay
When setting up the H20 2 assay (see section 3.2), the choice of plates and 
protein coating and the subsequent effect they may have had on the adhesion assay was 
also considered. Clearly any plate with a particular protein coating that caused 
spontaneous H20 2 release was discounted as the effects between eosinophil H20 2 
production and adhesion were being assessed. Therefore, uncoated plates, ELISA 
plates and the coatings BSA, FCS, fibronectin and gelatin were not considered. Figure
4.1 shows that fibrinogen (lOmg/ml) and laminin (3/xg/ml) allowed different 
magnitudes of eosinophil adhesion to various added agonists. The window of detection 
was wider in flexipates when comparing vehicle treated cells to C5a stimulated cells 
as opposed to the titertek plates.
Though fibrinogen and laminin gave similar responses of changes in eosinophil 
adhesion to added agonist, fibrinogen had the capacity to avidly bind the rose bengal 
stain in wells where no cells were present. This in some circumstances could of made 
it difficult to detect whether any eosinophils had adhered to the plate at all. Laminin 
appeared to be the best protein coating in the H20 2 assay and the preferred protein 
coating for the adhesion assay. In conclusion laminin-coated microtitre flexiplates gave 







Figure 4.1 Adhesion of guinea pig eosinophils in either flexiplates or titertek plates. 
Wells were left blank (□) or contained eosinophils that were either unstimulated ( it)  
or stimulated with C5a (100nM)(H) or PM A (100nM)(B) in laminin-coated (3/xg/ml) 
or fibrinogen-coated (lOmg/ml) microtitre plates at t=30min. Bars indicate optical 
density o f eosinophil rose bengal uptake at 540nm for n=3 experiments.
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4.2  Guinea pig eosinophils
4.2 .1 Effect of added agonist on adhesion
To assess whether adhesion was a requisite or an enhancer for H20 2 production, 
after each assay the non-adherent cells were removed and adhesion quantified by rose 
bengal stain. Figure 4.2 shows a representative experiment o f calibrating the number 
of cells with rose bengal uptake. This was a reproducible linear relationship. A linear 
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Figure 4.2 Standard curve for number o f guinea pig eosinophils with rose bengal 
uptake. Trace indicates optical density measured at 540nm from triplicate wells. 
Representative o f 2 experiments.
Using the equation 2.7 the number o f cells adhered to the laminin-coated
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microtitre plate was calculated for all subsequent experiments.




























Figure 4.3 Adhesion of guinea pig eosinophils stimulated with C5a (l-100nM )(ll), 
LTB4 ( ln M -l^M )(^ ) or PAF (lnM -lj*M )(B ) at t=90min. Bars indicate mean±sem 
total number o f cells adhered to the plate after the H20 2 assay for n=3-7 different 
eosinophil preparations. Significantly increased adhesion compared with basal cellular 
adhesion: *, p<0.05 ; ** , p<0.01.
When guinea pig eosinophils were stimulated with C5a, LTB4 and PAF all
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agonists were able to cause significant adherence of eosinophils at both lOnM and 
lOOnM (figure 4.3). At lOnM all agonists had approximately the same effect on 
adhesion, whereas they had differing effects on H20 2 production (see figure 3.4). As 
with H20 2 release LPS, fMLP and IL-8 had no effect on guinea pig adhesion.
4.2 .2  Effect of extracellular cationic conditions on adhesion
Similar to the inhibition of H20 2 production, the absence of extracellular 
calcium and magnesium caused inhibition of guinea pig adhesion to laminin-coated 
microtitre plates. This was significant for C5a (lOOnM) and PMA (30nM) stimulated 
cells, however significance was not acheived for either LTB4 or PAF treated cells due 
to poor adhesion in positive controls (figure 4.4). In buffer containing calcium only 
(Im M ), the effect of adhesion was quite variable as shown by the large error bars, but 





Figure 4.4 Adhesion of guinea pig eosinophils stimulated with C5a (lOOnM ), LTB4 
(lOOnM), PAF (lOOnM) and PMA (30nM) to laminin-coated microtitre plates in the 
presence of Im M  Ca2+/Mg2+ (■), ImM EGTA (H) or ImM EDTA (□ ) at t=90min. 
Bars indicate mean±sem total number o f eosinophils adhered after H20 2 assay for 
n=3-9 different eosinophil preparations. Significantly increased adhered cells 
compared with basal cellular adhesion: ** , p<0.01. Significantly reduced adhesion 
compared with ImM Ca2+/M g2+ containing cells: # ,p < 0 .0 5 ;# # ,p < 0 .0 1 .
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Figure 4.5 Adhesion o f guinea pig eosinophils stimulated with C5a (l-100nM), 
LTB4 (l-100nM) or PAF (l-100nM) to laminin-coated microtitre plates in the presence 
of Ca2+/Mg2+ (lmM)(D) or NiCl2 (lm M )(H ) at t=90 min. Bars indicate mean+sem 
total number o f cells adhered after H20 2 assay for triplicate wells. Representative of 
2 experiments.
Though extracellular nickel (Im M ) had no effect on H20 2 production from 
adherent guinea pig eosinophils by any agonist tested, nickel had a marked effect on 
adhesion. The number of adhered cells was increased by more than 300% for vehicle, 
C5a (l-100nM) and PAF (l-100nM) treated cells. Interestingly on both occasions 
tested, as the dose o f LTB4 increased, the effect of increased adhesion caused by the 
presence o f extracellular nickel was reduced (figure 4.5).
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Figure 4.6 Adhesion o f guinea pig eosinophils stimulated with SK&F 96365 (30- 
100/xM)(i1) or C5a (100nM)(li) to laminin-coated microtitre plate at t=90min. Bars 
indicate mean±sem total number of cells adhered after H20 2 assay for n=3 different 
eosinophil preparations. Significantly increased adhered cells compared with basal 
cellular adhesion: *, p<0.05.
The ROCC blocker SK&F 96365 was also tested for its effect on adhesion. At 
all concentrations tested (30-100/xM), SK&F 96365 had no significant effect on 
adhesion (figure 4.6). This is very different to the result SK&F 96365 has on H20 2 
production from guinea pig eosinophils (figure 3.9). When SK&F 96365 was tested 
in conjunction with C5a (lOOnM) and PAF (lOOnM) the adhesion was markedly 













Figure 4.7 Adhesion o f guinea pig eosinophils either unstimulated or stimulated 
with C5a (lOOnM) or PAF (lOOnM) in conjuction with vehicle (□), 30/uM (H), 60/iM 
(H) or 100/^M (■ ) o f SK&F 96365 to laminin-coated microtitre plates at t=90min. 
Bars indicate mean+sem total number of cells adhered after H20 2 assay for triplicate 
wells. Representative o f 2 experiments.
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4 .2 .5  Effect of the specific PKC inhibitor, Ro 3 1 -8 2 2 0 /0 0 2 ,  
on adhesion
Previous experiments (figure 4.3) indicated a dissociation o f mechanisms of 
action between H20 2 production and cellular adhesion existed. When guinea pig 
eosinophils were incubated with the PKC inhibitor Ro 31-8220/002 for 20 min at 
37°C, an effect on adhesion was detected after the H20 2 assay.
to 100-
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Figure 4.8 Adhesion o f guinea pig eosinophils pretreated with vehicle (□), 300nM 
(II), 1/jlM (IM), 3^M (■) o f the PKC selective inhibitor, Ro 31-8220/002 (for 20min 
at 37°C before stimulation), with C5a (30nM), LTB4 (30nM) or PMA (300pM) to 
laminin-coated microtitre plates at t=90min. Bars indicate mean±sem total number 
o f cells adhered after H20 2 assay for n=4-7 different eosinophil preparations. 
Significantly increased adhesion compared with basal cellular adhesion: *, p<0.05; 
** , p<0.01. Significantly reduced adhesion compared with vehicle treated cells: #, 
p<0.05; p<0.01.
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The adhesion of eosinophils was inhibited dose-dependently in C5a (30nM),
LTB4 (30nM) and PMA (300pM) stimulated cells. This was only significant in C5a 
and PMA stimulated cells as LTB4 did not significantly increase eosinophil adhesion 
above basal levels in vehicle treated cells (figure 4.8).
4 .2 .6  Effect of the tyrosine kinase inhibitors, herbimycin A  and 
genistein on adhesion
Basal C5a PAF PMA
Figure 4.9 Adhesion o f guinea pig eosinophils pretreated with vehicle (□ ) or the 
tyrosine kinase inhibitors herbimycin A (l/zM )(!i) or genistein (for 2
hours at 37°C) before stimulation with C5a (lOOnM), PAF (lOOnM) or PMA (3nM) 
to laminin-coated microtitre plates at t=90min. Bars indicate mean±sem total number 
of cells adhered after H20 2 assay for triplicate wells. Representative o f 2 experiments.
The effect o f a 2 Vi hour preincubation of eosinophils with tyrosine kinase
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inhibitors on cellular adhesion was also measured after H20 2 production. Both 
herbimycin A (100/*M) and genistein (100/aM ) enhanced the adhesion of eosinophils 
stimulated with C5a (lOOnM), PAF (lOOnM) or PMA (3nM) to laminin-coated 
microtitre plates above control levels (figure 4.9). These control levels were 
measurably lower than those detected in figure 4.3. This was probably due to the long 
preincubation times with the tyrosine kinase inhibitors, but the eosinophils were still 
>99%  viable after the H20 2 assay.
4 .2 .7  Effect of wortmannin on adhesion
The effect of the specific PI 3-kinase inhibitor, wortmannin was also tested on 
the adhesion of eosinophils. Figure 4.10 shows that in C5a (lOOnM), PAF (lOOnM) 
or PMA (In M ) stimulated cells, the effect of adhesion was always reduced by 
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Figure 4.10 Adhesion of guinea pig eosinophils pretreated with vehicle (□) 3nM (H), 
lOnM (H) or 30nM (■) of the PI 3-kinase inhibitor wortmannin (for lOmin at 37°C), 
before stimulation with C5a (lOOnM), PAF (lOOnM) or PMA (InM ) to laminin-coated 
microtitre plates at t=60min. Bars indicate mean±sem total number o f cells adhered 
after H20 2 assay for n=3 different eosinophil preparations.
4 .2 .8  Adhesion of BAL eosinophils stimulated with different 
agonists
In addition to guinea pig eosinophils obtained by peritoneal lavage, BAL 
eosinophils were also harvested from control and OA-challenged guinea pigs, to 
determine i f  there were any differences between the different ways the cells were 
elicited. The levels o f adhesion of BAL eosinophils acquired from OA-challenged 
animals were always greater than the levels o f adhesion from BAL eosinophils obtained 
from non-/sham-challenged animals in C5a (30-lOOnM) and PAF (30-lOOnM)
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stimulated cells as shown in figure 4.11. Experiments with BAL eosinophils from non- 
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Figure 4.11 Adhesion o f guinea pig BAL eosinophils o f non-/sham-challenged 
animals (II) or OA-challenged (M) stimulated with C5a (30-lOOnM), PAF (30-lOOnM) 
or PMA (3nM) to laminin-coated microtitre plates at t=90min. Bars indicate 
mean±sem total number o f cells adhered after H20 2 asay for n=3-5 different 
eosinophil preparations. Significantly increased adhesion compared with relative-basal 
control cellular adhesion: *, p<0.05; **, p<0.01.
4 .3 Human eosinophils
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4.3 .1 Effect of added agonists, including the C-C chemokines 
and cytokines, on adhesion
C5a (lOOnM), IL-5 (40nM) and PMA (InM ) could significantly increase the
adhesion of human eosinophils to laminin-coated microtitre plates above basal levels.
MCP-3 (lOOnM) and RANTES (lOOnM) always stimulated a greater level o f adhesion
compared to basal levels, but did not reach significance (figure 4.12).
160 n
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Adhesion o f human eosinophils stimulated with C5a (100nM)(li), 
RANTES (100nM)(«), MCP-3 (100nM)(B), IL-5 (40nM)(B) and PMA (lnM )(H ) to 
laminin-coated microtitre plates at t=60min. Bars indicate mean±sem total number 
o f cells adhered after H20 2 assay for n=3-6 different eosinophil preparations. 
Signifcantly increased adhesion compared with basal cellular adhesion: *, p<0.05.
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Table 4.2 Effect of M IP -la /p  and MCP-3 on adhesion of human 
eosinophils at t=60m in. Data indicates mean+sem total number of 
cells adhered after H20 2 assay from triplicate wells. Representative of 
2 experiments.
Agonist Cells adhered 
(x\0A) at t=60m in
Basal 3.21+0.49
M IP -la  (lOOnM) 2.90+0.03
M IP -lp  (lOOnM) 3.45+0.50
MCP-1 (lOOnM) 3.49+0.67
C5a (lOOnM) 7.62+0.40
The C-C chemokines M IP -la (lOOnM), M IP-lp (lOOnM) and MCP-1 (lOOnM) 
had no effect on adhesion (table 4.2).
4.3 .2  Effect of Ro 31 -8 2 2 0 /0 0 2  on adhesion
The effect of the selective PKC inhibitor, Ro 31-8220/002, on human 
eosinophil adhesion was also determined. Ro 31-8220/002 (0.3-3/uM) dose- 
dependently inhibited the adhesion of eosinophils stimulated by PMA (In M ), MCP-3 
(lOOnM) and IL-5 (40nM). Interestingly, in unstimulated and C5a (lOOnM) stimulated 
eosinophils, Ro 31-8220/002 (0.3-3/xM) appeared to enhance the adhesion of human 
eosinophils (figure 4.13). However when the basal levels of adhesion was subtracted 





Basal C5a RANTES PMA MCP-3 IL-5
Adhesion of human eosinophils pretreated with vehicle (□), 300nM (II), 
1/zM (H) or 3/zM (■) of the selective PKC inhibitor Ro 31-8220/002 (for 20min at 
37°C), before stimulation with C5a (lOOnM), RANTES (lOOnM), PMA (InM ), 
MCP-3 (lOOnM) or IL-5 (40nM) to laminin-coated microtitre plates at t=60min. Bars 
indicate mean±sem total number o f cells adhered after H20 2 assay for triplicate wells. 
Representative of 2 experiments. Experiment with MCP-3 and IL-5 was conducted on 
a different eosinophil preparation that had a higher basal adhesion as indicated by the 
dotted line.
4 .4  Summary of adhesion experiments
•  Guinea pig and human eosinophils have enhanced adhesion when stimulated 
with particular soluble stimuli.
•  Guinea pig eosinophils have a significantly increased adhesion when stimulated 
by C5a, LTB4, PAF and PMA.
•  Human eosinophils have a significantly increased adhesion when stimulated by
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C5a, MCP-3, IL-5 and PMA. RANTES also augments adhesion.
Guinea pig eosinophil adhesion is dependent on calcium and magnesium. 
Guinea pig eosinophil adhesion is enhanced when extracellular nickel is present. 
The ROCC blocker SK&F 96365 does not effect guinea pig eosinophil 
adhesion, but when used in conjunction with the added agonists C5a and PAF, 
SK&F 96365 inhibited the adhesion of eosinophils.
Adhesion of guinea pig eosinophils was enhanced by the tyrosine kinase 
inhibitors herbimycin A and genistein.
Guinea pig eosinophil adhesion could be inhibited by nanomolar concentrations 
of the specific PI 3-kinase inhibitor, wortmannin.
Both guinea pig and human eosinophil adhesion could be dose-dependently 
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5.1 Guinea pig eosinophil
5.1.1 Effect of the added agonists C5a, LTB4 and PAF
The guinea pig eosinohil prepartions used had a basal intracellular free calcium 
concentration ([Ca2+]j) of 59+9nM  (n=12). Upon stimulation with C5a, LTB4 and 
PAF all agonists produced characteristic responses (figure 5.1). Elevations in [Ca2+]j 
stimulated with PAF were less rapid than those shown by C5a and LTB4. Furthermore 
it was demonstrated that LTB4 elicited a biphasic response at InM  and above. All three 
agonists produced dose related increases of [Ca2+]j above basal levels. The maximal 
elevation in response to each agonist was similar though PAF and C5a had maximal 
effects at lOOnM whereas maximal LTB4 responses were observed between InM  and 
lOnM. This was emphasised when analyzing the data over 5-6 independent 
experiments (figure 5.2). Each agonist at lOnM and lOOnM induced similar significant 
elevations in [Ca2+]i? whereas LTB4 was the only agonist to stimulate a significant rise 
of [Ca2+]j at InM . Again as in the H20 2 experiments fMLP, LPS and IL-8 had little 
effect on the cells (table 5.1). In addition, other work in the laboratories has shown 
that human chemokines are also unable to induce [Ca2+]j elevation in guinea pig 
eosinophils (data not shown).
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Figure 5.1 Time courses of [Ca2+]j elevation in fura-2-loaded guinea pig eosinophils 
(2x l06) stimulated with (a) C5a (l-100nM), (b) LTB4 (0.1-10nM) or (c) PAF (1- 
lOOnM). Traces are representative o f 5-6 experiments.
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Figure 5.2 [Ca2+]j levels in fura-2-loaded guinea pig eosinophils either unstimulated
(□ ) or stimulated with C5a (II), LTB4 (M) or PAF (■). Bars indicate mean±sem 
maximal [Ca2+]/2 x l0 6cells for n=5-6 different eosinophil preparations. Significantly 
increased [Ca2+]j elevation compared with basal [Ca2+]j levels: *, p<0.05; ** ,
p<0.01.
Table 5.1 Effects of IL-8, fMLP and LPS on [Ca2+]; in guinea pig 
eosinophils. Data indicates mean±sem for maximal [Ca2+]j/2x l06 cells 
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5.1.2 Effect of extracellular ionic conditions
The effect of varying the extracellular ions on free calcium elevation was the 
same for each agonist tested viz. C 5a , LTB4 and PAF (lOnM). In the presence of 
calcium (Im M ) only, there seemed to be little change in agonist-induced elevation of 
free calcium. In the presence of magnesium (Im M ) only, in nominal calcium and 
magnesium (50-100^M) or in the presence of the calcium chelator EGTA (Im M ), the 
maximal [C a 2+]j elevated was markedly reduced by 80-90% (figures 5.3 and 5.4). 
This is in contrast to H20 2 experiments where extracellular magnesium was found to 
be an important factor (figure 3.5). From figure 5.4 it can be seen that the basal 
[C a 2+]i was reduced in cells that had nominal or no extracellular calcium suggesting 
some calcium store depletion.
Figure 5.3 (see next page') Time courses of [Ca2+]j elevation in fura-2-loaded guinea 
pig eosinophils (2xl06) stimulated at 40 seconds with (a) C5a (lOnM), (b) LTB4 
(lOnM) or (c) PAF (lOnM) in the presence of (i) Ca2+/M g2+ (Im M ), (ii) Ca2+ (Im M ) 
only, (iii) Mg2+ (Im M ) only, (iv) nominal Ca2+/M g2+ (~50-100j*M) or (v) EGTA 
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Figure 5.4 [Ca2+] ; levels in fura-2-loaded guinea pig eosinophils stimulated with
C5a, LTB4 or PAF (lOnM) in the presence o f Ca2+/M g2+ ( lm M )( l) ,  Ca2+ (Im M ) 
only (H), Mg2+ (Im M ) only (M), nominal Ca2+/Mg2+ (-50-100/iM)(«) or EGTA 
(lm M )(D ). Basal [Ca2+] i levels (□). Bars indicate mean±sem maximal 
[Ca2+]j/2x l06cells for n=3 different eosinophil preparations. Significantly increased 
[Ca2+]j elevation compared with basal [Ca2+]j levels: * * , p<0.01. Significantly 
reduced [Ca2+]j elevation compared with Ca2+/Mg2+ (Im M ) containing cells:
p<0.01.
5 .1 .3  Effect of nickel on [Ca2+]j
The previous experiments suggested that for [Ca2+]j elevation, extracellular 
calcium was important. Thus nickel, which blocks membrane calcium channels and 
subsequent influx into the cell, was used to investigate the role o f extracellular calcium. 
Nickel which does not interfere with fura-2 fluoresence, also has the advantage that
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extracellular Ca2+ (Im M ) can be present, thus minimising the effects of calcium store
depletion. Figure 5.5 demonstrates that nickel (Im M ) reduced the elevation of [Ca2+]j 
in C5a (lOnM), LTB4 (lOnM) and PAF (lOnM) stimulated eosinophils by a small 
amount. In most cases it removed the second peak in the LTB4 biphasic response 
suggesting that this increase was due to calcium influx. Figure 5.6 shows the pooled 
data and indicates a consistent reduction (though not significant) of agonist-induced 
[Ca2+]j elevation in guinea pig eosinophils. This inhibition was greater than the 
reduction which occurred on basal [Ca2+]j levels when nickel was added.
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Figure 5.5 Time courses of [Ca2+]j elevation in fura-2 loaded guinea pig eosinophils 
(2xl06) stimulated with (a) C5a (lOnM), (b) LTB4 (lOnM) or (c) PAF (lOnM) in the 
presence of extracellular Ca2+/M g2+ (Im M ) or Ca2+/N i2+ (Im M ). Agonists added at 
40 seconds for Ca2+/Mg2+ experiments and at 60 seconds (20 seconds post-nickel 
addition) for Ca2+/N i2+ experiments. Traces are representative o f 3 experiments.
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Figure 5.6 [Ca2+]j levels in fura-2 loaded guinea pig eosinophils either unstimulated
or stimulated with C5a, LTB4 or PAF (lOnM) in the presence of Ca2+/M g2+ (lm M )(D ) 
or Ca2+/N i2+ ( lm M )(^ ). Bars indicate mean±sem maximal [Ca2+]j/2x l06cells for 
n =  3 different eosinophil preparations. Significantly increased [Ca2+]j elevation 
compared to respective basal [Ca2+]j levels: **, p<0.01. Significantly reduced [Ca2+]j 
elevation compared with cells in the presence of Ca2+/M g2+: #, p<0.05; p<0.01.
5 .1 .4  Effect of manganese on [Ca2+],
To investigate further the role calcium influx in guinea pig eosinophils, 
extracellular manganese was used. Manganese can be used as a surrogate ion for 
calcium in influx experiments and it has the additional property o f having a greater 
a ffin ity for fura-2 than calcium. Experiments were performed at fura-2’s isobestic 
point (360nm). Figure 5.7 demonstrates how useful manganese is in detecting influx 
by comparing the effect o f ionomycin (10^M) to vehicle-treated cells.
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Figure 5.7 Time courses o f fluoresence in fura-2-loaded guinea pig eosinophils 
(2x l06) either unstimulated or stimulated with PAF (lOOnM), C5a (lOOnM), LTB4 
(1/mM) or ionomycin (10/xM) in the presence of Ca2+ (50/xM)/Mg2+ (Im M ) with either 
(a) 300/xM MnCl2 or (b) 100/*M MnCl2 added (Ex=360nm and Em=510nm). Traces 
are representative o f 2-3 experiments.
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In contrast, PAF (lOOnM), C5a (lOOnM) and LTB4 (1/xM) cause very small
amounts of manganese influx, if any, when comparing vehicle-treated cells. This 
implies calcium influx is a minor component of the signalling system and the 
suppression seen in section 5.1.2 was likely due to depletion of intracellular calcium 
stores.
5.1.5  Effect of SKSCF 96365  on [Ca2+],
The specific ROCC blocker SK&F 96365 (10-60/xM) was tested for its effect 
on [Ca2+]i. Figure 5.8 demonstrates that SK&F 96365 (10-60/iM) caused a 
concentration-dependent increase in [Ca2+]j in guinea pig eosinophils. This was 
followed by a concentration-dependent inhibition of [Ca2+]j elevation in response to 
C5a (lOnM) and PAF (lOnM). This effect was also observed for the enantiomers of 
SK&F 96365 and these appeared to be as effective as each other. Figure 5.9 shows 
that the addition of PAF (lOnM) before SK&F 96365 (60^M) had no effect on 
elevation of [Ca2+]i. Figure 5.10 shows the pooled data of the 'agonist' effect of 
SK&F 96365 and its enantiomers on [Ca2+]j and figure 5.11 shows the pooled data of 
the inhibitory effects SK&F 96365 and its enantiomers on [Ca2+]j in guinea pig 
eosinophils.
F igure 5.8 (see next pagel Time courses of [Ca2+]i elevation in fura-2-loaded guinea 
pig eosinophils (2xl06) either stimulated with (i) SK&F 96365 (10-60^M), (ii) (-) 
SK&F 96365 (10-60/xM) or (iii) (+)SK & F 96365 (10-60/xM) then either (a) C5a 
(lOnM) or (b) PAF (lOnM). In panel (i), control experiments with no SK&F 96365 
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Figure 5.9 Time course of [Ca2+]j elevation in fura-2-loaded guinea pig eosinophils 
(2 x l0 6) stimulated with PAF (lOnM) then SK&F 96365 (60^M). Trace is 
representative o f one experiment.
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Figure 5.10 [Ca2+]j levels in fura-2-loaded guinea pig eosinophils either
unstimulated (□) or stimulated with SK&F 96365 (10-60pM) (M), (-)SK&F 96365 (10- 
100/zM) (II) or (+)SK&F 96365 (10-100/zM) {W). Bars indicate mean+sem maximal 
[Ca2+]i/2x l06cells for n=4 different eosinophil preparations. Significantly increased 
[Ca2+]j elevation compared with basal [Ca2+]j levels: *, p<0.05; * * , p<0.01.
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Figure 5.11 Elevation of [Ca2+]j in fura-2-loaded guinea pig eosinophils stimulated 
with vehicle (□), SK&F 96365 (10-60/*M) (H), (-)SK&F 96365 (10-100/xM) (M) or 
(+ )S K & F  96365 (10-100/xM) (M)  then either (a) C5a (lOnM) or (b) PAF (lOnM). 
Bars indicate mean±sem A[Ca2+y 2 x l0 6cells for n=3-6 different eosinophil 
preparations. Significantly reduced [Ca2+]j elevation compared with vehicle stimulated 
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5 .1 .6  Effect of the PKC inhibitor, Ro 3 1 -8 2 2 0 /0 0 2 , on 
[Ca2+]j elevation
To investigate the role o f PKC in calcium signalling, the elevation o f free 
calcium was monitored in response to suboptimal doses of C5a (30nM) and LTB4 
(30nM) in cells preincubated with Ro 31-8220/002 (0.3-3/xM). Interestingly, the 
inhibitor dose-dependently potentiated the maximal responses as shown in figure 5.12. 
It can be clearly observed in the LTB4 biphasic response that it is the second peak of 
the response that is enhanced. Both C5a and LTB4 exhibited a significant rise at 3^tM 
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Figure 5.12 Time courses of [Ca2+]j elevation in fura-2-loaded guinea pig eosinophils 
(2 x l0 6) pretreated with the PKC selective inhibitor Ro 31-8220/002 (for 20min at 
37°C) then stimulated with either (a) C5a (30nM) or (b) LTB4 (30nM). Traces are 
representative o f 4 different eosinophil preparations.
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Figure 5.13 Elevation o f [Ca2+]j in fura-2-loaded guinea pig eosinophils pretreated 
with vehicle (§1), 300nM (■), 1/uM (H) or 3/xM (■) o f the PKC selective inhibitor Ro 
31-8220/002 (for 20min at 37°C) then stimulated with either C5a (30nM) or LTB4 
(30nM). Basal [Ca2+]j levels (□). Bars indicate mean±sem maximal 
[Ca2+]i/2x l06cells for n=4 different eosinophil preparations. Significantly increased 
[Ca2+]j elevations compared with vehicle treated cells: *, p<0.05; * * , p<0.01.
5 .1 .7  Effect of the tyrosine kinase inhibitors genistein, 
erbstatin, herbimycin A  and tyrphostin A -4 7
The role o f tyrosine kinase on calcium signalling was also investigated. For 
similar reasons to those for the H20 2 assay, before any experiments were done the 
effect of each inhibitor on fluorescence was first investigated. Figure 5.14 shows that 
erbstatin (100/xM) and tyrphostin A-47 (10/uM) had significant effects on the fura-2 
fluorescence signal. Similarly erbstatin (100/>eM), tyrphostin A-47 (100/xM) and
* *
■;5&:
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genistein (300^M) had significant effects on fluo-3. Herbimycin A was the only
inhibitor that did not affect fura-2 and genistein (100/zM) was safe to use with fluo-3 
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Figure 5.14 Effect of the fluorescent properties of different specific tyrosine kinase 
inhibitors on (i) free fura-2 (Exl =340nm, Ex2=280nm and Em=510nm) or (ii) free 
fluo-3 (Ex=510nm and Em=526nm): (a&d) erbstatin (1-KXfyiM); (b&e) tyrphostin 
A-47 (1-100/xM); (c) herbimycin A (0.175-1.75/zM) and (f) genistein (10-300^M).
Herbimycin A or genistein had no effect on [Ca2+]i elevation in guinea pig 
eosinophils. Figure 5.15 shows the identical traces obtained in C5a (lOnM) or PAF 
(lOnM) stimulated eosinophils incubated with either vehicle or herbimycin A (1/*M) 
(the data for genistein is not shown).
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Figure 5.15 Time courses of [Ca2+]j elevation in fura-2-loaded guinea pig eosinophils 
(2xl06) pretreated with herbimycin A ( l^M ) for 20min at 37°C before stimulation with 
(a) C5a (lOnM) or (b) PAF (lOnM). Traces are representative o f 2 experiments.
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5.2 Human eosinophil
5.2.1 Effect of added agonists including chemokines and the
cytokine IL-5
The human eosinophil preparations had a basal [Ca2+]j of 75.7±5.3nM  (n=8). 
Upon stimulation with RANTES, M IP -la , MCP-1 and MCP-3 (l-100nM ) all the 
chemokines produced characteristic responses (figure 5.16). After addition of the 
agonist, elevations in [Ca2+]j were rapid (within the first 2sec following addition) with 
a gradual decrease back to near basal levels over the next 20-30sec. RANTES, 
M IP -la  and MCP-3 produced a dose-related increase in [Ca2+]j above basal levels that 
were significant at lOnM and lOOnM for each agonist. The MCP-1 induced elevation 
was only significant at lOOnM as shown in figure 5.17(b). Neither M IP -ip  nor IL-5 
could elevate calcium in human eosinophils (figure 5.16). The lack of activity of IL-5 
was in contrast to its very potent effect in the H20 2 assay (figures 3.21 and 3.22). In 
addition to the human cytokines, the agonists C5a and PAF were also tested for their 
ability to elevate [Ca2+]j in human eosinophils. As figure 5.17(a) demonstrates both 
C5a and PAF were potent inducers of [Ca2+]j elevation. Unlike the effect on guinea 
pig eosinophils where these agonists were approximately equipotent, in human 
eosinophils C5a caused [Ca2+]j elevations at concentrations as low as 30pM and 
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Time courses o f [Ca2+]j elevation in fura-2-loaded human eosinophils 
(lx lO 6) stimulated with (a) RANTES (l-100nM), (b) M IP -la  (l-100nM), (c) M IP -lp  
(lOOnM), (d) MCP-1 (10-lOOnM), (e) MCP-3 (l-100nM) or (f) IL-5 (40nM). Traces 
are representative o f 2-6 experiments.
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Figure 5.17 [Ca2+]j levels in fura-2-loaded human eosinophils (a) stimulated with the
agonists C5a (0.3-30nM)(ll) or PAF (l-100nM)(H) or (b) stimulated with the 
chemokines RANTES (l-100nM)(*), M IP-la (l-100nM )(*), MCP-1 (10-100nM)(H), 
MCP-3 (l-100nM)(H). Basal [Ca2+I  levels (□). Bars indicate mean±sem maximal 
[Ca2+]j/ lx l0 6cells for n=3-8 different eosinophil preparations. Significantly increased 
[Ca2+]j elevation compared with basal levels: *, p<0.05 ; ** , p<0.01.
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5.2.2  Desensitisation experiments between RANTES and 
MCP-3
Previously it has been reported using desensitisation experiments that a 
RANTES specific receptor and a M IP-la/RANTES receptor exists (44,236). These 
experiments have been successfully repeated (data not shown). I then further 
investigated whether the chemokines MCP-1 and MCP-3 used a common chemokine 
receptor or used specfic receptors of their own. Figure 5.18(a) demonstrates that 
desensitisation was observed when human eosinophils were stimulated with RANTES 
followed by MCP-3, but not vice versa. This indicates MCP-3 responses are mediated 
by the RANTES receptor and these data are in agreement with the only previous study 
(236). MCP-1 receptors have been reported not to exist on eosinophils (44) however 
a significant response to MCP-1 (lOOnM) on human eosinophils was detected (figure 
5.16). Figure 5.18(b) shows that MCP-3 desensitises the response elicited by MCP-1 
but not vice versa. MCP-1 is not acting via the RANTES receptor. This is ruled out 
by the activity of the chemokine MCP-3.
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Figure 5.18 Time courses o f [Ca2+]j elevation cross-desensitisation experiments in 
fura-2-loaded human eosinophils (lx lO 6) stimulated with (a) MCP-3/RANTES (lOnM) 
or (b) MCP-1/MCP-3/RANTES (lOnM). Traces are representative o f 2 experiments.
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5 .2 .3  Effect of EGTA and EDTA on [Ca2^
To ascertain the effect o f extracellular calcium on human eosinophils [Ca2+]j, 
preliminary experiments were performed using EGTA and EDTA (4mM). Figure 5.19 
shows that when eosinophils were stimulated with RANTES (lOnM) in the presence 
of EGTA, the response was attenuated by around 80%. The effect o f EDTA was more 
minimal with only a partial reduction (25%) of the signal. Both these results again 
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Figure 5.19 Time courses o f [Ca2+]j elevation in fura-2-loaded human eosinophils 
( lx lO 6) in the presence of vehicle, EGTA (4mM) or EDTA (4mM) then stimulated 
with RANTES (lOnM). Traces are representative of 2 experiments.
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5.2 .4  Effect of the ROCC blocker, SKscF 963 65 , on [Ca2+]j
On guinea pig eosinophils, SK&F 96365 appeared to have an 'agonistic' effect 
in [Ca2+]i elevation. Thus the compound was tested for its effect on human eosinophils 
in [Ca2+]i elevation. As in the case of H20 2 production, the effects of SK&F 96365 
on human eosinophils in [Ca2+]j elevations were very different to the case of guinea pig 
eosinophils. Figures 5.20 and 5.21 illustrate that SK&F 96365 (10-60/*M) did not 
affect [Ca2+]j elevation in human eosinophils, however these concentrations all caused 
a significant [Ca2+]j elevations in guinea pig eosinophils (figures 5.8 and 5.10). Only 
at the highest dose tested ( lOOfxM), was a small significant rise in [Ca2+]j detected. 
Figure 5.20 shows that SK&F 96365 (10-100/xM) dose-dependently inhibited the 
subsequent response to the added agonists PAF (lOnM) and RANTES (lOOnM). 
Figure 5.22 shows the inhibition to be significant by analysing pooled data from 
several experiments. In addition the agonist C5a (300pM) was tested.
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Figure 5.20 Time courses o f [Ca2+]j elevation in fura-2-loaded human eosinophils 
(lxlC^cells) pretreated with SK&F 96365 (10-100^M) added at 40 seconds then either 
(a) PAF (lOnM) or (b) RANTES (lOOnM) added at 110 seconds. Traces are 
representative o f 3-5 experiments.
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Figure 5.21 [Ca2+]j levels in fura-2-loaded eosinophils after the addition o f SK&F
96365: 10/xM (II); 30/xM (■); 60/aM (B); 100/xM (■). Basal [Ca2+] t levels (□). Bars 
indicate mean+sem maximal [Ca2+y i x l0 6 cells for n=5 different eosinophil 
preparations. Significantly increased [Ca2+]i elevation compared with basal [Ca2+]j 
levels: * * , p<0.01.
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Figure 5.22 Elevation o f [Ca2+]j in fura-2-loaded eosinophils after the addition of 
SK&F 96365: vehicle (□); 10/xM (II); 30/xM (« ); 60^M (Si); 100mM (■) then 
stimulated with either (a) C5a (300pM), (b) PAF (lOnM) or (c) RANTES (lOOnM). 
Bars indicate mean±sem A[Ca2H'] i/ lx  106 cells for n=3 different eosinophil 
preparations. Significantly increased [Ca2+]j elevation compared with basal [Ca2+]j 
levels. Significantly reduced [Ca2+]j elevation compared with vehicle stimulated cells: 
p<0.05 ; p<0.01.
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5 .2 .5  Effect of the selective PI 3-kinase inhibitor, wortmannin, 
in [Ca2+]j
The specific PI 3-kinase inhibitor, wortmannin, greatly affected H20 2 
production from both guinea pig and human eosinophils. Its effect was thus tested on 
[Ca2+]j elevation in human eosinophils. Figure 5.23 shows that the addition of 
wortmannin (3-30nM) did not alter the [Ca2+]j in human eosinophils. After a lOmin 
incubation at 37°C the chemokine RANTES (lOOnM), the response which was 
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Time courses o f [Ca2+]j elevation in fura-2-loaded human eosinophils 
( lx l0 6cells) pretreated with vehicle or the PI 3-kinase specific inhibitor wortmannin 
(for lOmin at 37°C) then stimulated with RANTES (lOOnM). The control response 
(without wortmannin) is shifted by 200nm for clarity. Traces are from a single 
experiment.
As illustrated in figure 5.23, both vehicle and wortmannin treated eosinophils
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elicited identical [Ca2+]j traces, suggesting PI 3-kinase did not affect the calcium
signalling pathway. In addition, it demonstrates that wortmannin did not affect the 
agonist receptors or was toxic to the cells.
5.3 Eol-ls and Eol-3s
5.3.1 Effect of added agonists
The human eosinophilic cell lines Eol-1 and Eol-3 were tested for their ability 
to elevate [Ca2+]i in response to various added agonists and chemokines. Both 
unmatured and cells matured with butyric acid were tested. From Leishman's stained 
cytospins of Eol-1 and Eol-3s of unmatured and matured cells, there was no visible 
differentiation from mononuclear blast-like cells towards the granulocytic eosinophil 
type cells. Figure 5.24 shows the response of unmatured and matured Eol-ls and 
Eol-3s when stimulated with the agonist PAF (lOOnM) and the chemokine RANTES 
(l-100nM ). It appears that Eol-ls are generally more responsive to agonists than 
Eol-3s. There was no difference between unmatured and matured Eol-ls; unmatured 
cells were thus used for most of the experiments. In contrast Eol-3s became more 
responsive as they matured with dubutyryl cAMP. However this applied to all the 
agonists tested and not those that were specific to human eosinophils. Figure 5.25 
shows the pooled data for all the agonists tested. PAF (10-lOOnM), RANTES (10- 
lOOnM) and MCP-1 (0.1-100nM) dose-dependently elevated [Ca2+]j in unmatured 
Eol-ls. The same was true for two-day dibutyryl cAMP (0.2mM) matured Eol-ls. 
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Figure 5.24 Time courses o f [Ca2'H] i elevation in fura-2-loaded Eol-ls and Eol-3s 
(IxK^cells) stimulated at 40 seconds with either PAF (lOOnM) or RANTES (1-lOOnM) 
in (a) unmatured Eol-ls; (b) two-day dibutyryl cAMP (0.2mM) matured Eol-ls; (c) 
unmatured Eol-3s or (d) two-day dibutyryl cAMP (0.2mM) matured Eol-3s. Traces 
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Figure 5.25 [Ca2+]j levels in fura-2-loaded Eol-ls and Eol-3s stimulated with C5a
(l-30nM)(£S), PAF (l-100nM)(H), RANTES (3-100nM)(^), MCP-1 (0.1-100nM)(B), 
IL-8 (100nM)(H) or NAP-2 (lOOnM)(0) in either (a) unmatured Eol-ls; (b) two-day 
dibutyryl cAMP (0.2mM) matured Eol-ls; (c) unmatured Eol-3s or (d) two-day 
dibutyryl cAMP (0.2mM) matured Eol-3s. Basal [Ca2+]j levels (□). Bars indicate 
mean+sem maximal [Ca2+]i/2x l06cells for n=3-6 different eosinophil preparations 
(except for two-day dibutyryl cAMP (0.2mM) matured Eol-ls where n = l) .  
Significantly increased [Ca2+]j elevation compared with basal [Ca2+]j levels: *, 
p<0.05; *♦, p<0.01.
Unmatured Eol-3s did elevate [Ca2+]j in response to C5a (30nM), PAF (10- 
lOOnM), RANTES (30-100nM) and MCP-1 (10-lOOnM). C5a (l-30nM), PAF (1-
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lOOnM), RANTES (30-100nM), MCP-1 (l-100nM) and IL-8 (lOOnM) elevated [Ca2+L
in two-day dibutyryl cAMP (0.2mM) matured Eol-3s. NAP-2 (lOOnM) did not affect 
the [Ca2+]j elevation in any of the cells tested.
5.3.2  Effect of the specific tyrosine kinase inhibitors genistein 
and herbimycin A  on unmatured Eol-ls
To investigate the role of tyrosine kinase in the eosinophilic cell line, unmatured 
Eol-ls were incubated overnight with vehicle, genistein (30/iM ) and herbimycin A 
(875nM), then loaded with fluo-3. Figure 5.26 shows the elevation of [Ca2+]j 
(calculated using the difference between fully bound and fully dissociated fluo-3 with 
calcium from a single excitation and single emission trace) in Eol-ls elicited by PAF 
(lOOnM), RANTES (30nM) and MCP-1 (lOnM) in the presence of genistein and 
herbimycin A. It can be seen that the inhibitors did not significantly effect the [Ca2+]j 
elevations to any of the agonists tested suggesting PAF, RANTES and MCP-1 did not 






































courses o f [Ca2+] ; elevation in fura-2 loaded unmatured Eol-ls 
ubated with vehicle or the specific tyrosine kinase inhibitors 
herbimycin A (875nM) (overnight at 37°C) then stimulated with 
OnM), (b) RANTES (30nM) or (c) MCP-1 (lOnM). Traces are 
experiments.
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Summary of [Ca2+]j experiments
Guinea pig eosinophils, human eosinophils and eosinophilic Eols can be 
stimulated to elevate [C a2+]i.
Order of potency for [Ca2+]j elevation in guinea pig eosinophils: LTB4 >  PAF 
>  C5a.
Order of potency for [C a2+]j elevation in human eosinophils: C5a >  PAF >  
RANTES, M IP -la  >  MCP-3 >  MCP-1.
Unmatured and matured Eol-ls were equally responsive to added agonists and 
the order of potency for [C a2+] j : MCP-1 >  RANTES= PAF >  C 5a  >  IL-8. 
Matured Eol-3s were more responsive to added agonists than unmatured Eol-3s 
and the order of potency for [C a2+] j : C 5a  >  PAF >  MCP-1 =  RANTES >  
IL-8.
fMLP, IL-5, IL-8 and NAP-2 were unable to elicit [C a 2+]j elevation in guinea 
pig eosinophils.
IL -5, IL-8 and NAP-2 were unable to elicit [C a2+]j elevation in human 
eosinophils.
Human eosinophils were found to exhibit a M IP-la/RA N TES receptor and a 
MCP-3/RANTES receptor.
Guinea pig and human eosinophils required extracellular calcium to enable 
normal [C a 2+]j elevation to added agonist. This avoids intracellular calcium 
store depletion.
Nickel and manganese experiments both suggested a small calcium influx 
component in guinea pig eosinophils.
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SK&F 96365 and its enantiomers concentration-dependently elevated [Ca2+]j
levels in guinea pig eosinophils and concentration-dependently inhibited [Ca2+]j 
elevation to the subsequent added agonist. However, the added agonist did not 
desensitise the effect of SK&F 96365.
In contrast, SK&F 96365 did not elevate [Ca2+]j levels in human eosinophils, 
but still concentration-dependently inhibited [Ca2+]i elevation to the subsequent 
added agonist.
The selective PKC inhibitor, Ro 31-8220/002, dose-dependently enhanced the 
[Ca2+]j elevations to added agonist in guinea pig eosinophils.
The specific tyrosine kinase inhibitors genistein and herbimycin A, failed to 
have an effect on either guinea pig eosinophil or unmatured Eol-1 [Ca2+]j 
responses to added agonist.
The specific PI 3-kinase inhibitor, wortmannin, had no effect on [Ca2+]i 
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6.1 Western blotting experiments
To ascertain whether tyrosine phosphorylation was occurring in either guinea 
pig eosinophils, human eosinophils or the eosinophilic cell lines Eol-1/ Eol-3, the 
technique of Western blotting was employed. This method has been successfully used 
on rabbit platelets (210) and T-lymphocytes (211).
6.1.1 Tyrosine phosphorylation in guinea pig eosinophils
Unstimulated and eosinophils stimulated with C5a and PAF showed extensive 
tyrosine phosphorylation with the antiphosphotyrosine specific murine monoclonal 
antibody PY20. To assess very rapid activation, tyrosine phosphorylation was 
measured at 2sec, 5sec, lOsec, 20sec, and 30sec in a stirred cell system. Despite the 
enormous amount of phosphorylation, there appeared to be very little up-regulation or 
down-regulation of the signal (see figure 6.1). Any changes that did occur were 
inconsistent. This was also the case for tyrosine phosphorylations measured for 
sustained activation, ie. lmin, 5min, 15min, 30min and 60min. However, when 
tyrosine phosphorylation was measured for sustained activation in laminin-coated 
tubes, there did appear to be an increase in the signal at around 60-65, 100 and 120kDa 
in C5a (lOOnM) and PAF (lOOnM) stimulated eosinophils (see figure 6.2). In PAF 
stimulated cells, a decrease in the 120kDa tyrosine phosphorylated band was observed 
at 45min, but all the phosphorylated bands were lower in this lane. This suggests 
unequal loading of the protein onto the gel has occurred. However, as can be also seen 
in figure 6.2, these increases were also detected in unstimulated cells.
Due to the high degree of basal of tyrosine phosphorylation detected, control
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experiments were performed to establish the amount o f nonspecific binding of the






Figure 6.1 Time courses o f tyrosine phosphorylation in guinea pig eosinophils. 
Stirred cells were incubated with C5a (lOOnM) at 37°C. Samples were run on a 10% 
SDS-PAGE gel, transferred to nitrocellulose membrane and were detected by Western 
blotting with PY20 and ECL. Representative o f 3 experiments.
Figure 6.2 (see next page! Time courses of tyrosine phosphorylation in guinea pig 
eosinophils incubated in laminin-coated-tubes. Cells were incubated with vehicle, C5a 
(lOOnM) and PAF (lOOnM) at 37°C. Samples were run on a 10% SDS-PAGE gel, 
transferred to nitrocellulose membrane and were detected by Western blotting with 
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These included excluding the first antibody (PY20) and substituting the first
antibody with whole mouse IgG. Also, the membrane was probed with PY20 in the 
presence of phosphotyrosine (Im M ). These results showed that without the first 
antibody, no tyrosine signal was detected. The amount of PY20 binding in the 
presence of phosphotyrosine was slightly lower than PY20 on its own. This suggested 
that a lot of nonspecific binding had taken place. Extensive binding also occurred with 
whole mouse IgG. Whole IgG is not an ideal control, as PY20 is an IgGpn Fc 
fragment. Therefore, the nonspecific binding may have been exaggerated in these 
experiments.
Another antiphosphotyrosine murine monoclonal antibody, 4G10, was also 
tested. This appeared to be more specific as experiments with 4G10 in the presence 
of phosphotyrosine showed minimal antibody binding patterns compared to 4G10 on 
its own. In addition, these patterns were not blocked by phosphoserine or 
phosphothreonine (see figure 6.3).
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Figure 6.3 Binding o f 4G10 and PY20 to blotted eosinophil lysates. Stirred cells 
were incubated with vehice or C5a (10-lOOnM) for 30 seconds at 37°C. Samples were 
run on a 10% SDS-PAGE gel, transferred to nitrocellulose membrane and were 
detected by Western blotting with PY20 in the presence or absence o f phosphotyrosine; 
4G10 in the presence or absence o f phosphotyrosine, phosphoserine or 
phosphothreonine; mouse whole IgG, or no first antibody. The blot was developed 
using ECL. Representative o f 2 experiments.
6.1.2
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Tyrosine phosphorylation in human eosinophils
Due to the number o f eosinophils required to assess tyrosine phosphorylation 
(2xl06cells/sample), very little work was possible with human eosinophils. Only two 
tyrosine phosphorylation experiments were performed in laminin-coated microtitre 
plates. These experiments showed the amount of basal tyrosine phosphorlation detected 
was less than in guinea pig eosinophil experiments. As figure 6.4 demonstrates, in 
RANTES (lOOnM) stimulated cells, the two main bands that appeared to be 
phosphorylated (detected by 4G10) occurred at 25-30kDa, 60-65kDa and a hint o f a 
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Figure 6.4 Time course o f tyrosine phosphorylation in human eosinophils. Cells 
were incubated with vehicle, C5a (lOOnM) and RANTES (lOOnM) fat 37°C. Samples 
were run on a 10% SDS-PAGE gel, transferred to nitrocellulose membrane and were 
detected by Western blotting with 4G10 and ECL. Representative o f 2 experiments.
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6 .1 .3  Tyrosine phosphorylation in the eosinophilic cell lines, 
Eol-1 and Eol-3
The advantage of the eosinophilic cell lines was that the experiments were not 
limited by the number of cells available. The first set of experiments were carried out 
on unmatured cells. These showed a marked difference in their phosphorylation 
patterns between the different cell lines, with Eol-ls having a greater extent of tyrosine 
phosphorylation than Eol-3s. The cell lines were stimulated with C5a (lOOnM), PAF 
(lOOnM), MCP-1 (lOOnM) and RANTES (100-300nM). None of the phosphorylation 
patterns (probed with PY20), changed with respect to time (see figures 6.5A &  6.6A  
for representative tyrosine patterns). The phosphorylation patterns did not change 
between experiments carried out on stirred cells or cells in laminin-coated tubes.
Control experiments did indicate that no nonspecific binding of the proteins 
occurred with the antibody PY20, as the binding was completely inhibited by Im M  
phosphotyrosine (blank blot not shown).
Figure 6.5 (see next pagel Time courses of tyrosine phophorylation in the 
eosinophilic cell line Eol-1. A) Unmatured Eol-ls were incubated with vehicle or 
RANTES (lOOnM) at 37°C. B) Eol-ls matured with butyric acid (0.5mM) were 
incubated with vehicle or RANTES (lOOnM) at 37°C. Samples were run on a 7-17% 
gradient SDS-PAGE gel, transferred to nitrocellulose membrane and were detected by 
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Upon maturation with butyric acid (0.5m M), there appeared to be some up-
regulation of a protein phosphorylated at 44kDa and a down regulation of a protein 
phosphorylated at llOkDa in the Eol-ls, but no change in the degree of tyrosine 
phosphorylation occurred in the Eol-3s (see figures 6.5B and 6.6B for representative 
tyrosine phosphorylation patterns).
6.2 Effect of the tyrosine kinase inhibitors, genistein, 
herbimycin A  and tyrphostin A -47  on tyrosine 
phosphorylation in guinea pig eosinophils and unmatured 
Eol-ls
Due to the inability to detect any change in the tyrosine phosphorylation 
patterns upon agonist stimulation, experiments were performed in the presence of 
various specific TK inhibitors to see if any changes in the phoshorylation patterns could 
be invoked.
Guinea pig eosinophils were incubated with herbimycin A (5/xM), genistein 
(300/*M ), tyrphostin A47 (IOOjiM ) and vehicle (0.1% DMSO) for one hour prior to 
stimulation with C5a (lOOnM) or HBSS, in laminin-coated eppendorfs.
F igure 6.6 (see previous page! Time courses of tyrosine phophorylation in the 
eosinophilic cell line Eol-3. A) Unmatured Eol-3s were incubated with PAF (lOOnM) 
or RANTES at 37°C. B) Eol-3s either unmatured of matured with butyric acid 
(0.5mM) were incubated with vehicle at 37°C. Samples were run on a 7-17% gradient 
SDS-PAGE gel, transferred to nitrocellulose membrane and were detected by Western 
blotting with PY20 and ECL. Representative of 2 experiments.
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As figure 6.7 demonstrates, though C5a treated eosinophils had a slightly
increased tyrosine phosphorylation compared with HBSS treated cells, no inhibition of 
phosphorylation could be achieved in either C5a or HBSS stimulated cells with any of 
the TK inhibitors. The apparent increase in phosphorylation detected in the tyrphostin 
experiment was due to a longer exposure of the membrane to the film.
Unmatured Eol-ls, which have extensive tyrosine phosphorylation that does not 
change upon agonist stimulation, were incubated with the TK inhibitors herbimycin A  
(875nM), genistein (30/uM) and vehicle (0.01% DMSO) overnight. The cells in 
suspension were then stimulated with MCP-1 (In M ), RANTES (30nM) or HBSS. 
Though there was no difference between the HBSS treated cells and the agonist- 
stimulated cells, there was a profound inhibition of the phosphorylation patterns by the 
TK inhibitors herbimycin A and to a lesser extent genistein (figure 6.8). The viability 
of these Eol-ls had been reduced by the overnight incubation with TK inhibitors to 
around 73% in the DMSO and herbimycin A treated Eol-ls, and 40% in the genistein 
treated Eol-ls. However, the cell concentration was adjusted before the start of the 
experiment to give equal numbers of viable cells in each sample.
F igure 6.7 (see next pagel Time courses of tyrosine phosphorylation in guinea pig 
eosinophils. Cells were pretreated with vehicle (DMSO 0.1 %), herbimycin A (5/xM), 
genistein (300/zM) or tyrphostin A-47 (100/xM) for 1 hour at 37°C and then stimulated 
with C5a (lOOnM) at 37°C. Samples were run on 10% SDS-PAGE gels, transferred 
to nitrocellulose membranes and were detected by Western blotting with PY20 and 
ECL. Representative of 2 experiments.
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Figure 6.8 Effect o f tyrosine kinase inhibitors on tyrosine phosphorylation in 
Eol-ls. Cells were pretreated with vehicle (DMSO 0.1 %), herbimycin A (875nM) or 
genistein (30/xM) overnight at 37 °C and then stimulated with either RANTES (30nM) 
or MCP-1 (InM). Samples were run on a 7-17% gradient SDS-PAGE gel, transferred 
to nitrocellulaise membrane and were detected by Western blotting with PY20 and 
ECL. Figure shows the result from a single experiment.
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Summary of the tyrosine phosphorylation experiments
Guinea pig eosinophils, human eosinophils and the eosinophilic cell line Eol-1, 
have extensive protein-tyrosine phosphorylation in their unstimulated and 
stimulated states.
The eosinophilic cell line Eol-3 has a much lower tyrosine phosphorylation 
content.
An up-regulation of three bands (60-65, 100 &  120 kDa) in guinea pig 
eosinophils could be induced when unstimulated and stimulated cells were 
incubated in laminin-coated tubes.
No up- or down-regulation of the TK patterns could be achieved in either 
human eosinophils and Eol-ls under any conditions, or in guinea pig 
eosinophils in suspension to any agonist tested.
Maturation of the eosinophilic cell lines Eol-1 with butyric acid induced an up- 
regulation of a 42kDa band and a down-regulation of a llOkDa band. 
However, maturation of Eol-3s had no effect on phosphorylation patterns. 
The specific inhibitors genistein, herbimycin A and tyrphostin A-47 had no 
effect on guinea pig eosinophil tyrosine phosphorylation 
Herbimycin A and genistein greatly reduced the amount of tyrosine 
phosphorylation in unmatured Eol-ls.
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7.1 Initial aims of this project
At the outset of this project, the importance of the eosinophil as a 
proinflammatory cell in asthma and various respiratory diseases had been well 
established from clinical studies, but the mechanisms of eosinophil activation were 
poorly characterised. The purpose of this study was to ascertain what caused 
eosinophil activation and induce the release of toxic oxygen metabolites. Once 
particular agents had been identified, these were used to deduce various signal 
transduction mechanisms that occur during activation. Specific therapeutic agents and 
subsequent intervention of these mechanisms during eosinophil activation could be 
useful in preventing these respiratory disorders from occurring.
7.2 Eosinophil H20 2 production
Results presented in this thesis show guinea pig eosinophils can be stimulated 
in vitro to produce significant amounts of H20 2 with the soluble stimuli C5a and LTB4. 
PAF was a weaker agent in eliciting H20 2 production at all doses tested. Previously 
eosinophils had been shown to produce H20 2 but substantial release was elicited by the 
phorbol ester PMA. Particulate stimuli were much less effective than PM A (212). In 
studies that measured 0 2 production rather that H20 2 released, eosinophils have been 
shown to be capable of eliciting 0 2 in response to various other stimuli. In guinea pig 
eosinophils this includes LTB4 (213), digitonin, NaF, A23187, and weakly by PAF and 
opsonised zymosan (75,107,189).
The advent of the magnetic assisted cell sorter (MACS) in conjunction with a 
CD 16 antibody has made the purification of peripheral blood eosinophils more feasible
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(207). CD 16 is a molecule present on neutrophils but not eosinophils and using the 
column, unstimulated eosinophils are negatively selected. Using this technique 
eosinophils were successfully isolated, and C5a and PAF were demonstrated to produce 
H20 2 from human eosinophils as well as from guinea pig eosinophils. LTB4 was not 
tested on human eosinophils, but it has been shown to induce chemotaxis and IgE 
binding of human eosinophils (214,214a). However, some functional responses have 
been reported to be lacking in response to LTB4 suggesting certain biochemical and 
functional differences exist between different species (214b). Human eosinophils have 
been shown to release the cationic proteins EPO and ECP in response to PAF and also 
release 0 2 at much higher agonist concentrations (l-30/*M ) (215). IgA and IgG have 
also been shown to cause degranulation (by measuring EDN) and this effect was 
enhanced by the cytokines GM-CSF and IL-3. In addition, a small amount of 
degranulation was caused by IL-5 (216).
Various cytokines and chemokines have been identified at sites of inflammation 
and are thought to have a role in recruitment and cellular function. It was thus 
important to establish whether these played a role in H20 2 production from human 
eosinophils.
It was demonstrated that various human cytokines, which were inactive when 
added to guinea pig eosinophils, were able to elicit H20 2 from human eosinophils. 
These included IL -5, MCP-3 and RANTES. Interestingly, all the agonist-induced 
responses followed a similar time course, with the cells releasing H20 2 from agonist 
stimulation reaching a maximal response by 30 minutes, except IL -5, which didn’t 
elicit a maximal response until one hour. The time courses followed similar patterns
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at lower doses, again reaching a plateau by 30 minutes or 60 minutes in the case of 
IL-5. Similarly, other studies have also shown the ability of agents to release H20 2 and 
0 2 from human eosinophils. Again, PMA has been shown to be very potent (212).
For reasons documented in the introduction, the scopletin based assay to 
measure H20 2 was used. Haynes and Fletcher (217) pointed out that the most accurate 
way of measuring the respiratory burst is by using the SOD-inhibitable reaction as SOD 
is specific to superoxide. However care must be taken as H20 2 formed by the 
dismutation can oxidise the reduced ferricytochrome c resulting in an underestimation 
of O’* Using the SOD-inhibitable method, 0 2 production was successfully measured, 
repeating the same order of potency that was achieved in the H20 2 experiments. 
However, the window of detection was much smaller than in the H20 2 assay.
The disadvantage of the scopoletin-based assay is that the method is sensitive 
to other hydrogen donors such as serum proteins. 75% inhibition could be obtained 
by catalase, which breaks down the H20 2 produced. The scopoletin based assay 
required fewer cells than the ferricytchrome c assay and was monitored with ease in 
the fluorescent plate reader.
To ascertain that the H20 2 being detected was being produced via the NADPH  
oxidase complex, various inhibitors were used. Diphenylene iodonium first produced 
by Collette et al (218) has been described to inhibit 0 2 generated by the NADPH  
oxidase by Cross and Jones in neutrophils (219) and Deme et al in the thyroid plasma 
membrane (220). However, this componud was insoluble at the concentrations 
required for inclusion in the H20 2 assay. Another reported NADPH oxidase inhibitor 
is HMAP (221), which has been shown to attenuate NF-kB induction (which occurs
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upon Cogeneration) in mesangial cells (208). HMAP proved to be a potent inhibitor 
of NADPH oxidase causing a 90% reduction in H20 2 production with no effect on 
viability. Whether HMAP had any other non-specific activities was not evaluated in 
this study.
The properties of 0~2generation and H20 2 production have been investigated in 
great detail in human neutrophils due to the large numbers that can be obtained. 
Comparing eosinophil responses to neutrophil responses some differences in function 
exist. Neutrophils on coated surfaces appeared to exhibit a lag period of between 15- 
90 minutes after addition of added agonist (196). No lag time was observed at all 
when either guinea pig or human eosinophils were stimulated with any agonist. In the 
case of guinea pig eosinophils it was thought that the cells were already primed by the 
method to elicit them, and thus any stimulus that caused H20 2 production immediately 
activated the respiratory burst. However, the fact that human eosinophils can be 
obtained from peripheral blood without apparent activation would indicate a closer 
association between the receptor and the respiratory burst. It has been well established 
that eosinophils have a greater capacity for 0 2 generation than neutrophils (189,222).
Nathan showed that some agents, TNFa/p, were unable to trigger H20 2 release 
when the cells were in suspension, but able to induce a massive, prolonged secretory 
response when the cells were plated on different protein surfaces. In conjunction with 
tte lag time, this data suggests that effect may be due to the assembly of 
microfilaments between the cell and membrane proteins before cellular activation 
(196). Though only a few suspension experiments were carried out for the protein 
kinase C studies, no difference was detected in activation time between the two types
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of experiments. In addition PAF, which was only a poor activator of guinea pig 
eosinophils in suspension (data not shown) was also a weak activator of eosinophils on 
laminin-coated plates.
Certain cytokines have the ability to prime granulocytes to enhance their 
actions. For example DiPersio et al have shown that a one hour incubation with GM- 
CSF can enhance the release of arachidonic acid from neutrophils in response to 
A23187, fMLP, PAF and LTB4 (223) and McColl et al show increase in the synthesis 
of LTB4 in response to GM-CSF in PAF stimulated neutrophils (224). Similarly, IL-3 
and IL-5 have been shown by Takafuji et al to enhance LTC4 synthesis by eosinophils 
in response to C5a and PAF, which were unable to induce LTC4 on their own (225). 
With respect to the oxidative mechanism, Weisbart et al have shown human neutrophils 
and a two hour pretreatment with GM-CSF can enhance the oxidative metabolism in 
response to fM LP, C5a and LTB4 but not PMA (226) and Yuo et al found that a 10 
minute preincubation with GM-CSF and TNF could enhance the IL-8 induced oxidative 
burst from human neutrophils (227). Interestingly, it has been shown that endotoxin 
is capable of priming neutrophils for enhanced oxidative responses in response to fMLP 
(226).
Any agonist that was not able to activate eosinophils in vitro could not be 
significantly enhanced by the suggested priming agents GM-CSF, IL-3 and IL-5, 
though some increases did occur. Even the response elicited by C5a in guinea pig 
eosinophils could not really be amplified by priming agents. Again the possibility that 
guinea pig eosinophils were already primed could be responsible for these negative 
responses.
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When the effects of the cytokines RANTES and IL-5 were tested by themselves 
on human eosinophils, each gave their respective response. When these agents were 
added together their responses was additive not synergistic. It was thought that 
RANTES-stimulated human eosinophil responses, could be enhanced with the cytokine 
IL-5. The result was the same if IL-5 was added prior to the addition of RANTES, or 
if they were added at the time. However, an investigation of the priming time was not 
carried out, hence eosinophils may need 2-3 hours before they are upregulated to have 
enhanced activity to any added agonist. The experiments when the cytokines were 
added together were left to run for 2Vi hours, so any effect on priming should of been 
observed.
Experiments were carried out on guinea pig eosinophils that were obtained from 
BALs from non-challenged and challenged animals rather than eosinophils elicited by 
horse serum in the peritoneal cavity. This was to establish if functional differences 
existed depending on the method of production. Very few eosinophils were obtained 
from non-challenged animals. When comparing eosinophils from challenged animals 
to non-challenged animals it appears that the cells are just as responsive to C5a, but 
PAF tended to elicit more H20 2 from eosinophils in challenged animals. This suggests 
the inflammation observed in response to OA-challenge enhances the activity of the cell 
to respond to certain stimuli. This enhanced response could be due to the eosinophils 
being primed by virtue of their recruitment to the bronchial lumen.
7.3 Eosinophil adhesion
The protein coating of laminin was selected empirically. Initially a broad range
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of coatings were used and these were narrowed down on practical cost and 
effectiveness to coat the plate. For eosinophils, unlike macrophages, coating the plate 
was necessary to stop spontaneous H20 2 release. Fibrinogen and laminin bind the 
ligands aMp2 (Mac-1), axp2 (pl50,95) and ajp! (VLA-1), a2pt (VLA-2), a3p! 
(V LA -3), a6pj (VLA-6), a7p l (VLA-7) respectively. Eosinophils are known to 
possess the p2-integrins, as these are present on all leukocytes and hence make 
fibrinogen an effective protein surface for the cells to adhere to. The presence of pr  
integrins on eosinophils had not been established except VLA-4, which binds to 
VCAM -1 and fibronectin. The function of laminin proved very effective for my 
experiments. Dri et al who have tested various physiological stimuli with eosinophils 
layered onto a variety of biological surfaces found plastic to give much higher 0 2 
readings than the different proteins (fibronectin, laminin, collagen type I &  IV  and 
fibrinogen) in response to basal, fMLP, TNFa and PAF (228). In agreement with this 
study, Dri found that eosinophils on laminin-coated surfaces were relatively inactive 
when stimulated with these agonists.
A functional laminin receptor, VLA-6, has only been recently described on 
human eosinophils by Georas et al (21). They found the presence of a4 and a6, but not 
«i» a2> a3> or as integrin subunits on human eosinophils. They found that the 
inhibition of eosinophils adhering to laminin could be caused by the anti-a6 monoclonal 
antibody, GoH3, and by the anti-pj monoclonal antibody, 33B6. Laminin has also 
been shown to interact with the integrin a6p4 (229), but Georas found no presence of 
the p4 integrin subunit on eosinophils either (21).
Not only did eosinophils appear to adhere to laminin for activation of eosinophil
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H20 2 release, but the level of adhesion in many instances altered depending on the 
agonist, suggesting a dynamic relationship between these two cellular functions. 
Guinea pig eosinophils had increased adhesion when stimulated with C5a, LTB4, PAF 
and PMA, and human eosinophil adhesion was increased by the agonists C5a, IL-5, 
MCP-3 and PMA.
In neutrophils a direct relationship between these two functions appears to exist. 
Shappell et al have demonstrated that inhibiting Mac-1 mediated adherence in these 
cells reduces H20 2 release upon fMLP stimulation (230). Walker et al demonstrated 
that eosinophils after migration across IL-1 stimulated HUVEC monolayers had 
upregulated C D llb  and CD35. This was only partially inducible with PAF or a 
variety of cytokines and it was postulated that cell-cell interactions rather than soluble 
factors were responsible for the altered eosinophil marker expression. This upregulated 
C D llb  was related to an increased capacity to generate 0 2 when stimulated by 
opsonized zymosan (231). Therefore adhesion may only increase H20 2 release from 
eosinophils, when certain adhesion molecules have been expressed.
PAF though a weaker activator of H20 2 release from guinea pig eosinophils 
than C5a and LTB4, was capable of causing eosinophils to adhere to laminin-coated 
plates to the same extent as C5a and LTB4. Kimani et al identified this PAF induced 
adherence to be regulated by the p2-subunit (232). In the case of PAF, it could mean 
that it is quite important in recruiting the eosinophils as well as other inflammatory 
cells, but not sufficient to cause major activation. This would avoid incorrect targeting 
of the functional response, which would otherwise be disasterous.
IL -5 not only caused significant H20 2 release from human eosinophils but
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upregulated adhesion. As mentioned earlier, the time course of H20 2 release from IL-5 
stimulated eosinophils was different from other agonists, where IL-5 caused release of 
H20 2 more slowly, and reaching a maximum at one hour rather than 30 minutes. This 
could indicate a role of adhesion priming the cell before activation (with some cells 
possibly primed during purification) or after subsequent activation by IL -5, the IL-5  
that is possibly released by the cell (233) could maintain the cellular adhesion/increase 
activation. Indeed the adhesion experiments were measured at the end of the assay, 
typically 90 minutes, in all experiments, and earlier or later time points could tell 
another story. Adhesion has been shown to prime cells for activation for other 
functional responses. For example Anwar et al have shown that eosinophils binding 
to fibronectin via VLA-4, enhanced the cells ability to release LTC4 to the calcium 
ionophore A23187. Interestingly, they found optimal adherence to occur at 60 
minutes, which was sustained until the end of the assay (120 minutes) (234).
Only 35-50% of the total number of eosinophils (depending on the agonist) 
adhered to the plate. Total adhesion might not be expected as a proportion of the cells 
may be non-adherent once they have been activated and released available H20 2. A 
number of eosinophils would be lost in the washing process after the H20 2 assay, 
though this should be a uniform error across the plate. A method for removing the 
cells with minimal shear force has been suggested by St. John et al (235).
7.4  [Ca2+]j elevation
The elevation of intracellular free calcium is now well documented in both 
guinea pig and human eosinophils (44,107,213,236,237). These are in agreement with
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data presented in this thesis. However, this study demonstrates that in guinea pig 
eosinophils these responses occur at physiological doses with both C5a and PAF 
eliciting calcium release at lOnM and LTB4 causing a significant response at InM  and 
above. With respect to human eosinophils, C5a, RANTES, M IP -la  and MCP-3 also 
caused significant elevations of intracellular free calcium. This has been also 
demonstrated by Rot et al and Dahinden et al (44,236). These groups have also carried 
out cross-desensitisation experiments between M IP -la  and RANTES. This study also 
establishes that human eosinophils were desensitised to MCP-3 by RANTES, but not 
vice versa, indicating the MCP-3 responses are mediated by RANTES. This effect has 
also been demonstrated by Dahinden (236). MCP-1 receptors have been reported not 
to exist on eosinophils (44), but I found a significant response elicited by MCP-1 in 
human eosinophils. The experiments in this study imply that the reaction initiated by 
MCP-1 acts through a receptor that is also activated by MCP-3, which is distinct to the 
MCP-3/RANTES receptor. Whether this is via an MCP-1 specific receptor or through 
a different chemokine receptor has yet to be determined. MCP-1 is not acting via the 
RANTES specific receptor, due to the activity of RANTES after the M CP-l/M CP-3  
response.
The first indications of diversity in signal transduction mechanisms became 
apparent by these observations. In H20 2 experiments PAF and M IP -la  were weak 
activators of the respiratory burst in guinea pig and human eosinophils respectively, 
whereas both these agonists were potent inducers of free calcium elevation. 
Conversely, IL-5 was a potent agonist causing a massive secretion of H20 2 from human 
eosinophils, but unable to cause calcium elevation. The PAF and M IP -la  data is in
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concordance with a study by Garland on human neutrophils where a rise in intracellular 
free calcium occurs prior to 0'2 generation, but this calcium signal is insufficient to 
elicit the respiratory burst (109). IL-5 probably uses a different mechanism for 
eosinophil H20 2 release. Table 7.1 shows a comprehensive list of all the agonists that 
activate eosinophils and all the agents that are released from eosinophils. This list has 
been compiled from this study and current literature.
Discussion 196
Table 7.1 Eosinophil receptors expressed and agonists produced
Eosinophil Receptors Role Reference
GM-CSF Cell survival (7)
IFNy Cell survival/delayed action (238)
IL-le Inhibits Oz production (239)
IL-2 Priming (41)
IL-3 Cell survival (7)
IL-4 Inhibits IgG receptor expression (240)
IL-5 Cell survival, Chemotaxis, 0 2 production (7,241,242)
IL-8 Chemotaxis (243)
ltb4 Chemotaxis, 0 2 production, [Ca2+], (38,214)
MCP-3 Chemotaxis, 0 2 production, [Ca2+]j (236,242)
MIP-la Chemotaxis,[Ca2+], (44)
PAF Chemotaxis, 0 2 production, [Ca2+], (36,107)
PDGF Degranulation (246)
RANTES Chemotaxis, 0 2 production, [Ca2+], (44,242)
TNFa/p Enhances LTC4 production (247)
Eosinophil Production Action Reference
GM-CSF Autocrine loop (86,88)
HLADR Interaction with CD4+ lymphocytes & elicit 
antigen specific responses
(248)
IL-la Acute inflammation (85)
IL-3 Priming (86)
IL-5 Priming, autocrine loop? (249)
IL-6 Acute inflammation? (89)
IL-8 Priming? (244,245)
ltc4 Contraction of smooth muscle, oedema & mucus 
production
(81,250)
MIP-la small chemotaxis (44,90)
PAF Chemotaxis of granulocytes (251)
pg d2 Mucus production & bronchconstricion (79)
PGE, Inhibition of mast cell degranulation (76,252)
TGFa/p, Chronic inflammation (83,84,253)
TNFa Acute inflammation? (90,91)
TxB2 Bronchoconstriction (79)
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7.5 A  role for extracellular divalent cations in eosinophil 
activation?
The calcium response caused by LTB4 was biphasic, and it is postulated that the 
first rise in intracellular concentration was mobilization from the intracellular stores 
and the second phase of the response was due to calcium influx.
This was on the basis that agonist-induced Ca2+ influx in human neutrophils was 
reported by Montero et al to be secondary to the emptying of intracellular Ca2+ stores 
(121). They found that release of Ca2+ from the internal stores activates the plasma- 
membrane Ca2+ channels by a mechanism involving microsomal cytochrome P-450.
Experiments were performed to ascertain whether calcium influx did occur. 
Removal of extracellular calcium inhibited [Ca2+]j elevation and suggested a large 
calcium influx. However, the replacement of calcium with manganese and nickel 
appeared to have no effect on calcium influx suggesting the eosinophils in the first set 
of experiments were probably store depleted.
Another tool available for investigating calcium influx is the proposed ROCC 
blocker SK&F 96365. In guinea pig eosinophils, SK&F 96365 was found to have an 
agonistic effect, though it did subsequently dose-dependently inhibit a rise of [Ca2+]j 
in cells stimulated by C5a and PAF. In contrast to these experiments, SK&F 96365 
caused no elevations of intracellular free calcium in human eosinophils (except at 
100/xM), but still caused a dose-dependent inhibition of subsequent calcium elevations 
in cells stimulated by C5a, PAF and RANTES. Grix et al have shown that eosinophil 
calcium responses do have a calcium influx component using the surrogate calcium ion, 
manganese (254).
The specificity of SK&F 96365 for ROCCs has been questioned. Merritt et al
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have used this compound in conjunction with human platelets, neutrophils and 
endothelial cells and SK&F 96365 has blocked receptor-mediated calcium entry over 
internal release. SK&F 96365 also blocked manganese influx into platelets and 
neutrophils. However, pituitary cells and rabbit ear-artery smooth-muscle cells held 
under voltage-clamp were also inhibited by SK&F 96365 suggesting an effect on 
VOCCs, though no VOCCs have been identified on eosinophils. Interestingly, the 
ATP-gated Ca2+-permeable channels of the rabbit ear-artery smooth muscle cells were 
unaffected by SK&F 96365 suggesting that it may be able to discriminate between 
some type of ROCCs channels (117,255).
Mason et al used SK&F 96365 and other imidazoles to investigate the role 
cytochrome P-450 has in regulating the plasma membrane Ca2+ permeability, by the 
release of Ca2+ from the Ins (l,4 ,5 )P 3-sensitive pool. In addition they found SK&F 
96365 caused a release of Ca2+ from thapsigargin-sensitive intracellular stores, 
consistent with inhibition of sarcoplasmic reticulum Ca2+-ATPase. They concluded 
that SK&F 96365 inhibited cytochrome P-450-independent filling of intracellular pools, 
and store-regulated Ca2+ entry (120). Perhaps this is the action of SK&F 96365 on 
guinea pig eosinophils, or alternatively the tertiary structure of SK&F 96365 may be 
so arranged that it binds to eosinophil membrane receptors in general. The subsequent 
inhibition of elevation in free calcium may be a desensitisation effect. When PAF was 
added prior to SK&F 96365, both agents were able elevate intracellular free calcium 
concentrations. This suggests that the actions for SK&F 96365 if via receptors, were 
not specific to one type.
The mechanism of direct non-specific action via agonist receptors would explain
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the release of H20 2 from guinea pig eosinophils, as SK&F 96365 was a potent 
stimulator of the respiratory burst.
As with the human calcium experiments the effect of SK&F 96365 was quite 
different on human eosinophils when looking at H20 2 release. It appears from 
preliminary experiments that SK&F 96365 was able to inhibit H20 2 production. 
Perhaps there is a calcium influx component that is necessary for activation or 
formation of the NADPH oxidase complex, especially if a role for PKC is implicated 
in the signalling pathway, which requires calcium for activation. These particular 
actions of SK&F 96365 have not yet been reported in the literature.
The role of extracellular divalent cations on H20 2 release from guinea pig 
eosinophils were investigated. Experiments showed that the removal of calcium 
inhibited the amount of H20 2 produced from eosinophils by approximately 50% in each 
of the agonists tested, whereas removal of magnesium as well as calcium caused total 
inhibition. Jones et al and Aoyagi et al (94,115) have already implied that magnesium 
is important in the NADPH oxidase complex in neutrophils, possibly through a G- 
protein and this work demonstrates that eosinophils are also dependent on extracellular 
magnesium.
This work is also in agreement with Yamashita &  Someya who showed both 
calcium and magnesium were necessary for maximal 0 2 production from guinea pig 
eosinophils stimulated with A23187. However, they reported magnesium inhibited 0 2 
generation at low extracellular calcium concentrations (<0 .2m M ) (256). This may be 
due to inhibition of ion influx from the medium into the cell, which may be required 
for activation of the NADPH oxidase complex.
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Ca2+ and Mg2+ are clearly required for the maintenance of the generation of 
H20 2 from guinea pig eosinophils as addition of EDTA at the beginning or during the 
middle of an experiment stops the production of H20 2 immediately. The addition of 
nickel, which blocks the ion channels, either at the beginning of the experiment or 
during the experiment, took about two minutes before the production of H20 2 ceased. 
This difference in action may be purely dynamic. With the addition of a high 
concentration of EDTA not only is the extracellular calcium chelated, but almost 
immediately the cell would be store depleted, and probably cause the disassembly of 
the NADPH oxidase complex and/or other cellular components. However, nickel, as 
well as steric hindrance, may slowly cause an imbalance of ionic conditions (as 
extracellular calcium was still present), due to the blocked channels. With the calcium 
channels blocked a negative feed back system might cause calcium release from the 
intracellular pools to stop, when the [Ca2+]j exceeded critical levels. This could 
subsequently lead to cellular deactivation. Azula et al have shown that nickel does not 
only block Ca2+ influx but dose-dependently inhibits platelet aggregation, mobilization 
and PLC activation induced by thrombin, PMA and A23187 (257).
Adhesion experiments were also disrupted by the removal of the divalent 
cations. As mentioned in the introduction, the integrins have potential divalent cation 
binding sites. The removal of Ca2+ appeared to have little effect on guinea pig 
adhesion, if anything it consistently enhanced the adhesion of guinea pig eosinophils 
to laminin-coated plates. The removal of both Ca2+ and Mg2+ significantly inhibited 
the adhesion in response to C5a and PMA, suggesting that Mg2+ is the important 
divalent cation in eosinophil adhesion. Dobrina et al showed that the adhesive
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mechanisms of eosinophils to be optimally active in the presence of both Ca2+ and 
Mg2+ and this was reduced by removal of either cation. It appears that VCAM-1 and 
VLA -4 are only, active when both Ca2+ and Mg2+ are present. Furthermore the 
CD11/CD18 integrin was inactive in calcium medium only (258). This is in agreement 
with this study where the removal of both cations reduces the adhesion of eosinophils 
when stimulated with added agonist.
Lundgen-Akerlund et al have indicated that adhesion was dependent on Mg2+, 
but not Ca2+, and the addition of manganese lead to enhanced neutrophil adhesion in 
vitro to protein coated surfaces (114). Manganese competes with divalent cations and 
binds to the integrin with higher affinity, which is thought to induce a conformational 
change (113).
This study also investigated the role of N i2+ and it was found that this ion 
markedly increases guinea pig eosinophil adhesion in unstimulated and stimulated cells. 
Ni2+ blocks the calcium influx channels. From this information and experiments with 
EGTA, extracellular Ca2+ does not appear to be essential for adhesion, but may have 
a role in ‘anti-adhesion’ after cellular activation.
When the ROCC blocker SK&F 96365 was tested for its role in adhesion, on 
unstimulated eosinophils, it had little or no effect. This suggested its action on H A  
release was direct, with no consequences on the cellular adhesion mechanisms. 
However, when added in conjunction with added agonist, SK&F 96365 reduced the 
eosinophil adhesion below basal levels. When SK&F 96365 was added in conjunction 
with added agonist in H20 2 experiments, the eosinophil was enhanced to release more 
H20 2, so again this loss of adhesion may be due to eosinophils becoming redundant
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after activation.
7.6 Action of PKC
Various cellular functions are believed to act via activation of PKC. For 
example, the chemotactic factor PAF binds with the cell surface receptor and in turn 
activates PLC. PLC then activates phosphatidyl inositol turnover and the resulting 
DAG activates PKC (75). PMA, a DAG substitute, bypasses this pathway to act 
directly on PKC. PMA-induced eosinophil H20 2 production was significantly inhibited 
using the selective PKC inhibitor Ro 31-8220/002 at concentrations of 300nM and 
above. The responses to soluble agonists were also dose-dependently inhibited by the 
PKC inhibitor by approximately 80% and 90% in guinea pig and human eosinophils 
respectively. This strongly indicates that activation of the NADPH oxidase complex 
occurs via a PKC-mediated phosphorylation of a component of the oxidase, which has 
been previously demonstrated in neutrophils by Cross and Jones (219).
Shute et al (75), have already shown that PKC is involved with 0 2 generation 
with the inhibitor trifluoperazine. They demonstrated a more potent inhibition of PKC 
than shown here, but Ro 31-8220/002 is believed to be a more specific PKC inhibitor. 
The IC 50 of Ro 31-8220/002 for inhibition of platelet aggregation was shown to be
0.7/xM by Murphy and Westwick (134), which is comparable to the effective 
concentrations used here.
As stated in the introduction, there are various PKC isozymes and these are 
poorly characterised in eosinophils. In neutrophils the main isozyme was found to be 
PKC-p, with some PKC-a and PKC-C (132). Several studies have identified a
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correlation between PKC activation and the respiratory burst (130,131).
A study by Bates et al using western blotting with isozyme-specific mAbs, has 
detected that PKC-p is present in human eosinophils, but not PKC-a or PKC-y. They 
also correlated the activity of PKC to normodense and hypodense eosinophils and found 
the activity of PKC is increased in hypodense eosinophils. LTC4 and O2 generation are 
also increased in hypodense eosinophils, suggesting PKC activity is related to cell 
density in blood-derived cells and cellular function (260). However, A li et al have 
demonstrated that in the eosinophilic-like cell line, HL-60, LTC4 synthesis is 
specifically inhibited by activation of PKC. This inhibition was restored using 
staurosporine and bisindolylmaleimide (261).
Bisindolylmaleimide is reported to be a potent and selective inhibitor of PKC 
(262). A recent investigation by Wenzel-Seifert et al using a bisindolylmaleimide, 
GF109203X, which inhibits both c- and n-PKC isozymes and an indocarbazole, 
Go6976, which inhibits c-PKC isozymes only, have shown that n-PKC isozymes rather 
than c-PKC isozymes may regulate neutrophil functions including O2 generation (263). 
This would suggest that other isozymes yet to be identified may be present in both 
neutrophils and eosinophils. The bisindolylmaleimide, Ro 31-8220/002 used in my 
studies, inhibits preferentially PKC-a over PKC-p, -y and -€ (264), indicating that a 
role does exists for c-PKC isozymes in H20 2 production in eosinophils. More specific 
inhibitors of PKC isozymes need to be designed if an individual PKC isozyme is to be 
associated with a particular cellular function.
A role of PKC in adhesion of guinea pig eosinophils was also apparent, by 
virtue of the ability of Ro 31-8220/002 to dose-dependently inhibit eosinophil adhesion
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in C5a, LTB4 and PMA stimulated cells. These inhibitions were significant in C5a and 
PMA stimulated cells. Basal adhesion was unaffected by Ro 31-8220/002. Previous 
experiments have suggested a dissociation of mechanisms exist between eosinophil 
H20 2 production and cellular adhesion, but this PKC data could indicate an important 
dependency of adhesion before subsequent activation. To investigate this hypothesis, 
the PKC inhibitor was used in the stirred cell system, thus preventing adhesion (though 
not aggregation), to monitor H20 2 production from guinea pig eosinophils. In both 
C5a and PMA stimulated cells, Ro 31-8220/002 prevented the release of H20 2, 
indicating that in vitro, though PKC is involved in both adhesion and the respiratory 
burst, the respiratory burst is not dependent on the eosinophils becoming adherent. 
However, the adhesion step could enhance the capability of the cells to produce H20 2.
Merrill et al have identified two pathways of CD 1 lb/CD 18-mediated neutrophil 
aggregation. One pathway, PMA stimulated neutrophils, appears to be sensitive to 
PKC inhibition (though the PKC inhibitor used was staurosporine). However the other 
pathway, in fMLP stimulated neutrophils, aggregation is enhanced by staurosporine. 
It is thought that the PKC acts via the CD 18 p-chain as a predominance of 
phosphoserine residues in CD 18 p-chains have been identified on PMA-treated 
monocytes (265). Sullivan et al have also investigated the role of PKC in upregulation 
of Mac-1 using the selective PKC inhibitor Ro 31-8425. In agreement with Merrill et 
a l, they found that phorbol stimulated adhesion could be inhibited by Ro 31-8425 
suggesting a PKC mechanism, but adhesion could not be down-regulated when more 
physiological agonists such as C5a were used to stimulate neutrophils (266). Assuming 
the p-integrins are similar in eosinophils, the inhibitions observed in this study could
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point to a PKC binding site present on or associated with VLA-4, which is specific for 
eosinophil adhesion.
In some H20 2 production and adhesion experiments, there appeared to be an 
increase in functional response to agonist stimulated cells incubated with the highest 
inhibitor dose used (3/xM). This could be due to the precipitation of the drug or an 
activation itself by the high concentration. Indeed a similar effect has been documented 
by Perkins et al stating that Ro 31-8220/002 (10/xM), though causing a slower rate of 
H20 2 release, actually increased the final amount of H20 2 produced. They have 
speculated that PKC has an inhibitory action on phosphoinositidase C (267).
The significant potentiation of [Ca2+]j elevation in guinea pig eosinophils by Ro 
31-8220/002 suggests that there is an association with PKC and free calcium elevation. 
As already indicated, calcium elevation in eosinophils, though predominantly 
mobilization, may also be subject to an influx component. The increase in the second 
peak in the LTB4-induced response could suggest that PKC has a negative feedback 
control on Ca2+ influx. However, very little influx was identified in eosinophil 
experiments, suggesting the PKC negative feedback may act on either DAG or the 
intracellular calcium stores. This also underlines the principle that a rise in [Ca2+]j is 
not sufficient to activate the NADPH oxidase complex and thus cause H20 2 release.
Grinstein and Furuya have found in neutrophils, cell activation is not just 
associated with PKC. Using various inhibitors, receptor-mediated stimulation persisted 
implying a role for other kinases (268). Souness et al have characterised 
phosphodiesterase activity in guinea pig eosinophils. They found the predominant form 
of cAMP phosphodiesterase (Type IV ) to be located in the membranes, and inhibition
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of 0~2could be achieved with Ro 20-1724, rolipram and denbufylline (269). cAMP is 
linked to cAMP-dependent protein kinases, which catalyse the transfer of the terminal 
phosphate group from ATP to specific serine or threonine residues of selected target 
proteins. This covalent phosphorylation regulates the activity of these proteins (100).
7.7  Tyrosine kinase interaction
Grinstein and Furuya implicated tyrosine phosphorylation with MAP kinase as 
a result of fM LP chemotactic stimulation in neutrophils. Rapid phosphorylation was 
evident within 15 seconds. The activation of tyrosine kinase also mimicked the time 
course and profile of the respiratory burst to fMLP in neutrophils. In their 
investigation they also noted threonine residues could also have been phosphorylated 
(270). Dusi et al have shown that tyrosine kinase phosphorylation of MAP kinase and 
an unidentified protein of 75kDa is involved in NADPH oxidase activation, which is 
coupled to Ca2+-dependent and Ca2+-independent mechanisms in human neutrophils 
stimulated with fMLP and concanavalin A respectively. However, concanavalin A still 
requires a Ca2+-dependent mechanism to activate the NADPH oxidase complex (271).
The fact that the PKC inhibitor could not inhibit H20 2 production or adhesion 
by more than 80-90% indicated that other signalling mechanisms may be involved, 
which may be redundant during normal cellular activation. Several experiments were 
undertaken to ascertain whether tyrosine kinase signalling was involved in eosinophil 
activation. These experiments involved using specific tyrosine kinase inhibitors in the 
functional assays and looking at the phosphorylation patterns.
Using the tyrosine kinase inhibitors, H20 2 production from C5a-stimulated
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guinea pig eosinophils could be inhibited by a small degree with herbimycin A and 
genistein, whereas only herbimycin A appeared to inhibit PMA-stimulated cells. The 
effect of herbimycin A was always consistent, though significance was not achieved. 
The role of tyrosine phosphorylation in the respiratory burst is still poorly understood. 
Grinstein and Furuya demonstrated that the accumulation of phosphotyrosine and 
activation of the NADPH oxidase in neutrophils had similar time courses and 
concentration dependency when stimulated with GTPYS suggesting a relationship 
between these mechanisms (272). However, there is a certain dissociation between 
these two events, as activation of PKC though stimulating oxygen consumption, 
appears to inhibit tyrosine kinase(s), implying PKC may be part of a negative feedback 
mechanism intended to control or terminate the responses generated by tyrosine 
phosphorylation (272).
A dependent/independent role of tyrosine kinase has also been established by 
Kusunoki et al. They showed that generation from neutrophils elicited by fMLP  
and soluble aggregated IgG were inhibited by the tyrosine inhibitors erbstatin and 
genistein, but O2 production by surface bound IgG was scarcely inhibited by either 
inhibitor. However, immunoblotting studies revealed specific tyrosine phosphorylation 
of a 40kDa protein by all three agents, and this could be inhibited by the tyrosine 
kinase inhibitors (273). Azuma et al have echoed this work finding a 42kDa protein 
that is tyrosine phosphorylated (presumably the same protein as the 40kDa protein 
detected by Kusunoki (273)). They postulated that the respiratory burst elicited by 
fMLP in human neutrophils is activated by pathways other than PKC and an increase 
in [Ca2+]i. The tyrosine phosphorylation is induced by PKC-dependent and
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independent mechanisms according to the stimuli, indicating that tyrosine 
phosphorylation is not necessarily related to activation of the respiratory burst (274). 
Uings et al have shown using specific inhibitors that tyrosine kinase is thought to be 
involved in receptor coupling to PLD but not to the phosphatidyl inositol-4,5 
bisphosphate-specific PLC, which in turn activates PKC (275).
Experiments by Fialkow et al have demonstrated that tyrosine phosphorylation 
is enhanced by exogenous oxidants such as diamide and direct stimulation of the GTP- 
binding proteins. This latter tyrosine phosphorylation was found to be NADPH- 
dependent as 0 2 generation was inhibited by DPI (an inhibitor of the flavoprotein of 
the NADPH oxidase (219)). In addition, patients with CGD, which are deficient in 
the production of reactive oxygen intermediates, demonstrated no such phosphotyrosine 
accumulation. The various tyrosine phosphorylation bands found to be enhanced were 
28, 42-44, 55, 68-70, and 90-110kDa (276).
In contrast to the small reduction of H20 2 release detected in this study, the 
tyrosine kinase inhibitors consistently enhanced the adhesion of guinea pig eosinophils 
in both vehicle and agonist-stimulated cells. Once again this highlights the divergence 
of mechanisms between cellular adhesion and the respiratory burst. Tiisala et al have 
also demonstrated this enhanced adhesive effect, where genistein (40jnM) upregulated 
the surface expression of p2-integrins in the monoblastic THP-1 and the promyelocytic 
HL-60 cell lines.
Genistein is also thought to modulate the expression of ICAM-1 (277). 
However, Naccache et al have found erbstatin and herbimycin A to inhibit the 
expression of C D llb  and CD 18 in human neutrophils, stimulated by the chemotactic
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inhibitors fMLP and LTB4. The anti-CD lib  induces the phosphorylation of a 120kDa 
substrate (278). This could be the same protein detected in the tyrosine phosphorylation 
experiments reported in this thesis, where C5a and PAF induced the phosphorylation 
of a 120kDa protein in human eosinophils. This would suggest that after 30 minutes 
the expression of C D llb  may decline with a corresponding increase in tyrosine 
phosphorylation.
The enhanced adhesion effect that herbimycin A and genistein had in these 
studies could indicate a different tyrosine phosphorylation pathway distinct from 
C D llb /C D 18, possibly VLA-4 or VLA-6. The effect detected by Tiisala et al may 
be due to the long incubation of the inhibitor (72 hours) with the cells, which are not 
stimulated with any agonist, suggesting an effect on differentiation/proliferation rather 
than on function (277).
The tyrosine kinase inhibitors had no effect on the phosphorylation patterns of 
guinea pig eosinophils. This was surprising considering the extensive phosphorylation 
that exists in the cells. A more detailed study of the incubation times of the inhibitors 
is required.
No effect was found of the tyrosine kinase inhibitors on [Ca2+]j elevation in 
guinea pig eosinophils. This again may be due to the short incubation times of the 
eosinophils with the inhibitors. However, even Eol-ls, which were incubated with the 
inhibitors overnight, failed to show any differences between vehicle and agonist- 
stimulated cells. This could suggest the action of tyrosine kinase is calcium 
independent. Nevertheless, Murphy et al have shown that genistein (IC50 around 
100/xM) is an inhibitor of PAF-induced [Ca2+]j elevation in rabbit platelets, affecting
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both influx and mobilization. This suggests genistein-sensitive PTKs regulate [Ca2+]j 
elevation either directly or indirectly (210).
The results obtained from western blotting experiments were disappointing. 
Guinea pig eosinophils appear to be heavily phosphorylated before any stimulation, 
with some strong bands at 25kDa, 42kDa and 68kDa. No change was observed upon 
stimulation in the stirred-cell system. Under the same conditions as the H20 2 assay, 
there was an upregulation of some bands over time. These were observed in both 
vehicle- and agonist-stimulated cells. The bands were 60-65kDa, lOOkDa and 120kDa. 
The strong phosphorylation present on the blot is most likely due to mechanisms 
activated upon transmigration, as the guinea pig eosinophils are elicited into the 
peritoneal cavity rather than obtained from peripheral blood as is the case for human 
eosinophils.
This hypothesis is reiterated when the blots of human eosinophils are observed. 
These have fewer PTK phosphorylated proteins than guinea pig eosinophils. The 
increase in the band in the laminin-coated eppendorfs must be due to some adhesive 
property or aggregation. When platelets aggregate three distinct proteins are tyrosine 
phosphorylated, 35-45, 66-90 and 90-150kDa (210). Two of these three bands 
coincide with patterns observed in guinea pig eosinophils. However, platelet 
aggregation occurs rapidly and the changes in phosphorylation are observed by 2 
seconds, whereas the changes in guinea pig eosinophils are not observed for 5 minutes 
but are sustained for up to an hour.
The blots obtained from human eosinophil experiments demonstrate 
phosphorylation of two main bands, one at 30kDa and another, a doublet, at 60kDa.
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Any tyrosine phosphorylated bands at low molecular weights are not separated on the 
10% gels. Again no changes were observed upon stimulation, suggesting protein- 
tyrosine kinases are not involved in the NADPH oxidase complex and the subsequent 
respiratory burst.
Very few studies of tyrosine kinase phosphorylation on eosinophils have been 
reported. Van der Bruggen et al demonstrated that priming of the respiratory burst in 
human eosinophils with GM-CSF, IL-3 and IL-5 did not cause a change in [Ca2+]j but 
did induce tyrosine phosphorylation of several proteins. The 102 and 122 kDa proteins 
appeared to be Ca2+ independent whereas the 66kDa protein appeared to be dependent 
on Ca2+. They suggested that the 122kDa protein could be the p-chain of the GM- 
CSF, IL-3 and IL-5 receptor. Erbstatin, an inhibitor of PTK, not only inhibited the 
cytokine-induced tyrosine phosphorylation, but also inhibited the respiratory burst 
(279).
Recently IL-5 has been shown to activate cells via a tyrosine phosphorylation 
pathway in an IL-5-dependent murine early B cell line by Sato et al (280) and in human 
eosinophils by van der Bruggen et al (29). Both these have reported that the IL-5 
signalling involves JAK2 kinase (a 130kDa tyrosine kinase protein) and van der 
Bruggen also showed that JAK2 subsequently activates a member of the Stat (signal 
transducers and activators of transcription) family, Statla (29).
The guinea pig and human eosinophil experiments were always limited by cell 
number and it was hoped that more information could be obtained from the 
eosinophilic cell lines Eol-1 and Eol-3. The cell lines have very different basal patterns 
compared to either the guinea pig or human eosinophils. The Eol-l's have a strong
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band at 1 lOkDa and a weaker band at 30kDa. Upon maturation with butyric acid there 
appears to be a change in the phosphorylation. The strong band at 1 lOkDa is less 
intense, whereas a band at 43kDa becomes upregulated, the band at 30kDa either 
becomes a doublet, or is down regulated and a different protein near this molecular 
weight is phosphorylated in the form of a doublet. Again, no change is observed over 
time with agonist-treated cells. The Eol-3 cell line had a very weak basal 
phosphorylation compared to the Eol-ls. However, the same bands of 1 lOkDa and 
30kDa were present. No changes in phosphorylation were observed upon maturation 
or stimulation.
The main difference between Eol-l's and Eol-3's was the rate at which the cells 
proliferated. Eol-ls could grow from 5xl05cells/ml to 2xl06cells/ml every three/four 
days, whereas Eol-3s only grew from 5xl05cells/ml to lx l0 6cells/ml every week. A 
family of proto-oncogenes that are phosphorylated on tyrosine are thought to encode 
proteins that are involved in the cascade of events by which growth factors stimulate 
normal cell division (281). This could account for the differences between the Eol cell 
lines and the change in patterns on Eol-1 maturation.
Eol-ls did show a marked reduction in tyrosine phosphorylation patterns with 
an overnight incubation with the tyrosine kinase inhibitors genistein and herbimycin A. 
This is almost certain to be associated with the inhibition of proliferation, as the total 




As stated in the introduction, PI3-kinase is thought to be a signalling molecule 
in its own right. It can be activated as a result of tyrosine phosphorylation or other 
kinases such as PKC-t. Wortmannin, reported to be a specific inhibitor of PI3-kinase 
at nanomolar concentrations (183), was found to inhibit agonist-stimulated H20 2 release 
from both guinea pig and human eosinophils, and agonist-stimulated adhesion of guinea 
pig eosinophils. However, it was unable to inhibit or change the agonist-induced 
responses in [Ca2+]j experiments. It is unlikely that these effects are through a 
tyrosine-phosphorylated pathway due to the lack of inhibition the PTK inhibitors 
appeared to have in eosinophils and the significant effect of wortmannin.
Wortmannin did not appear to be acting non-specifically as H20 2 could still be 
elicited from eosinophils by a submaximal dose of PMA and no effect of wortmannin 
was demonstrated on elevation of [Ca2+]j. Only two reports have previously 
documented the effects of wortmannin on eosinophils. One by Kapp et al but the 
concentration used was 1/xM, which could result in non-specific effects and no data was 
actually presented (282). The second was by Bach et al when the actions of 
wortmannin were not understood (283).
The data presented in this thesis implies that PKC-C could be the molecule 
activated by PI3-kinase as this is not activated by DAG or phorbol esters (282), and 
wortmannin failed to inhibit H20 2 elicited by PMA in human eosinophils. Many 
reports suggest that wortmannin blocks the activation of PLD (284,285), but 
wortmannin does not inhibit PMA-induced PLD activity and even enhances the 
production of phosphatidic acid in some cell types. Therefore PLD is unlikely to be
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the molecular target for the inhibitor (183). However, PI3-kinase could be upstream 
of PLD and this would account for some of the differences reported in the literature.
Wortmannin has also been reported to block the activation of the MAP kinase 
pathway in guinea pig neutrophils (286) and in L6 skeletal muscle cells (287). MAP 
kinase is a PTK of 42-44kDa, which is in turn activated by a protein cascade thought 
to involve first the GTP-binding protein ras and then the serine/threonine kinases and 
the MAP kinase kinase (287). The role of PI3-kinase in this pathway is still poorly 
understood and if it exists PI3-kinase may be the signalling step between ras and raf. 
PI3-kinase has been connected with the respiratory burst in human neutrophils 
(183,288) and my data suggests this is also true for eosinophils.
The effect of wortmannin on adhesion implies that PI3-kinase also regulates the 
expression of adhesion integrins. To my knowledge this is the first data reported 
connecting leukocyte adhesion and PI3-kinase.
7.9 Comparison of functional studies between guinea pig and 
human eosinophils
At the outset of the project, human eosinophils were difficult to purify and the 
yield and percentage of purity were low. Guinea pig eosinophils were used as a good 
source of eosinophils where high numbers could be easily induced. I successfully 
demonstrated that guinea pig eosinophils upon agonist-stimulation could adhere, 
produce H20 2 and elevate [Ca2+]j. One of the drawbacks of this model was the 
relatively few number of agonists that could activate the cell. This was especially 
disappointing with the increasing field of cytokines, which have been implicated in 
numerous inflammatory responses. With the magnetic assisted cell sorter, human
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eosinophils could be successfully purified and this study demonstrated, as suspected, 
that some of the cytokines could induce activation of human eosinophils. The inability 
of these cytokines to activate guinea pig eosinophils must have been due to species 
variation. The functional studies were all very similar, ie. the amount of H20 2 
produced, the number of cells adhered and the levels of [Ca2+]i. The drawback with 
human eosinophil experiments, is the variability of cells numbers obtained, the cost and 
most importantly the availability of donors.
In conclusion this study has shown that guinea pig eosinophils are a good 
substitute for human eosinophils as long as care is taken when interpreting the results, 
eg. the actions of SK&F 96365. More recently the guinea pig chemokine, eotaxin, has 
been identified by Jose et al. Eotaxin, which is generated in vivo in a guinea pig model 
of allergic inflammation, has been found to be a potent eosinophil chemoattractant
(289). The cloning by Rothenberg et al of the cDNA has revealed high homology with 
the human cytokines MCP-3, MCP-1 and to a lesser degree M IP -la  and RANTES
(290). In our own laboratories guinea pig RANTES has been produced. With the 
identification of further guinea pig cytokines, the guinea pig eosinophil will prove a 
useful tool in assessing the functional properties of these cytokines.
7 .10  Eosinophilic cell lines - a good substitute?
The matured Eol-ls failed to take on any of the eosinophil characteristics. They 
did not appear to develop cytoplasmic granules or the nucleus did not become multi- 
lobed as observed under the microscope. They were very poor producers of H20 2 
when stimulated by any agonist including PMA. They did elevate [Ca2+]j, but not only
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to agonists characteristic of eosinophils. Finally, looking at phosphorylation patterns, 
upon maturation, they did not appear to resemble the patterns present in human 
eosinophils. In conclusion, the eosinophilic cell lines were a poor substitute for the 
primary cells due to the inability to successfully mature the cells. Eols may still prove 
to be useful, but further studies on maturation are required.
7.11 Implications on future therapeutic strategies in asthma
This work has been carried out to indentify early stages in eosinophil recuitment 
and/or function which may lead to possible routes of intervention in respiratory 
disesases including asthma. Bronchodilators are the most commonly used drugs for 
asthma; they relieve the symptoms generated by histamine and other 
bronchoconstrictors soon after exposure to an allergen. Historically, xanthines were 
introduced in the 1930s, corticosteroids in the 1950s, (3 agonists in the 1960s and 
sodium cromoglicate in the 1970s. These have been improved over the last two 
decades to produce the xanthines, glucocorticoids and p2“agonists used today (291) (see 
table 7.2).
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Table 7.2 Classification and action of anti-asthma drugs. Adapted 
from TIPS 1992. 13(March), ‘Pharmacology of Asthma’ poster.
Anti-asthma drug Classification Action
p 2-agonists
eg. terbutaline (short) 
salmeterol (long)
Symptomatic Blocks mast cell activation. Reduces 











Reduces bronchconstriction, oedema 





Reduces oedema, leukocyte 
chemotaxis, and reduces scar 
formation from tissue damage. 
Blocks acute bronchial 
hyperresponsiveness
Cromoglicate Prophylactic Inhibits eosinophil, macrophage and 
platelet activation.
Mast cell stabilisation?
Reduces neural stimulation &  
leukocyte chemotaxis/ activation. 
Blocks acute bronchial 
hyperresponsiveness
The present treatments for asthma are highly efficient and improve the quality 
of life for the patient tremendously, but glucocorticoids and p2-agonists do not cure 
asthma. Once treatment has ceased, relapse of the disease often occurs with the same 
severity of bronchial hyperreactivity and other symptoms. Also, side effects are 
frequently associated with steroidal treatment. Apart from the symptoms that can be 
alleviated by the current drugs, bronchial asthma leads to permenant architectural 
changes in the lung. These changes include subepithelial fibrosis and bronchial smooth 
muscle thickening and may account for the persistant bronchial hyperresponsiveness
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characteristic of the disease. Existing therapies do not reverse these manifestations.
Clearly, PKC and PI 3-kinase are involved in eosinophil function. For these 
pathways to be used in the development of a therapy, the specific role of PKC and PI 
3-kinase in eosinophils needs to be investigated. Different inhibitors of the specific 
PKC isotypes need to be identified and tested individually to see how these effect 
eosinophil function. Wortmannin appears to be non-specific at quite low doses (0.05- 
lfiM ) and various derivitives based on this compound with more specificity need to be 
produced.
7.12  Final conclusions
This thesis presents eosinophil functional data, where various agonists 
implicated in inflammation are able to elicit H20 2 production, cause cellular adhesion 
and [Ca2+]j elevation from eosinophils. For many of the agonists this study was the 
first characterisation that they were able to elicit such functional responses in human 
eosinophils. Different functional states of guinea pig eosinophils also appeared to exist 
as activity could be up-regulated as demonstrated by GM-CSF and IL-5 or modulated 
by recruitment into the lung from blood circulation. This data was not obtained for 
human eosinophils. The effect of recruitment into the lung on human eosinophil 
function will be very difficult to quantify as many patients will be already undergoing 
treatment which may adversely effect the results.
This study indicates that the transduction mechanisms for cellular adhesion may 
lead to the respiratory burst, but the respiratory burst can be activated by an 
independent mechanism as demonstrated by H20 2 production from eosinophils in
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suspension. Also, eosinophil adhesion and the respiratory burst were dependent on 
extracellular Ca2+ and Mg2+, whereas [Ca2+]j elevation was partly dependent on 
extracellular Ca2+ but not Mg2+. Another important result to note is that a rise in 
[Ca2+]j elevation was not sufficient to activate the NADPH oxidase complex.
A key role exists for cPKC, and PI3-kinase possibly through aPKC-C in H20 2 
production stimulated by soluble agonists relevant to allergic inflammation. The 
significant inhibition of H20 2 production by either Ro 31-8220/002 or wortmannin 
suggests these two pathways maybe in some way connected, perhaps different stages 
in the signalling cascade. Some PTKs may also play a role in 0 2 generation as 
demonstrated by the PTK inhibitor herbimycin A. This mechanism may be largely 
redundant due to the presence of other intracellular signalling pathways, but when they 
are inhibited by either Ro 31-8220/002 or wortmannin, a PTK pathway may account 
for the residual H20 2 production detected.
The cPKC and PI3-kinase pathways are also involved/linked to eosinophil 
adhesion as the selected inhibitors caused reductions in eosinophil adhesion. This is 
quite distinct from the PTK pathway, where the tyrosine kinase inhibitors potentiated 
guinea pig adhesion. A schematic diagram in figure 7.1 shows the possible signalling 
pathways.
The guinea pig eosinophils were a good model of human eosinophils but with 
limitations. They exhibited similar functional pathways to human eosinophils with 
respect to cPKC and PI 3-kinase, however differences occurred between the influx 
experiments in particular the SK&F 96365 results. In addition there were far fewer 
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F igure 7.1 Possible signal transduction mechanisms leading to 
eosinophil activation
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This thesis also looked at the cell lines Eol-1 and Eol-3 as viable alternatives 
to human mature eosinophils for investigation into the functional responses to added 
agonists. It became apparent that the Eol’s were still a long way removed from the 
fully differentiated cells (even though many maturation processes were tested) and as 
such were not useful in determining any of the eosinophil functions. This is a 
particular area of research that should be pursued as one problem with eosinophil 
research is that only small numbers of primary cells can be obtained, a particular 
problem for Western blotting experiments. New cell lines should be developed that are 
more closely related to mature eosinophils.
It is obvious from the experiments presented in this thesis that cellular functions 
of both guinea pig and human eosinophils can be activated by a wide range of agonists. 
With the role of the eosinophil implicated in respiratory diseases the strategic approach 
in developing future therapies would be not to target specific agonists and their 
receptors as new agonists are constantly being identified, but look at pivotal points in 
the activation pathway. This research has identified some of the common links 
between the pathways from receptor activation to functional response eg. PKC and PI 
3-kinase, and some distinct pathways of activation eg. requirement for [Ca2+]j for 
PKC/NADPH oxidase activation though not essential. The potential target points need 
to be selected with great care to avoid disruption of similar pathways in other cell 
types. Also depending of the particular patient requirements, any therapeutic approach 
needs to be balanced so that the eosinophil does not become completely inoperable. 
Thus, selective control of different elements in each pathway in conjunction with 
existing methods for the specific control of airway disease should be developed.
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